dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Pöördumine

Sotsiaalministeerium · 2. detsember 2020
Viit
1.4-2/3485-1
Registreeritud
2. detsember 2020
Dokumendi liik
Sissetulev kiri
Adressaat
World Health Organization
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2020
Vastutaja
Hanna Alajõe (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Euroopa Liidu ja väliskoostöö osakond)

Failid

  • 📎C.L.54.2020 Recommended INN list 84.pdf6670 KB
  • 📎E-kiri.pdf68 KB

Sisu (failidest)

Saatja: <[email protected]> Saadetud: 02.12.2020 14:38 Teema: WHO: C.L.54.2020 (recommended INN list 84) Dear Member States of the World Health Organization,Please find attached, in the six official languages, C.L54.2020 regarding the list of recommended international nonproprietary names for pharmaceutical substances which has been published by the World Health Organization in WHO Drug Information, Vol. 34, N°3, 2020.The annex is the same in all languages and is attached to the English version.Best regards,Department of Governing BodiesWorld Health Organization 20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Ref.: C.L.54.2020 The World Health Organization presents its compliments and has the honour to forward herewith, in accordance with Articles 3.A and 7 of the “Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances” adopted by the Executive Board in its resolution EB15.R71, a list of names which has been published as International Nonproprietary Names recommended by the World Health Organization (abbreviation Rec. INN). In accordance with Article 8 of the above-mentioned Procedure, the World Health ... Organization requests that the enclosed list of names* be recognized as the nonproprietary names for the substances in question, and that the necessary steps be taken to prevent the acquisition of proprietary rights in the names, including prohibition of registration of the names as trade-marks or trade-names. GENEVA, 1 December 2020 1 Annex to resolution EB15.R7, Off. Rec. Wld Hlth Org., No. 60, pp. 3 and 55. This text was amended by resolution EB43.R9, Off. Rec. Wld Hlth Org., No. 173, p. 10 and resolution EB115.R4, Executive Board, 115th Session, Resolutions and Decisions (EB115/2005/REC/1), p. 2. ... ENCL.: (1)* Rec. INN: List 84 published in WHO Drug Information, Vol. 34, No.3, 2020. WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 84 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–1117) and Recommended (1–78) International Nonproprietary Names can be found in Cumulative List No. 17, 2017 (available in CD-ROM only). Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 84 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–117) et recommandées (1–78) dans la Liste récapitulative No. 17, 2017 (disponible sur CD-ROM seulement). Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) Denominaciones Comunes Internacionales RECOMENDADAS: Lista 84 De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas (1–78) se encuentran reunidas en Cumulative List No. 17, 2017 (disponible sólo en CD-ROM). 687 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 Latin, English, French, Spanish: Chemical name or description; Molecular formula; Recommended INN Graphic formula DCI Recommandée Nom chimique ou description; Formule brute; Formule développée DCI Recomendada Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada acidum aligomanuxicum aligomanuxic acid O-[oligo-(1→4)-β-D-mannopyranuronan-β-osyl]-(1→3)- D-mannaric, -(1→2)-D-arabinaric, -(1→3)-D-arabinaric, (1→2)-D-erythraric, -(1→2)-D-threaric, and -(1→2)- glyceraric acids, produced from alginates of brown seaweeds by acid-catalysed partial hydrolysis, isolation of oligomannuronans and oxidation of the reducing end group acide aligomanuxique acides O-[oligo-(1→4)-β-D-mannopyranuronan-β-osyl]- (1→3)-D-mannarique, -(1→2)-D-arabinarique, -(1→3)- D-arabinarique, (1→2)-D-érythrarique, -(1→2)-D- thréarique, et -(1→2)-glycérarique, produits à partir d'algues brunes par hydrolyse partielle par catalyse acide, isolation des oligomannuronanes et oxydation du groupe réducteur terminal ácido aligomanúxico ácidos O-[oligo-(1→4)-β-D-manopiranuronan-β-osil]- (1→3)-D-manárico, -(1→2)-D-arabinárico, -(1→3)-D- arabinárico, (1→2)-D-eritrárico, -(1→2)-D-treárico, y -(1→2)-glicerárico, producido a partir de algas pardas por hidrólisis parcialmente por catálisis ácida, aislamiento de los oligomanuronanos y oxidación del grupo reductor terminal (C6H8O6)n (CH2O)m+m' C3H4O5 acidum norucholicum norucholic acid 3α,7β-dihydroxy-24-nor-5β-cholan-23-oic acid acide norucholique acide 3α,7β-dihydroxy-24-nor-5β-cholan-23-oïque ácido norucólico ácido 3α,7β-dihidroxi-24-nor-5β-colan-23-oico 688 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 C23H38O4 acoramidisum acoramidis 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4- fluorobenzoic acid acoramidis acide 3-[3-(3,5-diméthyl-1H-pyrazol-4-yl)propoxy]-4- fluorobenzoïque acoramidis ácido 3-[3-(3,5-dimetil-1H-pirazol-4-il)propoxi]-4- fluorobenzoico C15H17FN2O3 adebrelimabum # adebrelimab immunoglobulin G4-kappa, anti-[Homo sapiens CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], monoclonal antibody; gamma4 heavy chain (1-446) [VH (Homo sapiens IGHV1-46*01 (89.8%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) - Homo sapiens IGHG4*01, G4v5 h P10, G4v4 CH2 A1.3, A1.2 (CH1 (120-217), hinge 1-12 S10>P (227) (218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133- 218')-disulfide with kappa light chain (1'-218') [V- KAPPA (Mus musculus IGKV3-5*01 (84.8%) - IGKJ2*03 (90.9%)/Homo sapiens IGKV4-1*01 (68.3%) -IGKJ2*01 (100%)) CDR-IMGT [10.3.9] (27-36.54- 56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (225-225":228-228")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa adébrélimab immunoglobuline G4-kappa, anti-[Homo sapiens CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], anticorps monoclonal; 689 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 chaîne lourde gamma4 (1-446) [VH (Homo sapiens IGHV1- 46*01 (89.8%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -Homo sapiens IGHG4*01, G4v5 h P10, G4v4 CH2 A1.3, A1.2 (CH1 (120-217), charnière 1-12 S10>P (227) (218-229), CH2 F1.3>A (233), L1.2>A (234) (230- 339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')- disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA (Mus musculus IGKV3-5*01 (84.8%) -IGKJ2*03 (90.9%)/Homo sapiens IGKV4-1*01 (68.3%) -IGKJ2*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (225-225":228-228")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa adebrelimab inmunoglobulina G4-kappa, anti-[Homo sapiens CD274 (ligando 1 de muerte programada, PDL1, PD-L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal; cadena pesada gamma4 (1-446) [VH (Homo sapiens IGHV1- 46*01 (89.8%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -Homo sapiens IGHG4*01, G4v5 h P10, G4v4 CH2 A1.3, A1.2 (CH1 (120-217), bisagra 1-12 S10>P (227) (218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA (Mus musculus IGKV3-5*01 (84.8%) -IGKJ2*03 (90.9%)/Homo sapiens IGKV4- 1*01 (68.3%) -IGKJ2*01 (100%)) CDR-IMGT [10.3.9] (27-36.54- 56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (225-225":228-228")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWMHWVRQA PGQGLEWMGR 50 IGPNSGFTSY NEKFKNRVTM TRDTSTSTVY MELSSLRSED TAVYYCARGG 100 SSYDYFDYWG QGTTVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200 TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL 250 MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300 VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350 PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400 GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK 446 Light chain / Chaîne légère / Cadena ligera DIVLTQSPAS LAVSPGQRAT ITCRASESVS IHGTHLMHWY QQKPGQPPKL 50 LIYAASNLES GVPARFSGSG SGTDFTLTIN PVEAEDTANY YCQQSFEDPL 100 TFGQGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150 QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200 THQGLSSPVT KSFNRGEC 218 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 146-202 260-320 366-424 22''-96'' 146''-202'' 260''-320'' 366''-424'' Intra-L (C23-C104) 23'-92' 138'-198' 23'''-92''' 138'''-198''' Inter-H-L (CH1 10-CL 126) 133-218' 133''-218''' Inter-H-H (h 8, h 11) 225-225'' 228-228'' N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl) H VH Q1: 1, 1'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 296, 296'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados 690 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 afamitresgenum autoleucelum # afamitresgene autoleucel Autologous CD4+ and CD8+ T cells obtained by leukapheresis, transduced with an HIV-derived self- inactivating (SIN) lentiviral vector, encoding an enhanced-affinity T cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE family member A4, antigen MAGE A4) HLA-A*02 peptide driven by the elongation factor 1 alpha (EF1α) promoter. Cells express lymphonode-homing markers CCR7 and CD62L, CD45 isoforms CD45RA and CD45R0, co- stimulatory markers CD27 and CD28, IL-7 receptor CD127, and chemokine receptor CXCR3. Cells secrete interleukin 2 (IL-2), tumor necrosis factor α (TNF-alpha, TNFα), interferon gamma (interferon γ, IFN-gamma), granzyme, interleukin 4 (IL-4), interleukin 13 (IL-13) and interleukin 17 (IL-17) upon activation. afamitresgène autoleucel Lymphocytes T CD4+ et CD8+ autologues obtenus par leucophérèse, transduits par un vecteur lentiviral auto- inactivant (SIN), dérivé du virus de l'immunodéficience humaine (VIH), codant pour un récepteur de lymphocytes T (TCR) à affinité augmentée spécifique du peptide HLA-A*02 de l'antigène du mélanome humain A4 (membre A4 de la famille MAGE, antigène MAGE-4), sous le contrôle d'un promoteur du facteur d'élongation alpha 1 (EF1α). Les cellules expriment les marqueurs de migration des ganglions lymphatiques CCR7 et CD62L, les isoformes CD45RA and CD45R0 du CD45, les marqueurs co-stimulateurs CD27 et CD28, le récepteur CD127 de l'interleukine 7 (IL-7) et les récepteurs de chimiokines CXCR3. Les cellules secrètent de l'interleukine 2 (IL-2), facteur de nécrose tumorale α (TNF-alpha, TNFα), interféron gamma (interféron γ, IFN-gamma), granzyme, interleukine 4 (IL-4), interleukine 13 (IL-13) et l'interleukine 17 (IL-17) au moment de leur activation afamitresgén autoleucel Linfocitos T CD4+ y CD8+ autólogos obtenidos por leucoaféresis, transducidos con un vector lentiviral auto inactivante derivado del HIV, que codifica para un receptor de linfocitos T (TCR) con afinidad aumentada, específico para el péptido del antígeno de melanoma humano A4 (MAGE A4) presentado por HLA-A*02, dirigido por un promotor del factor de elongación 1 alfa (EF1α). Las células expresan los marcadores de migración a ganglios linfáticos CCR7 y CD62L, las isoformas CD45RA y CD45R0 de CD45, los marcadores coestimuladores CD27 y CD28, el receptor de IL-7 CD127, y el receptor de quimoquinas CXCR3. Las células secretan interleukina 2 (IL-2), factor de necrosis tumoral (TNF-alfa, TNFα), interferón gamma (interferón γ, IFN-gamma), granzima, interleukina 4 (IL-4), interleukina 13 (IL-13) e interleukina 17 (IL-17) tras su activación. 691 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 alsevalimabum # alsevalimab immunoglobulin G1-kappa, anti-[Homo sapiens VTCN1 (V-set domain containing T cell activation inhibitor 1, B7-H4, B7H4)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) - IGHJ5*02 (93.8%)) CDR-IMGT [10.7.12] (26-35.53- 59.98-109) (1-120) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')- disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (96.8%) - IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50- 52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO-FUT8-/-) cells, glycoform alfa alsévalimab immunoglobuline G1-kappa, anti-[ Homo sapiens VTCN1 (inhibiteur 1 de l'activation des cellules T contenant un V-set domain, B7-H4, B7H4)], anticorps monoclonal Homo sapiens; chaîne lourde gamma1 Homo sapiens (1-450) [VH (Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) - IGHJ5*02 (93.8%)) CDR-IMGT [10.7.12] (26-35.53- 59.98-109) (1-120) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')- disulfure avec la chaîne légère kappa Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (96.8%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27- 32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (229-229'':232-232'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO- FUT8-/-), glycoforme alfa alsevalimab inmunoglobulina G1-kappa, anti-[ Homo sapiens VTCN1 (inhibidor 1 de la activación de las células T que contiene un dominio V-set, B7-H4, B7H4)], anticuerpo monoclonal Homo sapiens; cadena pesada gamma1 Homo sapiens (1-450) [VH (Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) - IGHJ5*02 (93.8%)) CDR-IMGT [10.7.12] (26-35.53- 59.98-109) (1-120) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')- disulfuro con la cadena ligera kappa Homo sapiens (1'- 214') [V-KAPPA (Homo sapiens IGKV3-15*01 (96.8%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50- 52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (229-229'':232-232'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO-FUT8-/-), forma glicosilada alfa 692 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 Heavy chain / Chaîne lourde / Cadena pesada QLQLQESGPG LVKPSETLSL TCTVSGGSIK SGSYYWGWIR QPPGKGLEWI 50 GNIYYSGSTY YNPSLRSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE 100 GSYPNQFDPW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200 YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350 VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400 LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450 Light chain / Chaîne légère / Cadena ligera EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG 50 ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YHSFPFTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-97 147-203 264-324 370-428 22''-97'' 147''-203'' 264''-324'' 370''-428'' Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) 223-214' 223''-214''' Inter-H-H (h 11, h 14) 229-229'' 232-232'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 300, 300'' Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados C-terminal lysine clipping H CHS K2: 450, 450'' amcenestrantum amcenestrant 8-(2,4-dichlorophenyl)-9-(4-{[(3S)-1-(3- fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H- benzo[7]annulene-3-carboxylic acid amcénestrant acide 8-(2,4-dichlorophényl)-9-(4-{[(3S)-1-(3- fluoropropyl)pyrrolidin-3-yl]oxy}phényl)-6,7-dihydro-5H- benzo[7]annulène-3-carboxylique amcenestrant ácido 8-(2,4-diclorofenil)-9-(4-{[(3S)-1-(3- fluoropropil)pirrolidin-3-il]oxi}fenil)-6,7-dihidro-5H- benzo[7]anuleno-3-carboxílico C31H30Cl2FNO3 F N O H CO2H Cl Cl amdakefalinum # amdakefalin [6-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-3,6- diazabicyclo[3.1.1]heptan-3-yl]acetic acid amdakéfaline acide [6-(D-phénylalanyl-D-phénylalanyl-D-leucyl-D- lysyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]acétique amdakefalina ácido [6-(D-fenilalanil-D-fenilalanil-D-leucil-D-lisil)-3,6- diazabiciclo[3.1.1]heptan-3-il]acético 693 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 C37H53N7O6 aramisulpridum aramisulpride 4-amino-5-(ethanesulfonyl)-N-{[(2R)-1-ethylpyrrolidin- 2-yl]methyl}-2-methoxybenzamide aramisulpride 4-amino-5-(éthanesulfonyl)-N-{[(2R)-1-éthylpyrrolidin- 2-yl]méthyl}-2-méthoxybenzamide aramisulprida 4-amino-5-(etanosulfonil)-N-{[(2R)-1-etilpirrolidin-2- il]metil}-2-metoxibenzamida C17H27N3O4S autogenum cevumeranum # autogene cevumeran A 5'-capped single-stranded messenger RNA (mRNA) construct for the expression of patient-specific tumour neoantigens comprising a 5'-cap, a 5'-untranslated region derived from human alpha-globin mRNA, an optimised Kozak sequence, sequences encoding a secretory signal peptide (sec2.0), transmembrane and cytoplasmic domains of a major histocompatibility complex (MHC) Class I molecule (MITD), a 3'- untranslated region (FI) and a poly(A)-tail; sequences encoding patient specific antigens are inserted between the secretory signal peptide and the transmembrane/cytoplasmic encoding domains. autogène cévuméran ARN messager (ARNm) de simple brin coiffé en 5' construit pour l'expression de néoantigènes tumoraux spécifiques du patient comprenant une coiffe en 5', une région en 5' non-traduite dérivée de l'ARNm de la globine alpha humaine, une séquence optimisée Kozak, et les séquences codant pour un peptide signal (sec2.0), les domaines transmembranaire et cytoplasmique du complexe majeur d'histocompatibilité de groupe I (CMH1) (MITD), une région non traduite en 3' (FI) et une queue poly(A) ; Les séquences codant les antigènes spécifiques du patient sont insérées entre celles codant le peptide signal et les domaines transmembranaire et cytoplasmique. 694 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 autogén cevumerán Un constructo de RNA mensajero (mRNA) de cadena sencilla y caperuza en 5', para la expresión de neoantígenos tumorales específicos de cada paciente, que contiene una caperuza 5' (5'-cap), una región 5' no traducida derivada del mRNA de la globina alfa humana, una secuencia optimizada Kozak, y las secuencias codificantes para el péptido señal (sec2.0), los dominios transmembrana y citoplásmico de complejo mayor de histocompatibilidad de grupo I (CMHI) (MITD), una región non-traducida en 3' (FI) y una cola poly(A); las secuencias que codifican los antígenos específicos del paciente se insertan entre las del péptido señal y de los dominios transmembrana y citoplásmico. azemiglitazonum azemiglitazone rac-(5R)-5-({4-[2-(3-methoxyphenyl)-2- oxoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione azémiglitazone rac-(5R)-5-({4-[2-(3-méthoxyphényl)-2- oxoéthoxy]phényl}méthyl)-1,3-thiazolidine-2,4-dione azemiglitazona rac-(5R)-5-({4-[2-(3-metoxifenil)-2-oxoetoxi]fenil}metil)- 1,3-tiazolidina-2,4-diona C19H17NO5S 695 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 belzupacapum sarotalocanum # belzupacap sarotalocan a modified human papillomavirus (HPV) type 16- derived empty nanoparticle, 55 nm in diameter conjugated to approximately 200 molecules of a phthalocyanine-based photosensitizer (sarotalocan group). Each nanoparticle is comprised of 72 capsomeres, made of 5 molecules of modified viral capsid protein L1 [P78>R, T176>N, D273>T, N285>T, S288>N, T353>P, T389>S] and one molecule of viral capsid protein L2; human papilloma virus type 16 (HPV16) capsid, a spherical shell of 72 self-assembling pentagonal (L1)5(L2)1 capsomere units comprising the recombinant viral capsid proteins L1 ([P78>R, T176>N, D273>T, N285>T, S288>N, T353>P, T389>S]-modified) and L2, conjugated to approximately 200 sarotalocan groups (near infrared absorbing dye) at N6 of lysine residues; produced by human embryonic kidney 293 (HEK293) cells belzupacap sarotalocan nanoparticle vide dérivée du virus du papillomavirus humain 16 (HPV) modifié, 55nm de diamètre, conjuguée à approximativement 200 molécules d'un photosensibilisant à base de phthalocyanine (groupe sarotalocan). Chaque particule est composée de 72 capsomères, faits de 5 molécules de protéine de capside virale L1 modifiée [P78>R, T176>N, D273>T, N285>T, S288>N, T353>P, T389>S] et d'une molécule de protéine de capside virale L2; capside du virus du papillomavirus humain 16 (HPV16), une coquille sphérique de 72 unités de capsomère pentagonal (L1)5(L2)1 s'auto-assemblant comprenant les protéines recombinantes de capside virale L1 ([P78>R, T176>N, D273>T, N285>T, S288>N, T353>P, T389>S]-modifiée) et L2, conjuguées à environ 200 groupes sarotalocan (colorant absorbant les proches infra-rouges) en N6 des résidus lysine ; produite par des cellules rénales embryonnaires humaines (HEK293) belzupacap sarotalocán nanopartícula vacía derivada del virus del papilomavirus humano 16 (HPV) modificado, 55nm de diámetro, conjugado con aproximadamente 200 moléculas de un fotosensibilizante a base de ftalocianina (grupo sarotalocán). Cada partícula se compone de 72 capsómeros, hechos de 5 moléculas de proteína de cápside viral L1 modificada [P78>R, T176>N, D273>T, N285>T, S288>N, T353>P, T389>S] y de una molécula de proteína de cápside viral L2; cápside del virus del papilomavirus humano 16 (HPV16), una cavidad esférica de 72 unidades de capsómero pentagonal (L1)5(L2)1 que se autoensamblan abarcando las proteínas recombinantes de cápside viral L1 ([P78>R, T176>N, D273>T, N285>T, S288>N, T353>P, T389>S]-modificada) y L2, conjugadas aproximadamente a 200 grupos sarotalocán (colorante absorbente infrarrojo cercano) en N6 de los residuos de lisina ; producido por las células renales embrionarias humanas (HEK293) 696 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 belzutifanum belzutifan 3-{[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7- (methanesulfonyl)-2,3-dihydro-1H-inden-4-yl]oxy}-5- fluorobenzonitrile belzutifan 3-{[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7- (méthanesulfonyl)-2,3-dihydro-1H-indèn-4-yl]oxy}-5- fluorobenzonitrile belzutifán 3-{[(1S,2S,3R)-2,3-difluoro-1-hidroxi-7- (metanosulfonil)-2,3-dihidro-1H-indén-4-il]oxi}-5-fluoro- benzonitrilo C17H12F3NO4S 697 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 bepranemabum # bepranemab immunoglobulin G4-kappa, anti-[Homo sapiens MAPT (microtubule-associated protein tau, tau)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-445) [VH (Homo sapiens IGHV4-4*08 (83.5%) -(IGHD) -IGHJ3*01 (93.3%)) CDR-IMGT [8.7.12] (26-33.51-57.96-107) (1- 118)-Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (119-216), hinge 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-219')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (Homo sapiens IGKV2-29*02 (90.0%) -IGKJ2*01 (100%)) CDR-IMGT [11.3.9] (27- 37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa bépranémab immunoglobuline G4-kappa, anti-[Homo sapiens MAPT (protéine tau associée aux microtubules, tau)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-445) [VH (Homo sapiens IGHV4-4*08 (83.5%) -(IGHD) -IGHJ3*01 (93.3%)) CDR-IMGT [8.7.12] (26-33.51-57.96-107) (1- 118) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (119-216), charnière 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119- 445)], (132-219')-disulfure avec la chaîne légère kappa humanisée (1'-219') [V-KAPPA (Homo sapiens IGKV2- 29*02 (90.0%) -IGKJ2*01 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'- 219')]; dimère (224-224":227-227")-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa bepranemab inmunoglobulina G4-kappa, anti-[Homo sapiens MAPT (proteína tau asociada a los microtúbulos, tau)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-445) [VH (Homo sapiens IGHV4-4*08 (83.5%) -(IGHD) - IGHJ3*01 (93.3%)) CDR-IMGT [8.7.12] (26-33.51- 57.96-107) (1-118) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (119-216), bisagra 1-12 S10>P (226) (217- 228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-219')-disulfuro con la cadena ligera kappa humanizada (1'-219') [V-KAPPA (Homo sapiens IGKV2-29*02 (90.0%) -IGKJ2*01 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'- 219')]; dímero (224-224":227-227")-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa 698 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 bersacapavirum bersacapavir N-(3-cyano-4-fluorophenyl)-1-methyl-4-{[(2S)-1,1,1- trifluoropropan-2-yl]sulfamoyl}-1H-pyrrole-2-carboxamide bersacapavir N-(3-cyano-4-fluorophényl)-1-méthyl-4-{[(2S)-1,1,1- trifluoropropan-2-yl]sulfamoyl}-1H-pyrrole-2-carboxamide bersacapavir N-(3-ciano-4-fluorofenil)-1-metil-4-{[(2S)-1,1,1- trifluoropropan-2-il]sulfamoil}-1H-pirrolo-2-carboxamida C16H14F4N4O3S bexmarilimabum # bexmarilimab immunoglobulin G4-kappa, anti-[Homo sapiens STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1, SCARH2)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-449) [VH (Homo sapiens IGHV2-5*09 (91.8%) -(IGHD) -IGHJ4*01 (100%)) [10.7.14] (1-122) -Homo sapiens IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-220), hinge 1-12 S10>P (230)(221-232), CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448- 449)) (123-449)], (136-215')-disulfide with kappa light chain humanized (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa 699 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 bexmarilimab immunoglobuline G4-kappa, anti-[Homo sapiens STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1, SCARH2)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-449) [VH (Homo sapiens IGHV2-5*09 (91.8%) -(IGHD) - IGHJ4*01 (100%)) [10.7.14] (1-122) -Homo sapiens IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-220), charnière 1-12 S10>P (230) (221-232), CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448-449)) (123- 449)], (136-215')-disulfure avec la chaîne légère kappa humanisée (1'-215') [V-KAPPA (Homo sapiens IGKV3- 20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (228-228'':231-231'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa bexmarilimab inmunoglobulina G4-kappa, anti-[Homo sapiens STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1, SCARH2)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-449) [VH (Homo sapiens IGHV2-5*09 (91.8%) -(IGHD) - IGHJ4*01 (100%)) [10.7.14] (1-122) -Homo sapiens IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123- 220), bisagra 1-12 S10>P (230) (221-232), CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448- 449)) (123-449)], (136-215')-disulfuro con la cadena ligera kappa humanizada (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 700 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 bomedemstatum bomedemstat N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}- 1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3- triazol-1-yl)benzamide bomédemstat N-[(2S)-5-{[(1R,2S)-2-(4-fluorophényl)cyclopropyl]amino}- 1-(4-méthylpipérazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3- triazol-1-yl)benzamide bomedemstat N-[(2S)-5-{[(1R,2S)-2-(4-fluorofenil)ciclopropil]amino}-1-(4- metilpiperazin-1-il)-1-oxopentan-2-il]-4-(1H-1,2,3-triazol-1- il)benzamida C28H34FN7O2 CH3 N O N F O H N N H N N N cevostamabum # cevostamab immunoglobulin G1-kappa, anti-[Homo sapiens FCRL5 (Fc receptor like 5, FCRH5, IRTA2, BXMAS1, CD307e)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], monoclonal antibody, bispecific tetravalent; gamma1 heavy chain anti-FCRL5 (1-450) [VH (Mus musculus IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/Homo sapiens IGHV4-4*08 (72.9%) -(IGHD) - IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96- 109) (1-120) -Homo sapiens IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223- 214')-disulfide with kappa light chain anti-FCRL5 (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (83.2%) - IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; gamma1 heavy chain anti-CD3 (1''-449'') [VH (Homo sapiens IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1''-119'') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120- 217), hinge 1-15 (218-232), CH2 N84.4>G (299) (233- 342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120''- 449'')], (222''-219''')-disulfide with kappa light chain anti- CD3 (1'''-219''') [V-KAPPA (Homo sapiens IGKV4-1*01 (88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56- 58.95-102) (1'''-112''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')]; dimer (229-228'':232-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells 701 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 cévostamab immunoglobuline G1-kappa anti-[Homo sapiens FCRL5 (récepteur Fc like 5, FCRH5, IRTA2, BXMAS1, CD307e)] et anti-[Homo sapiens CD3E (CD3 epsilon, Leu- 4)], anticorps monoclonal, bispécifique tétravalent; chaîne lourde gamma1 anti-FCRL5 (1-450) [VH (Mus musculus IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/Homo sapiens IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96-109) (1-120) -Homo sapiens IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), charnière 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère kappa anti-FCRL5 (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27- 32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; chaîne lourde gamma1 anti-CD3 (1''-449'') [VH (Homo sapiens IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1''-119'') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120-217), charnière 1-15 (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120''-449'')], (222''-219''')-disulfure avec la chaîne légère kappa anti-CD3 (1'''-219''') [V-KAPPA (Homo sapiens IGKV4-1*01 (88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1'''-112''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')]; dimère (229-228'':232-231'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) cevostamab inmunoglobulina G1-kappa anti-[Homo sapiens FCRL5 (receptor Fc like 5, FCRH5, IRTA2, BXMAS1, CD307e)] y anti-[Homo sapiens CD3E (CD3 épsilon, Leu- 4)], anticuerpo monoclonal, biespecífico tetravalente; cadena pesada gamma1 anti-FCRL5 (1-450) [VH (Mus musculus IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/Homo sapiens IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96-109) (1-120) -Homo sapiens IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), bisagra 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera kappa anti-FCRL5 (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27- 32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; cadena pesada gamma1 anti-CD3 (1''-449'') [VH (Homo sapiens IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1''-119'') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120-217), bisagra 1-15 (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120''-449'')], (222''- 219''')-disulfuro con la cadena ligera kappa anti-CD3 (1'''-219''') [V- KAPPA (Homo sapiens IGKV4-1*01 (88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1'''-112''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')]; dímero (229-228'':232-231'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO) 702 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 ciltacabtagenum autoleucelum # ciltacabtagene autoleucel autologous peripheral blood mononuclear cell (PBMC)-derived T lymphocytes transduced ex vivo with a non-replicating, self- inactivating (SIN) lentiviral vector encoding a chimeric antigen receptor (CAR) targeting two epitopes of the human B cell maturation antigen (BCMA) under the control of a human elongation factor 1 alpha (EF1α) promoter The coding sequence comprises a human CD8 alpha signal peptide (CD8α SP), a BCMA targeting domain consisting of two variable heavy chain-only antibodies (VHH1 and VHH2) targeting two distinct BCMA epitopes, a human CD8 alpha hinge and transmembrane domain (CD8α hinge + TM), a human CD137 cytoplasmic domain (4-1BB) and a human CD3 zeta cytoplasmic domain (CD3ζ). The vector genome contains a chimeric Rous sarcoma virus (RSV)/truncated 5'LTR and a self-inactivating 3'LTR-SIN (∆- U3). 703 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 ciltacabtagène autoleucel lymphocytes T autologues dérivés de cellules mononuclées du sang périphérique (PBMC) transduits ex vivo avec un vecteur lentiviral non-répliquant, auto- inactivant (SIN) codant pour un récepteur d'antigène chimérique (CAR) ciblant deux épitopes de l'antigène de maturation des lymphocytes B (BCMA) humains sous le contrôle d'un promoteur du facteur d'élongation 1-alpha humain (EF1α) La séquence code pour un peptide signal CD8 alpha humain (CD8α SP), un domaine ciblant le BCMA consistant en seulement la partie variable des chaînes lourdes (VHH1 and VHH2) de deux anticorps dirigés contre deux épitopes du BCMA, une charnière et un domaine transmembranaire du CD8 alpha humain, un domaine cytoplasmique du CD 137 humain (4-1BB) et un domaine cytoplasmique du CD3 zêta humain (CD3ζ). Le génome du vecteur contient en 5', une séquence LTR (terminale longue répétée) tronquée d'un virus du sarcome de Rous (RSV) chimérique et en 3', une séquence LTR-SIN (∆-U3) auto-inactivante. ciltacabtagén autoleucel linfocitos T autólogos derivados de células mononucleares de sangre periférica (PBMC) transducidos ex vivo con un vector lentiviral no replicativo, auto inactivante (SIN), que codifica para un receptor de antígenos quimérico (CAR) dirigido a dos epítopos del antígeno de maduración de linfocitos B (BCMA) humano bajo el control de un promotor del factor de elongación 1 alfa humano (promotor EF1α) La secuencia codificante consta de un péptido señal del CD8 alfa humano, un dominio dirigido a BCMA consistente en sólo la parte variable de las cadenas pesadas (VHH1 y VHH2) de dos anticuerpos dirigidos a dos epítopos de BCMA, una bisagra y un dominio transmembrana del CD8 alfa humano, un dominio citoplásmico del CD137 humano (4-1BB) y un dominio citoplásmico del CD3 zeta humano (CD3ζ). El genoma del vector contiene un LTR 5' truncado/RSV (virus del sarcoma de Rous) quimérico y un LTR 3'-SIN auto inactivante (∆-U3). conendostatinum conendostatin L-methionyl-human endostatin [human collagen type XVIII α-1 (COL18A1) C-terminal (1572-1754)-fragment (1-183)], canonical D104, R110, S150 form, produced in Escherichia coli conendostatine L-méthionyl-endostatine humaine [fragment C-terminal (1572-1754) du collagène humain de type XVIII α-1 (COL18A1) (1-183)], forme canonique D104, R110, S150, produit dans Escherichia coli conendostatina L-metionil-endostatina humana [fragmento C-terminal (1572-1754) del colágeno humano de tipo XVIII α-1 (COL18A1) (1-183)], forma canónica D104, R110, S150, producido en Escherichia coli 704 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 cudarolimabum # cudarolimab immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, ACT35, OX40, CD134)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-453) [VH (Homo sapiens IGHV3-30*03 (100%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51- 58.97-113) (1-124) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS K>del (453)) (125-453)], (227-213')- disulfide with kappa light chain Homo sapiens (1'-213') [V-KAPPA (Homo sapiens IGKV1-33*01 (96.8%) - IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89- 96) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (233-233'':236-236'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa cudarolimab immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF4 (membre 4 de la superfamille des récepteurs du facteur de nécrose tumorale, ACT35, OX40, CD134)], anticorps monoclonal Homo sapiens; chaîne lourde gamma1 Homo sapiens (1-453) [VH (Homo sapiens IGHV3-30*03 (100%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51- 58.97-113) (1-124) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (221) (125-222), charnière 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS K>del (453)) (125-453)], (227-213')- disulfure avec la chaîne légère kappa Homo sapiens (1'-213') [V-KAPPA (Homo sapiens IGKV1-33*01 (96.8%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27- 32.50-52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (233-233'':236-236'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa cudarolimab inmunoglobulina G1-kappa, anti-[Homo sapiens TNFRSF4 (miembro 4 de la superfamilia de los receptores del factor de necrosis tumoral, ACT35, OX40, CD134)], anticuerpo monoclonal Homo sapiens; 705 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 cadena pesada gamma1 Homo sapiens (1-453) [VH (Homo sapiens IGHV3-30*03 (100%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51- 58.97-113) (1-124) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (221) (125-222), bisagra 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS K>del (453)) (125-453)], (227-213')- disulfuro con la cadena ligera kappa Homo sapiens (1'- 213') [V-KAPPA (Homo sapiens IGKV1-33*01 (96.8%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50- 52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (233-233'':236-236'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV 50 ISYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGR 100 PWYSETGTSA FDIWGQGTMV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150 CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200 GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250 PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300 EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350 REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400 TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450 SPG 453 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCQASQDIS NYLNWYQQKP GKAPKLLIYD 50 ASNLETGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ SDHYPTFGGG 100 TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150 NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200 SSPVTKSFNR GEC 213 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 151-207 268-328 374-432 22''-96'' 151''-207'' 268''-328'' 374''-432'' Intra-L (C23-C104) 23'-88' 133'-193' 23'''-88''' 133'''-193''' Inter-H-L (h 5-CL 126) 227-213' 227''-213''' Inter-H-H (h 11, h 14) 233-233'' 236-236'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 304, 304'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados dapatifagenum navolactibacum # dapatifagene navolactibac A recombinant live attenuated Lactococcus lactis, subspecies cremoris (strain MG1363), expressing a fusion protein comprising lactococcal secretion leader SSusp45 and human trefoil factor protein 1 (hTFF1), driven by the promoter from the homologous hllA gene (PhllA); the transduced gene is located in the thymidylate synthase A (thyA) locus which has been deleted (930102-930469). dapatifagène navolactibac Lactococcus lactis, sous-espèce cremoris, recombinante (souche MG1363), vivante atténuée exprimant une protéine de fusion consistant en le leader de sécrétion lactoccique SSusp45 et le facteur en trèfle-1 humain (hTFF1), sous le contrôle du promoteur du gène homologue hIIA (PhllA); le gène transduit est localisé sur le locus de la thymidylate synthase A (thyA) qui a été supprimé (930102- 930469). 706 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 dapatifagén navolactibac Lactococcus lactis, subespecie cremoris (cepa MG1363), recombinante, viva atenuada, que expresa una proteína de fusión consistente en el leader de secreción lactocócica SSusp45 y la proteína 1 del factor trébol humano (hTFF1), dirigida por el promotor del gen homólogo hIIA (PhIIA); el gen transducido se localiza en el locus de la timidilato sintasa A (thyA), que ha sido delecionado (930102- 930469). datopotamabum # datopotamab immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-451) [VH (Homo sapiens IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.14] (1-121) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa datopotamab immunoglobuline G1-kappa, anti-[Homo sapiens TACSTD2 (transducteur 2 de signaux calciques associé aux tumeurs, composant membranaire du chromosome 1 marqueur de surface 1, M1S1, antigène GA7331 associé aux tumeurs gastrointestinales, protéine GA733-1 marqueur de carcinomes pancréatiques, glycoprotéine épithéliale 1, EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à la surface des cellules, TROP2)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-451) [VH (Homo sapiens IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.14] (1-121) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), charnière 1-15 (220- 234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa 707 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 datopotamab inmunoglobulina G1-kappa, anti-[Homo sapiens TACSTD2 (transductor 2 de señales cálcicas asociado a los tumores, componente membranario del cromosoma 1 marcador de superficie 1, M1S1, antígeno GA7331 asociado a los tumores gastrointestinales, proteína GA733-1 marcador de carcinomas pancreáticos, glicoproteína epitelial 1, EGP-1, antígeno 2 del trofoblasto, glicoproteína Trop-2 en la superficie de las células, TROP2)], anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-451) [VH (Homo sapiens IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.14] (1-121) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), bisagra 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (230-230'':233-233'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGASVKV SCKASGYTFT TAGMQWVRQA PGQGLEWMGW 50 INTHSGVPKY AEDFKGRVTI SADTSTSTAY LQLSSLKSED TAVYYCARSG 100 FGSSYWYFDV WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150 KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200 TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350 QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400 VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450 K 451 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS 50 ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGQ 100 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 148-204 265-325 371-429 22''-96'' 148''-204'' 265''-325'' 371''-429'' Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) 224-214' 224''-214''' Inter-H-H (h 11, h 14) 230-230'' 233-233'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 301, 301'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados C-terminal lysine clipping: H CHS K2: 451, 451'' datopotamabum deruxtecanum # datopotamab deruxtecan immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative; 708 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 gamma1 heavy chain humanized (1-451) [VH (Homo sapiens IGHV1-3*01(79.6%) -(IGHD) - IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51- 58.97-110) (1-121) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122- 451)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR- IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa, conjugated, on an average of 4 cysteinyl, to deruxtecan, comprising a linker and a camptothecin derivative datopotamab déruxtécan immunoglobuline G1-kappa, anti-[Homo sapiens TACSTD2 (transducteur 2 de signaux calciques associé aux tumeurs, composant membranaire du chromosome 1 marqueur de surface 1, M1S1, antigène GA7331 associé aux tumeurs gastrointestinales, protéine GA733-1 marqueur de carcinomes pancréatiques, glycoprotéine épithéliale 1, EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à la surface des cellules, TROP2)], anticorps monoclonal humanisé conjugué au déruxtécan, comprenant un linker et un dérivé de la camptothécine; chaîne lourde gamma1 humanisée (1-451) [VH (Homo sapiens IGHV1-3*01 (79.6%) -(IGHD) - IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51- 58.97-110) (1-121) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), charnière 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122- 451)], (224-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure; produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa, conjugué sur une moyenne de 4 cystéines au déruxtécan, comprenant un linker et un dérivé de la camptothécine datopotamab deruxtecán inmunoglobulina G1-kappa, anti-[Homo sapiens TACSTD2 (transductor 2 de señales cálcicas asociado a los tumores, componente membrana del cromosoma 1 marcador de superficie 1, M1S1, antígeno GA7331 asociado a los tumores gastrointestinales, proteína GA733-1 marcador de carcinomas pancreáticos, glicoproteína epitelial 1, EGP-1, antígeno 2 del trofoblasto, glicoproteína Trop-2 en la superficie de las células, TROP2)], anticuerpo monoclonal humanizado conjugado con deruxtecán, que comprende un enlace y un derivado de la camptotecina; 709 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 cadena pesada gamma1 humanizada (1-451) [VH (Homo sapiens IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1- 121) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), bisagra 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR- IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (230-230'':233-233'')-bisdisulfuro; producido por células ováricas de hamster chino (CHO), forma glicosilada alfa, conjugado con una media de 4 cisteinas al deruxtecán, que comprende un enlace y un derivado de la camptotecina. Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGASVKV SCKASGYTFT TAGMQWVRQA PGQGLEWMGW 50 INTHSGVPKY AEDFKGRVTI SADTSTSTAY LQLSSLKSED TAVYYCARSG 100 FGSSYWYFDV WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150 KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200 TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350 QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400 VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450 K 451 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS 50 ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGQ 100 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 148-204 265-325 371-429 22''-96'' 148''-204'' 265''-325'' 371''-429'' Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126)* 224-214' 224''-214''' Inter-H-H (h 11, h 14)* 230-230'' 233-233'' *The four inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker. *Les quatre ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif. *Faltan los cuatro puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo. N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 301, 301'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados. C-terminal lysine clipping: H CHS K2: 451, 451'' Potential modified residues / résidus modifiés potentiels / restos modificados potenciales O O H Gly Gly Phe Gly N O O NH H N O C* O O N N CO2H OH H H3C S CH3 O H NH2 F 710 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 demupitamabum # demupitamab immunoglobulin G1-kappa, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine- protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-449) [VH (Homo sapiens IGHV4-61*01 (89.9%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53- 59.98-108) (1-119) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K (448-449)) (120-449)], (222-214')- disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (94.7%) - IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50- 52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa démupitamab immunoglobuline G1-kappa, anti-[Homo sapiens EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé; chaîne lourde gamma1 Homo sapiens (1-449) [VH (Homo sapiens IGHV4-61*01 (89.9%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53- 59.98-108) (1-119) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (216) (120-217), charnière 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K (448-449)) (120-449)], (222-214')- disulfure avec la chaîne légère kappa Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27- 32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa demupitamab inmunoglobulina G1-kappa, anti-[Homo sapiens EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erb-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado; cadena pesada gamma1 Homo sapiens (1-449) [VH (Homo sapiens IGHV4-61*01 (89.9%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53- 59.98-108) (1-119) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (216) (120-217), bisagra 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K (448-449)) (120-449)], (222-214')- disulfuro con la cadena ligera kappa Homo sapiens (1'- 214') [V-KAPPA (Homo sapiens IGKV1-33*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50- 52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa 711 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 docaravimabum # docaravimab immunoglobulin G2B-kappa, anti-[rabies virus strain ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III], Mus musculus monoclonal antibody; gamma2b heavy chain Mus musculus (1-455) [VH (Mus musculus IGHV2-6-7*01 (92.8%) -(IGHD) - IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51- 57.96-108) (1-119) -Mus musculus IGHG2B*02 (CH1 (120-216), hinge 1-22 (217-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (120-455)], (134-214')- disulfide with kappa light chain Mus musculus (1'-214') [V-KAPPA (Mus musculus IGKV10-96*01 (93.7%) - IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99- 107) (1'-106') -Mus musculus IGKC*01 (100%) (108'- 214')]; dimer (228-228":231-231":234-234":237-237")- tetrakisdisulfide, produced in mouse myeloma cell line SP2/0-Ag14, glycoform alfa docaravimab immunoglobuline G2B-kappa, anti-[ectodomaine épitope G-III glycoprotéine du virus de la rage souche ERA (Evelyn-Rockitniki-Abelseth)], anticorps monoclonal Mus musculus; chaîne lourde gamma2b Mus musculus (1-455) [VH (Mus musculus IGHV2-6-7*01 (92.8%) -(IGHD) - IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51- 57.96-108) (1-119) -Mus musculus IGHG2B*02 (CH1 (120-216), charnière 1-22 (217-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (120-455)], (134- 214')-disulfure avec la chaîne légère kappa Mus musculus (1'-214') [V-KAPPA (Mus musculus IGKV10- 96*01 (93.7%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-107) (1'-106') -Mus musculus IGKC*01 (100%) (108'-214')]; dimère (228-228":231-231":234-234":237-237")- tétrakisdisulfure, produite dans la lignée cellulaire de myélome murin SP2/0-Ag14, glycoforme alfa 712 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 docaravimab inmunoglobulina G2B-kappa, anti-[ectodominio epítopo G-III glicoproteína del virus de la rabia cepa ERA (Evelyn-Rockitniki- Abelseth)], anticuerpo monoclonal Mus musculus; cadena pesada gamma2b Mus musculus (1-455) [VH (Mus musculus IGHV2-6-7*01 (92.8%) -(IGHD) -IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51-57.96-108) (1-119) -Mus musculus IGHG2B*02 (CH1 (120-216), bisagra 1-22 (217-238), CH2 (239- 348), CH3 (349-453), CHS (454-455)) (120-455)], (134-214')- disulfuro con la cadena ligera kappa Mus musculus (1'-214') [V- KAPPA (Mus musculus IGKV10-96*01 (93.7%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-107) (1'-106') -Mus musculus IGKC*01 (100%) (108'-214')]; dímero (228-228":231-231":234-234":237-237")-tetrakisdisulfuro, producida en la línea celular de mieloma murino SP2/0-Ag14, glicoforma alfa Heavy chain / Chaîne lourde / Cadena pesada QVQLKESGPG LLAPSQSLSI TCTVSGFSLT GHGVNWVRQP PGKGLEWLGI 50 IWADGTTNYN SALKSRLSIS KDNSKSQVFL KMNSLQTDDT ASYYCAREGD 100 ISGYYFDYWG QGTTLTVSSA KTTPPSVYPL APGCGDTTGS SVTLGCLVKG 150 YFPESVTVTW NSGSLSSSVH TFPALLQSGL YTMSSSVTVP SSTWPSQTVT 200 CSVAHPASST TVDKKLEPSG PISTINPCPP CKECHKCPAP NLEGGPSVFI 250 FPPNIKDVLM ISLTPKVTCV VVDVSEDDPD VQISWFVNNV EVHTAQTQTH 300 REDYNSTIRV VSTLPIQHQD WMSGKEFKCK VNNKDLPSPI ERTISKIKGL 350 VRAPQVYILP PPAEQLSRKD VSLTCLVVGF NPGDISVEWT SNGHTEENYK 400 DTAPVLDSDG SYFIYSKLNM KTSKWEKTDS FSCNVRHEGL KNYYLKKTIS 450 RSPGK 455 Light chain / Chaîne légère / Cadena ligera DVQMTQTTSS LSASLGDRVT ITCRPSQDIN NYLSWYQQKP DGTVKLLIYY 50 TSRLHSGVPS RFSGSGSGTD YSLTISNLEQ EDFATYFCQQ GNTLPPTFGG 100 GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150 DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200 STSPIVKSFN RNEC 214 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-95 146-201 269-329 375-433 22''-95'' 146''-201'' 269''-329'' 375''-433'' Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (CH1 11-CL 126) 134-214' 134''-214''' Inter-H-H (h 12, h 15, h 18, h 21) 228-228'' 231-231'' 234-234'' 237-237'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 305, 305'' Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados ebopiprantum ebopiprant (3S)-3-[(2S)-3-([1,1'-biphenyl]-4-sulfonyl)-1,3-thiazolidine-2- carboxamido]-3-(4-fluorophenyl)propyl L-valinate ébopiprant L-valinate de (3S)-3-[(2S)-3-([1,1'-biphényl]-4-sulfonyl)-1,3- thiazolidine-2-carboxamido]-3-(4-fluorophényl)propyle ebopiprant L-valinato de (3S)-3-[(2S)-3-([1,1'-bifenil]-4-sulfonil)-1,3- tiazolidina-2-carboxamido]-3-(4-fluorofenil)propilo C30H34FN3O5S2 713 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 efanesoctocogum alfa # efanesoctocog alfa human coagulation factor VIII (FVIII, antihemophilic factor, AHF, procoagulant component) with replaced B-domain (746-1648)- sequence [FVIII domains A1-a1-A2-a2 (1-740) and N-terminal B-domain fragment (741-745), fused via a synthetic 291-peptide linker of 24 repeating 12-peptides (4 types) (746-1033) plus tripeptide ASS (1034-1036) to the FVIII C-terminal (1649-2332)-domains a3-A3-C1- C2 (1037-1720)], fused to a human immunoglobulin G1 C-terminal K>del Fc fragment (1721-1946), (1726-663':1729-666')-bisdisulfide with the TIL3-D3-TIL4 domain-containing fragment 742-1218 of the human von Willebrand factor (1'-477') [(C1077>A336',C1120>A379')-mutant] fused via a synthetic 148-peptide linker of 12 repeating 12-peptides (4 types) plus tetrapeptide GASS (478'-625') to a thrombin cleavable FVIII fragment 712-743 (626'-657') [thrombin-cleavable acidic region 2 plus B3 domain (1-3)-peptide] fused to a human immunoglobulin G1 C-terminal K>del Fc fragment (658'-883'), produced in human embryonic kidney 293 (HEK293) cells, glycoform alfa éfanésoctocog alfa facteur de coagulation VIII humain (FVIII, facteur antihémophilique, AHF, composant procoagulant) dont le domaine B a été remplacé (746-1648) [domaines A1-a1-A2-a2 du FVIII (1-740) et fragment N-terminal du domaine B (741-745), fusionné via un peptide synthétique de 291 acides aminés, fait de 24 peptides de 12 acides aminés chacun, se répétant (4 types) (746-1033), et d'un tripeptide ASS (1034-1036), à la partie C-terminale des domaines a3-A3-C1-C2 1649-2332 du FVIII (1037-1720)], fusionné au fragment Fc C-terminal K>del de l'immunoglobuline G1 humaine (1721-1946), (1726- 663':1729-666') lié par des ponts disulfure au fragment contenant le domaine TIL3-D3-TIL4 du facteur de von Willebrand humain 742-1218 (1'-477') [(C1077>A336',C1120>A379')-mutant] fusionné via un peptide synthétique de 148 acides aminés, fait de 12 peptides de 12 acides aminés chacun, se répétant (4 types), plus un tétrapeptide GASS (478'-625'), à un fragment du FVIII clivable par la thrombine 712-743 (626'-657') [région 2 acide clivable par la thrombine plus le (1-3)- peptide du domaine B3] fusionné au fragment Fc C-terminal K>del de l'immunoglobuline G1 humaine (658'-883'), produit dans des cellules rénales embryonnaires humaines 293 (HEK293), glycoforme alfa efanesoctocog alfa factor de coagulación VIII humano (FVIII, factor antihemofílico, AHF, componente procoagulante) en el dominio B reemplazado (746-1648) [dominios A1-a1-A2-a2 del FVIII (1-740) y fragmento N-terminal del dominio B (741-745), fusionado a través de un péptido sintético de 291 aminoácidos, hecho de 24 péptidos de 12 aminoácidos cada uno, que se repiten (4 tipos) (746-1033), y de un tripéptido ASS (1034- 1036), con la parte C-terminal de los dominios a3-A3-C1-C2 1649- 2332 del FVIII (1037-1720)], fusionado con el fragmento Fc C-terminal K>del de la inmunoglobulina G1 humana (1721-1946), (1726- 663':1729-666') unido por puentes disulfuro con el fragmento que contiene el dominio TIL3-D3-TIL4 del factor de von Willebrand humano 742-1218 (1'-477') [(C1077>A336',C1120>A379')-mutante] fusionado a través de un péptido sintético de 148 aminoácidos, hecho de 12 péptidos de 12 aminoácidos cada uno, que se repiten (4 tipos), además un tetrapéptido GASS (478'-625'), con un fragmento del FVIII escindible por la trombina 712-743 (626'-657') [región 2 ácido escindible por la trombina además el (1-3)-péptido del dominio B3] fusionado con el fragmento Fc C-terminal K>del de la inmunoglobulina G1 humana (658'-883'), producido en las células renales embrionarias humanas 293 (HEK293), glicoforma alfa 714 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 Sequence / Séquence / Secuencia (a) BddFVIII-Fc chain: ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV 80 YDTVVITLKN MASHPVSLHA VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD PLCLTYSYLS 160 HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR 240 SLPGLIGCHR KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL MDLGQFLLFC HISSHQHDGM 320 EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400 APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI 480 TDVRPLYSRR LPKGVKHLKD FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP LLICYKESVD 560 QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL 640 SIGAQTDFLS VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR GMTALLKVSS CDKNTGDYYE 720 DSYEDISAYL LSKNNAIEPR SFSQNGTSES ATPESGPGSE PATSGSETPG TSESATPESG PGSEPATSGS ETPGTSESAT 800 PESGPGTSTE PSEGSAPGSP AGSPTSTEEG TSESATPESG PGSEPATSGS ETPGTSESAT PESGPGSPAG SPTSTEEGSP 880 AGSPTSTEEG TSTEPSEGSA PGTSESATPE SGPGTSESAT PESGPGTSES ATPESGPGSE PATSGSETPG SEPATSGSET 960 PGSPAGSPTS TEEGTSTEPS EGSAPGTSTE PSEGSAPGSE PATSGSETPG TSESATPESG PGTSTEPSEG SAPASSEITR 1040 TTLQSDQEEI DYDDTISVEM KKEDFDIYDE DENQSPRSFQ KKTRHYFIAA VERLWDYGMS SSPHVLRNRA QSGSVPQFKK 1120 VVFQEFTDGS FTQPLYRGEL NEHLGLLGPY IRAEVEDNIM VTFRNQASRP YSFYSSLISY EEDQRQGAEP RKNFVKPNET 1200 KTYFWKVQHH MAPTKDEFDC KAWAYFSDVD LEKDVHSGLI GPLLVCHTNT LNPAHGRQVT VQEFALFFTI FDETKSWYFT 1280 ENMERNCRAP CNIQMEDPTF KENYRFHAIN GYIMDTLPGL VMAQDQRIRW YLLSMGSNEN IHSIHFSGHV FTVRKKEEYK 1360 MALYNLYPGV FETVEMLPSK AGIWRVECLI GEHLHAGMST LFLVYSNKCQ TPLGMASGHI RDFQITASGQ YGQWAPKLAR 1440 LHYSGSINAW STKEPFSWIK VDLLAPMIIH GIKTQGARQK FSSLYISQFI IMYSLDGKKW QTYRGNSTGT LMVFFGNVDS 1520 SGIKHNIFNP PIIARYIRLH PTHYSIRSTL RMELMGCDLN SCSMPLGMES KAISDAQITA SSYFTNMFAT WSPSKARLHL 1600 QGRSNAWRPQ VNNPKEWLQV DFQKTMKVTG VTTQGVKSLL TSMYVKEFLI SSSQDGHQWT LFFQNGKVKV FQGNQDSFTP 1680 VVNSLDPPLL TRYLRIHPQS WVHQIALRME VLGCEAQDLY DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT 1760 CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 1840 GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 1920 NVFSCSVMHE ALHNHYTQKS LSLSPG 1946 (b) vWF fragment-FVIII a2-Fc chain: SLSCRPPMVK LVCPADNLRA EGLECTKTCQ NYDLECMSMG CVSGCLCPPG MVRHENRCVA LERCPCFHQG KEYAPGETVK 80 IGCNTCVCRD RKWNCTDHVC DATCSTIGMA HYLTFDGLKY LFPGECQYVL VQDYCGSNPG TFRILVGNKG CSHPSVKCKK 160 RVTILVEGGE IELFDGEVNV KRPMKDETHF EVVESGRYII LLLGKALSVV WDRHLSISVV LKQTYQEKVC GLCGNFDGIQ 240 NNDLTSSNLQ VEEDPVDFGN SWKVSSQCAD TRKVPLDSSP ATCHNNIMKQ TMVDSSCRIL TSDVFQDCNK LVDPEPYLDV 320 CIYDTCSCES IGDCAAFCDT IAAYAHVCAQ HGKVVTWRTA TLCPQSCEER NLRENGYEAE WRYNSCAPAC QVTCQHPEPL 400 ACPVQCVEGC HAHCPPGKIL DELLQTCVDP EDCPVCEVAG RRFASGKKVT LNPSDPEHCQ ICHCDVVNLT CEACQEPGTS 480 ESATPESGPG SEPATSGSET PGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGTS TEPSEGSAPG SPAGSPTSTE 560 EGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGSP AGSPTSTEEG SPAGSPTSTE EGASSDKNTG DYYEDSYEDI 640 SAYLLSKNNA IEPRSFSDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE 720 VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SRDELTKNQV 800 SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 880 SPG 883 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro (a) 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821, 1867-1925 (Cys-SH: 310, 692, 1388); (b) 4'-45', 13'-41', 25'-36', 29'-64', 47'-58', 66'-88', 83'-100', 86'-95', 104'-233', 126'-268', 135'-230', 151'-158', 283'-326', 297'-321', 308'-348', 328'-334', 338'-363', 367'-410', 386'-406', 390'-402', 394'-433', 414'-427', 436'-464', 459'-474', 462'-471', 698'-758', 804'-862' (a)-(b) intermolecular: 1726-663', 1729-666' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación N41, N239, N1198, N1506, N1797 and N94', N384', N734' O-glycosylation sites / Sites de O-glycosylation / Posiciones de O-glicosilación potentially each Ser and Thr in the linker peptides 746-1036 and 478'-625' Tyr-sulfation sites / Sites de Tyr-sulfation / Posiciones de Tyr-sulfación 346, 718, 719, 723, 729, 1052, 1068 and 632', 633', 637', 643' eflepedocokinum alfa # eflepedocokin alfa human interleukin 22 (IL22, cytokine Zcyto18, IL10- related T-cell-derived inducible factor, IL-TIF) (1-146), fused via a GSG3S(G4S)2 peptide linker (147-162) to a human immunoglobulin G2 C-terminal Fc fragment (163-385), P269>S-mutant S316>A-variant, dimer (165- 165':168-168')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa 715 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 eflépédocokine alfa interleukine 22 humaine (IL22, cytokine Zcyto18, facteur inductible dérivé des lymphocytes T lié à IL10, IL-TIF) (1-146), fusionnée via un peptide liant GSG3S(G4S)2 (147-162) au fragment Fc C-terminal de l'immunoglobuline G2 humaine (163-385), P269>S- mutant S366>A-variant, dimère (165-165':168-168')- bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa eflepedocokina alfa interleukina 22 humana (IL22, citoquina Zcyto18, factor inducible derivado de los linfocitos T relacionado con IL10, IL-TIF) (1-146), fusionada a través de un péptido que se une a GSG3S(G4S)2 (147-162) con el fragmento Fc C-terminal de la inmunoglobulina G2 humana (163-385), P269>S-mutante S366>A-variante, dímero (165-165':168-168')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa Sequence / Séquence / Secuencia APISSHCRLD KSNFQQPYIT NRTFMLAKEA SLADNNTDVR LIGEKLFHGV 50 SMSERCYLMK QVLNFTLEEV LFPQSDRFQP YMQEVVPFLA RLSNRLSTCH 100 IEGDDLHIQR NVQKLKDTVK KLGESGEIKA IGELDLLFMS LRNACIGSGG 150 GSGGGGSGGG GSVECPPCPA PPVAGPSVFL FPPKPKDTLM ISRTPEVTCV 200 VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV VSVLTVVHQD 250 WLNGKEYKCK VSNKGLPASI EKTISKTKGQ PREPQVYTLP PSREEMTKNQ 300 VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV 350 DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 385 Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro intramolecular: 7-99 56-145 199-259 305-363 7'-99' 56'-145' 199'-259' 305'-363' intermolecular: 165-165' 168-168' Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación N21, N35, N64, N235 N21', N35', N64', N235' Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal H CHS K2: 385, 385' efmarodocokinum alfa # efmarodocokin alfa human interleukin 22 (IL22, cytokine Zcyto18, IL10- related T-cell-derived inducible factor, IL-TIF) (1-146), fused to a human immunoglobulin G4 C-terminal Fc fragment (147-377), S158>P, N227>G-mutant; dimer (156-156':159-159')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa efmarodocokine alfa interleukine 22 humaine (IL22, cytokine Zcyto18, facteur inductible dérivé des lymphocytes lié à l'IL10, IL-TIF) (1-146), fusionnée au fragment Fc C-terminal de l'immunoglobuline G4 humaine (147-377), mutant S158>P, N227>G, dimère (156-156':159-159')- bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa efmarodocokina alfa interleukina 22 humana (IL22, citoquina Zcyto18, IL10- relacionada factor inducible derivado de células T, IL- TIF) (1-146), fusionada con el fragmento Fc C-terminal de la inmunoglobulina G4 humana (147-377), mutante S158>P, N227>G, dímero (156-156':159-159')- bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa 716 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 Sequence / Séquence / Secuencia APISSHCRLD KSNFQQPYIT NRTFMLAKEA SLADNNTDVR LIGEKLFHGV 50 SMSERCYLMK QVLNFTLEEV LFPQSDRFQP YMQEVVPFLA RLSNRLSTCH 100 IEGDDLHIQR NVQKLKDTVK KLGESGEIKA IGELDLLFMS LRNACIRVES 150 KYGPPCPPCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED 200 PEVQFNWYVD GVEVHNAKTK PREEQFGSTY RVVSVLTVLH QDWLNGKEYK 250 CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK 300 GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG 350 NVFSCSVMHE ALHNHYTQKS LSLSLGK 377 Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro intramolecular: 7-99 56-145 191-251 297-355 7'-99' 56'-145' 191'-251' 297'-355' intermolecular: 156-156' 159-159' Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación N21, N35, N64, N143 N21', N35', N64', N143' Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal H CHS K2: 377, 377' eliapixantum eliapixant 3-(5-methyl-1,3-thiazol-2-yl)-5-{[(3R)-oxolan-3-yl]oxy}- N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5- yl]ethyl}benzamide éliapixant 3-(5-méthyl-1,3-thiazol-2-yl)-5-{[(3R)-oxolan-3-yl]oxy}- N-{(1R)-1-[2-(trifluorométhyl)pyrimidin-5- yl]éthyl}benzamide eliapixant 3-(5-metil-1,3-tiazol-2-il)-5-{[(3R)-oxolan-3-il]oxi}-N- {(1R)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamida C22H21F3N4O3S elinzanetantum elinzanetant 2-[3,5-bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2- methylphe-nyl)-6-[(7S,9aS)-7- (hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin- 8(1H)-yl]pyridin-3-yl}-N,2-dimethylpropanamide élinzanétant 2-[3,5-bis(trifluorométhyl)phényl]-N-{4-(4-fluoro-2- méthylphényl)-6-[(7S,9aS)-7- (hydroxyméthyl)hexahydropyrazino[2,1-c][1,4]oxazin- 8(1H)-yl]pyridin-3-yl}-N,2-diméthylpropanamide elinzanetant 2-[3,5-bis(trifluorometil)fenil]-N-{4-(4-fluoro-2- metilfenil)-6-[(7S,9aS)-7- (hidroximetil)hexahidropirazino[2,1-c][1,4]oxazin- 8(1H)-il]piridin-3-il}-N,2-dimetilpropanamida 717 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 C33H35F7N4O3 F H3C CH3 CH3 CH3 F3C N H O N N O H CF3 HO N enflicoxibum enflicoxib rac-4-[(5R)-5-(2,4-difluorophenyl)-3-(trifluoromethyl)- 4,5-dihydro-1H-pyrazol-1-yl]benzene-1-sulfonamide enflicoxib rac-4-[(5R)-5-(2,4-difluorophényl)-3-(trifluorométhyl)- 4,5-dihydro-1H-pyrazol-1-yl]benzène-1-sulfonamide enflicoxib rac-4-[(5R)-5-(2,4-difluorofenil)-3-(trifluorometil)-4,5- dihidro-1H-pirazol-1-il]benceno-1-sulfonamida C16H12F5N3O2S esamisulpridum esamisulpride 4-amino-5-(ethanesulfonyl)-N-{[(2S)-1-ethylpyrrolidin- 2-yl]methyl}-2-methoxybenzamide ésamisulpride 4-amino-5-(éthanesulfonyl)-N-{[(2S)-1-éthylpyrrolidin- 2-yl]méthyl}-2-méthoxybenzamide esamisulprida 4-amino-5-(etanosulfonil)-N-{[(2S)-1-etilpirrolidin-2- il]metil}-2-metoxibenzamida C17H27N3O4S exalurenum exaluren 4-O-(2-amino-2,7-dideoxy-D-glycero-α-D-gluco- heptopyranosyl)-5-O-(5-amino-5,6-dideoxy-α-L- talofuranosyl)-2-deoxy-D-streptamine exalurène 4-O-(2-amino-2,7-didésoxy-D-glycéro-α-D-gluco- heptopyranosyl)-5-O-(5-amino-5,6-didésoxy-α-L- talofuranosyl)-2-désoxy-D-streptamine 718 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 exalureno 4-O-(2-amino-2,7-didesoxi-D-glicero-α-D-gluco- heptopiranosil)-5-O-(5-amino-5,6-didesoxi-α-L- talofuranosil)-2-desoxi-D-estreptamina C19H38N4O10 NH2 H2N OH H2N O OH O H HO O OH CH3 HO O OH H H3C NH2 ezabenlimabum # ezabenlimab immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-446) [VH (Homo sapiens IGHV3-23*04 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120)-Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (121-218), hinge 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS K2>del (446)) (121-446)], (134-218')-disulfide with kappa light chain humanized (1'-218') [V-KAPPA (Homo sapiens IGKV3D-11*01 (79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (226-226":229-229")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa ézabenlimab immunoglobuline G4-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-446) [VH (Homo sapiens IGHV3-23*04 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (121-218), charnière 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS K2>del (446)) (121-446)], (134-218')-disulfure avec la chaîne légère kappa humanisée (1'-218') [V-KAPPA (Homo sapiens IGKV3D-11*01 (79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (226-226":229-229")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa ezabenlimab inmunoglobulina G4-kappa, anti-[Homo sapiens PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado; 719 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 cadena pesada gamma4 humanizada (1-446) [VH (Homo sapiens IGHV3-23*04 (86.7%) -(IGHD) - IGHJ4*01 (100%)) [8.8.13] (1-120) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (121-218), bisagra 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341- 445), CHS K2>del (446)) (121-446)], (134-218')- disulfuro con la cadena ligera kappa humanizada (1'- 218') [V-KAPPA (Homo sapiens IGKV3D-11*01 (79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (226-226":229-229")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa ezeprogindum ezeprogind N-[3-(4-{3-[bis(2-methylpropyl)amino]propyl}piperazin- 1-yl)propyl]-1H-benzimidazol-2-amine ézéprogind N-[3-(4-{3-[bis(2-méthylpropyl)amino]propyl}pipérazin- 1-yl)propyl]-1H-benzimidazol-2-amine ezeprogind N-[3-(4-{3-[bis(2-metilpropil)amino]propil}piperazin-1- il)propil]-1H-benzimidazol-2-amino C25H44N6 720 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 feladilimabum # feladilimab immunoglobulin G4-kappa, anti-[Homo sapiens ICOS (inducible T-cell costimulator, activation-inducible lymphocyte immunomediatory molecule, AILIM, CD278)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-448) [VH (Homo sapiens IGHV1-69*04 (84.7%) -(IGHD) -IGHJ6*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219), hinge 1- 12 S10>P (229)(220-231), CH2 L1.2>E (236) (232- 341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfide with kappa light chain humanized (1'-213') [V-KAPPA (Homo sapiens IGKV3-11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa féladilimab immunoglobuline G4-kappa, anti-[Homo sapiens ICOS (costimulateur inductible du lymphocyte T, molécule immunomédiateur lymphocytaire inductible par activation, AILIM, CD278)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-448) [VH (Homo sapiens IGHV1-69*04 (84.7%) -(IGHD) - IGHJ6*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219), charnière 1-12 S10>P (229) (220-231), CH2 L1.2>E (236) (232-341), CH3 (342-446), CHS (447-448)) (122- 448)], (135-213')-disulfure avec la chaîne légère kappa humanisée (1'-213') [V-KAPPA (Homo sapiens IGKV3- 11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (227-227'':230-230'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa feladilimab inmunoglobulina G4-kappa, anti-[Homo sapiens ICOS (coestimulador inducible del linfocito T, molécula inmunomediadora linfocitaria inducible para activación, AILIM, CD278)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-448) [VH (Homo sapiens IGHV1-69*04 (84.7%) -(IGHD) - IGHJ6*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122- 219), bisagra 1-12 S10>P (229) (220-231), CH2 L1.2>E (236) (232-341), CH3 (342-446), CHS (447- 448)) (122-448)], (135-213')-disulfuro con la cadena ligera kappa humanizada (1'-213') [V-KAPPA (Homo sapiens IGKV3-11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (227-227'':230-230'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 721 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 felzartamabum # felzartamab immunoglobulin G1-lambda, anti-[Homo sapiens CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10)], humanized monoclonal antibody; gamma1 heavy chain (1-450) [VH (Homo sapiens IGHV3-30*01 (90.8%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) - Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-212')-disulfide with lambda light chain (1'-213') [V-LAMBDA (Homo sapiens IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-IMGT [6.3.10] (26-31.49-51.88-97) (1'-107') -Homo sapiens IGLC2*01 (100%) (108'-213')]; dimer (229-229'':232-232'')-bisdisulfide, produced in human cell line PER.C6, glycoform alfa felzartamab immunoglobuline G1-lambda, anti-[Homo sapiens CD38 (ADP-ribosyl cyclase 1, ADP-ribose cyclique hydrolase 1, cADPr hydrolase 1, T10)], anticorps monoclonal humanisé ; chaîne lourde gamma1 (1-450) [VH (Homo sapiens IGHV3-30*01 (90.8%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) - Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-212')-disulfure avec la chaîne légère lambda (1'-213') [V-LAMBDA (Homo sapiens IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR- IMGT [6.3.10] (26-31.49-51.88-97) (1'-107') -Homo sapiens IGLC2*01 (100%) (108'-213')]; dimère (229-229'':232-232'')-bisdisulfure, produite dans des cellules humaines PER.C6, glycoforme alfa 722 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 felzartamab inmunoglobulina G1-lambda, anti-[Homo sapiens CD38 (ADP- ribosil ciclasa 1, ADP-ribosa cíclica hidrolasa 1, cADPr hidrolasa 1, T10)], anticuerpo monoclonal humanizado ; cadena pesada gamma1 (1-450) [VH (Homo sapiens IGHV3- 30*01 (90.8%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), bisagra 1-15 (219- 233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-212')-disulfuro con la cadena ligera lambda (1'-213') [V-LAMBDA (Homo sapiens IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-IMGT [6.3.10] (26-31.49-51.88-97) (1'- 107') -Homo sapiens IGLC2*01 (100%) (108'-213')]; dímero (229-229'':232-232'')-bisdisulfuro, producida por células humanas PER.C6, glicoforma alfa Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG LVQPGGSLRL SCAASGFTFS SYYMNWVRQA PGKGLEWVSG 50 ISGDPSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDL 100 PLVYTGFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200 YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400 LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450 Light chain / Chaîne légère / Cadena ligera DIELTQPPSV SVAPGQTARI SCSGDNLRHY YVYWYQQKPG QAPVLVIYGD 50 SKRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQTY TGGASLVFGG 100 GTKLTVLGQP KAAPSVTLFP PSSEELQANK ATLVCLISDF YPGAVTVAWK 150 ADSSPVKAGV ETTTPSKQSN NKYAASSYLS LTPEQWKSHR SYSCQVTHEG 200 STVEKTVAPT ECS 213 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 147-203 264-324 370-428 22''-96'' 147''-203'' 264''-324'' 370''-428'' Intra-L (C23-C104) 22'-87' 135'-194' 22'''-87''' 135'''-194''' Inter-H-L (h 5-CL 126) 223-212' 223''-212''' Inter-H-H (h 11, h 14) 229-229'' 232-232'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 300, 300'' Fucosylated complex bi-antennary PER.C6-type glycans / glycanes de type PER.C6 bi-antennaires complexes fucosylés / glicanos de tipo PER.C6 biantenarios complejos fucosilados filapixantum filapixant 3-{[(2R)-4-methylmorpholin-2-yl]methoxy}-5-(5-methyl-1,3-thiazol- 2-yl)-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide filapixant 3-{[(2R)-4-méthylmorpholin-2-yl]méthoxy}-5-(5-méthyl-1,3-thiazol- 2-yl)-N-{(1R)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}benzamide filapixant 3-{[(2R)-4-metilmorfolin-2-il]metoxi}-5-(5-metil-1,3-tiazol-2-il)-N- {(1R)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamida C24H26F3N5O3S 723 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 fosciclopiroxum fosciclopirox [(6-cyclohexyl-4-methyl-2-oxopyridin-1(2H)- yl)oxy]methyl dihydrogen phosphate fosciclopirox dihydrogénophosphate de [(6-cyclohexyl-4-méthyl-2- oxopyridin-1(2H)-yl)oxy]méthyle fosciclopirox dihidrogenofosfato de [(6-ciclohexil-4-metil-2- oxopiridin-1(2H)-il)oxi]metilo C13H20NO6P H3C HO OH N P O O O O fosifidancitinibum fosifidancitinib (5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5- methylpyrimidin-4-yl]amino}-2-oxo-1,3-benzoxazol- 3(2H)-yl)methyl dihydrogen phosphate fosifidancitinib dihydrogénophosphate de (5-{[2-(4-fluoro-3-methoxy- 5-methylanilino)-5-methylpyrimidin-4-yl]amino}-2-oxo- 1,3-benzoxazol-3(2H)-yl)méthyle fosifidancitinib dihidrogenofosfato de (5-{[2-(4-fluoro-5-metilanilino-3- metoxi)-5-metilpirimidin-4-il]amino}-2-oxo-1,3- benzoxazol-3(2H)-il)metilo C21H21FN5O7P O OH P O O OH N OCH3 O H3C F N N N N CH3 H H genisteinum genistein 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one génistéine 5,7-dihydroxy-3-(4-hydroxyphényl)-4H-chromén-4-one genisteína 5,7-dihidroxi-3-(4-hidroxifenil)-4H-cromen-4-ona C15H10O5 HO O OH O OH 724 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 giloralimabum # giloralimab immunoglobulin G1-kappa, anti-[Homo sapiens CD40 (tumor necrosis factor receptor super family member 5, TNFRSF5)], monoclonal antibody; gamma1 heavy chain (1-442) [VH (Homo sapiens IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) - Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (209) (113-210), hinge 1-15 (211-225), CH2 V37>E (268) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215- 219')-disulfide with kappa light chain (1'-219') [V- KAPPA (Mus musculus IGKV1-122*01 (89.0%) - IGKJ4*01 (91.7%)/Homo sapiens IGKV2-29*02 (86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27- 37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (221-221":224-224")-bisdisulfide giloralimab immunoglobuline G1-kappa, anti-[Homo sapiens CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)], anticorps monoclonal; chaîne lourde gamma1 (1-442) [VH (Homo sapiens IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) - Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (209) (113-210), charnière 1-15 (211- 225), CH2 V37>E (268) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215-219')-disulfure avec la chaîne légère kappa (1'- 219') [V-KAPPA (Mus musculus IGKV1-122*01 (89.0% -IGKJ4*01 (91.7%)/Homo sapiens IGKV2-29*02 (86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27- 37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (221-221":224-224")-bisdisulfure giloralimab inmunoglobulina G1-kappa, anti-[Homo sapiens CD40 (miembro 5 de la superfamilia de los receptores del TNF, TNFRSF5)], anticuerpo monoclonal; cadena pesada gamma1 (1-442) [VH (Homo sapiens IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) - Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (209) (113-210), bisagra 1-15 (211- 225), CH2 V37>E (268) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215-219')-disulfuro con la cadena ligera kappa (1'- 219') [V-KAPPA (Mus musculus IGKV1-122*01 (89.0% -IGKJ4*01 (91.7%)/Homo sapiens IGKV2-29*02 (86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27- 37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (221-221":224-224")-bisdisulfuro 725 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 giredestrantum giredestrant 3-[(1R,3R)-1-(2,6-difluoro-4-{[1-(3- fluoropropyl)azetidin-3-yl]amino}phenyl)-3-methyl- 1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]-2,2- difluoropropan-1-ol girédestrant 3-[(1R,3R)-1-(2,6-difluoro-4-{[1-(3- fluoropropyl)azétidin-3-yl]amino}phényl)-3-méthyl- 1,3,4,9-tétrahydro-2H-pyrido[3,4-b]indol-2-yl]-2,2- difluoropropan-1-ol giredestrant 3-[(1R,3R)-1-(2,6-difluoro-4-{[1-(3-fluoropropil)azetidin- 3-il]amino}fenil)-3-metil-1,3,4,9-tetrahidro-2H- pirido[3,4-b]indol-2-il]-2,2-difluoropropan-1-ol C27H31F5N4O 726 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 icenticaftorum icenticaftor 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2- methylpropyl]-5-(trifluoromethyl)pyridine-2- carboxamide icenticaftor 3-amino-6-méthoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2- méthylpropyl]-5-(trifluorométhyl)pyridine-2- carboxamide icenticaftor 3-amino-6-metoxi-N-[(2S)-3,3,3-trifluoro-2-hidroxi-2- metilpropil]-5-(trifluorometil)piridina-2-carboxamida C12H13F6N3O3 icerguastatum icerguastat (2E)-2-[(2-chlorophenyl)methylidene]hydrazine-1- carboximidamide icerguastat (2E)-2-[(2-chlorophényl)méthylidène]hydrazine-1- carboximidamide icerguastat (2E)-2-[(2-clorofenil)metilideno]hidrazina-1- carboximidamida C8H9ClN4 idetrexedum idetrexed N-(4-{[(6S)-2-(hydroxymethyl)-4-oxo-4,6,7,8- tetrahydro-1H-cyclopenta[g]quinazolin-6-yl](prop-2-yn- 1-yl)amino}benzoyl)-L-γ-glutamyl-D-glutamic acid idétrexed acide N-(4-{[(6S)-2-(hydroxyméthyl)-4-oxo-4,6,7,8- tétrahydro-1H-cyclopenta[g]quinazolin-6-yl](prop-2-yn- 1-yl)amino}benzoyl)-L-γ-glutamyl-D-glutamique idetrexed ácido N-(4-{[(6S)-2-(hidroximetil)-4-oxo-4,6,7,8- tetrahidro-1H-ciclopenta[g]quinazolin-6-il](prop-2-in-1- il)amino}benzoil)-L-γ-glutamil-D-glutámico C32H33N5O10 O CO2H CH N H H N CO2H O N H O N HO CO2H N H 727 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 ifidancitinibum ifidancitinib 5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5- methylpyrimidin-4-yl]amino}-1,3-benzoxazol-2(3H)-one ifidancitinib 5-{[2-(4-fluoro-3-méthoxy-5-méthylanilino)-5- méthylpyrimidin-4-yl]amino}-1,3-benzoxazol-2(3H)-one ifidancitinib 5-{[2-(4-fluoro-5-metilanilino-3-metoxi)-5-metilpirimidin- 4-il]amino}-1,3-benzoxazol-2(3H)-ona C20H18FN5O3 imaradenantum imaradenant 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)- 1,2,4-triazin-3-amine imaradénant 6-(2-chloro-6-méthylpyridin-4-yl)-5-(4-fluorophényl)- 1,2,4-triazin-3-amine imaradenant 6-(2-cloro-6-metilpiridin-4-il)-5-(4-fluorofenil)-1,2,4- triazin-3-amina C15H11ClFN5 N NH2 N Cl N N CH3 F inavolisibum inavolisib (2S)-2-({2-[(4S)-4-(difluoromethyl)-2-oxo-1,3- oxazolidin-3-yl]-5,6-dihydroimidazo[1,2- d][1,4]benzoxazepin-9-yl}amino)propenamide inavolisib (2S)-2-({2-[(4S)-4-(difluorométhyl)-2-oxo-1,3- oxazolidin-3-yl]-5,6-dihydroimidazo[1,2- d][1,4]benzoxazépin-9-yl}amino)propenamide inavolisib (2S)-2-({2-[(4S)-4-(difluorometil)-2-oxo-1,3-oxazolidin- 3-il]-5,6-dihidroimidazo[1,2-d][1,4]benzoxazepin-9- il}amino)propanamida 728 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 C18H19F2N5O4 O O N O N H CH3 N H NH2 N F H F O insulinum efsitorum alfa # insulin efsitora alfa human insulin B-chain (1-30) variant (Y16>E, F25>H, T27>G, P28>G, K29>G, T30>G) fused via a G2SG4 peptide linker (31-37) to human insulin A-chain (38-58) variant (I10>T47, Y14>D51, N21>G58) and via a (G4Q)3G5 peptide linker (59-78) to a human immunoglobulin G2 C-terminal K>del Fc fragment (79-299), dimer (80- 80':83-83')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa insuline efsitora alfa chaîne B de l'insuline humaine (1-30) variant (Y16>E, F25>H, T27>G, P28>G, K29>G, T30>G) fusionné via un peptide liant G2SG4 (31-37) à la chaîne A de l'insuline humaine (38-58) variant (I10>T47, Y14>D51, N21>G58) et via un peptide liant (G4Q)3G5 (59-78) au fragment Fc C-terminal K>del de l'immunoglobuline G2 humaine (IgG2) (79-299), dimère (80-80':83-83')-bisdisulfure, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa insulina efsitora alfa cadena B de la insulina humana (1-30) variante (Y16>E, F25>H, T27>G, P28>G, K29>G, T30>G) fusionada a través de un péptido que se une G2SG4 (31-37) a la cadena A de la insulina humana (38-58) variante (I10>T47, Y14>D51, N21>G58) y a través de un péptido que se une (G4Q)3G5 (59-78) al fragmento Fc C- terminal K>del de la inmunoglobulina G2 humana (IgG2) (79-299), dímero (80-80':83-83')-bisdisulfuro, producido por las células ováricas de hamster chino (CHO), glicoforma alfa Sequence / Séquence / Secuencia FVNQHLCGSH LVEALELVCG ERGFHYGGGG GGSGGGGGIV EQCCTSTCSL 50 DQLENYCGGG GGQGGGGQGG GGQGGGGGEC PPCPAPPVAG PSVFLFPPKP 100 KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN 150 STFRVVSVLT VVHQDWLNGK EYKCKVSNKG LPAPIEKTIS KTKGQPREPQ 200 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM 250 LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 299 Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro B-A 7-44 19-57 B'-A' 7'-44' 19'-57' A-A 43-48 A'-A' 43'-48' Intra-Fc 114-174 220-278 114'-174' 220'-278' Inter-Fc 80-80' 83-83' Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación N150, N150' Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados iptacopanum iptacopan 4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol- 4-yl)methyl]piperidin-2-yl}benzoic acid 729 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 iptacopan acide 4-{(2S,4S)-4-éthoxy-1-[(5-méthoxy-7-méthyl-1H- indol-4-yl)méthyl]pipéridin-2-yl}benzoïque iptacopán ácido 4-{(2S,4S)-4-etoxi-1-[(7-metil-5-metoxi-1H-indol-4- il)metil]piperidin-2-il}benzoico C25H30N2O4 CO2H HN N H3C OCH3 O CH3 isecarosmabum # isecarosmab immunoglobulin single chain VH-VH', anti-[Homo sapiens ADAMTSL5 (ADAMTS like 5, THSD6, thrombospondin type I domain 6)] and anti-[Homo sapiens ALB (albumin, human serum albumin, HSA)], Lama glama and humanized monoclonal antibody, bispecific bivalent; sc VH-VH'(1-275) [Lama glama VH anti-ADAMTSL5 (Lama glama IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01 (100%)/Homo sapiens IGHV3-23*04 (80.2%) -(IGHD) - IGHJ1*01 (100%) [8.8.17] (1-124)) -35-mer (GGGGS)7 linker (125-159)-humanized VH anti-ALB (Homo sapiens IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8] (160-275), produced in Pichia pastoris yeast, non-glycosylated isécarosmab immunoglobuline single chaîne VH-VH', anti-[Homo sapiens ADAMTSL5 (ADAMTS like 5, thrombospondine type I domaine 6)] et anti-[Homo sapiens ALB (albumine, sérum albumine humaine, SAH)], anticorps monoclonal Lama glama et humanisé, bispécifique bivalent; sc VH-VH' (1-275) [Lama glama VH anti-ADAMTSL5 (Lama glama IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01 (100%)/Homo sapiens IGHV3-23*04 (80.2%) -(IGHD) - IGHJ1*01 (100%) [8.8.17] (1-124)) -35-mer (GGGGS)7 linker (125-159)-VH humanisé anti-ALB (Homo sapiens IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8] (160-275), produit dans la levure Pichia pastoris, non-glycosylé isecarosmab inmunoglobulina cadena simple VH-VH', anti-[Homo sapiens ADAMTSL5 (ADAMTS like 5, trombospondina tipo I dominio 6)] y anti-[Homo sapiens ALB (albúmina, sero albúmina humana, SAH)], anticuerpo monoclonal Lama glama y humanizado, biespecífico bivalente; sc VH-VH' (1-275) [Lama glama VH anti-ADAMTSL5 (Lama glama IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01 (100%)/Homo sapiens IGHV3-23*04 (80.2%) -(IGHD) - IGHJ1*01 (100%) [8.8.17] (1-124)) -linker 35-mer (GGGGS)7 (125-159)-VH humanizado anti-ALB (Homo sapiens IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8] (160-275), producido en la levadura Pichia pastoris, no glicosilado 730 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 itacnosertibum itacnosertib N4-([2,2'-bipyridin]-3-yl)-N2-[3-methoxy-4-(4-methylpiperazin-1- yl)phenyl]pyrimidine-2,4-diamine itacnosertib N4-([2,2'-bipyridin]-3-yl)-N2-[3-méthoxy-4-(4-méthylpipérazin-1- yl)phényl]pyrimidine-2,4-diamine itacnosertib N4-([2,2'-bipiridin]-3-il)-N2-[4-(4-metilpiperazin-1-il)-3- metoxifenil]pirimidina-2,4-diamina C26H28N8O itepekimabum # itepekimab immunoglobulin G4-kappa, anti-[Homo sapiens IL33 (interleukin 33, interleukin-1 family member 11, IL1F11, nuclear factor for high endothelial venules, NF-HEV)], monoclonal antibody; gamma4 heavy chain (1-449) [VH (Homo sapiens IGHV3-23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), hinge 1-12 S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa itépékimab immunoglobuline G4-kappa, anti-[Homo sapiens IL33 (interleukine 33, membre 11 de la famille 1 d'interleukines, IL1F11, facteur nucléaire des veinules à haut endothélium, NF-HEV)], anticorps monoclonal; chaîne lourde gamma4 (1-449) ) [VH (Homo sapiens IGHV3- 23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) - Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), charnière 1-12 S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (96.8%) - IGKJ5*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa 731 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 itepekimab inmunoglobulina G4-kappa, anti-[Homo sapiens IL33 (interleukina 33, miembro 11 de la familia 1 de interleukinas, IL1F11, factor nuclear de las vénulas del endotelio alto, NF-HEV)], anticuerpo monoclonal; cadena pesada gamma4 (1-449) ) [VH (Homo sapiens IGHV3-23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), bisagra 1-12 S10>P (230)(221- 232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (Homo sapiens IGKV1- 12*01 (96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa izaflortaucipirum (18F) izaflortaucipir (18F) 2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5- c']dipyridine izaflortaucipir (18F) 2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5- c']dipyridine izaflortaucipir (18F) 2-(2-(18F)fluoropiridin-4-il)-9H-pirrolo[2,3-b:4,5- c']dipiridina 732 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 C15H918FN4 izokibepum # izokibep fusion protein composed of 3 binding domains consisting of three-alpha-helix motifs, each derived from the immunoglobulin (Ig)-binding Z-domain of staphylococcal protein A (SpA), engineered for binding to two homodimer subunits of human interleukin 17A (IL17A) with the two identical N- and C-terminal domains (1-58, 116-173) and to the domain II of human serum albumin (HSA) with the central domain (59-110), connected via a G4S peptide linker (111- 115); [IL17A-binding engineered SpA peptide (1-58)]-[HSA- binding engineered SpA peptide (59-110)]-[G4S linker (111-115)]-[IL17A-binding engineered SpA peptide (116-173] fusion protein; produced in Escherichia coli izokibep protéine de fusion composée de 3 domaines liants, chacun consistant en un motif à 3 hélices alpha dérivé du domaine Z de la protéine staphylococcique A (SpA) se liant à l'immunoglobuline (Ig), mis au point pour se lier aux deux homodimères des sous-unités de l'interleukine 17A humaine (IL17A) avec les deux domaines N- et C-terminaux identiques (1-58, 116- 173), et au domaine II de l'albumine sérique humaine (ASH, HSA) avec le domaine central (59-110), connecté via un peptide liant G4S (111-115); protéine de fusion [peptide SpA mis au point pour se lier à l'IL17A (1-58)]-[peptide SpA mis au point pour se lier au HSA (59-110)]-[peptide liant G4S (111-115)]- [peptide SpA mis au point pour se lier à l'IL17A (116- 173)]; produite par Escherichia coli izokibep proteína de fusión compuesta de 3 dominios de unión, cada uno consistente en un motivo con 3 hélices alfa derivado del dominio Z de la proteína estafilocócica A (SpA) que se une a la inmunoglobulina (Ig), diseñado para unirse a los dos homodímeros de las sub- unidades de la interleukina 17A humana (IL17A) con los dos dominios N- y C-terminal idénticos (1-58, 116- 173), y con el dominio II de la albúmina sérica humana (ASH, HSA) con el dominio central (59-110), conectado a través de un péptido que se une a G4S (111-115); proteína de fusión [péptido SpA diseñado para unirse a la IL17A (1-58)]-[péptido SpA diseñado para unirse al HSA (59-110)]-[G4S linker (111-115)]-[péptido SpA diseñado para unirse a la IL17A (116-173)]; producida por Escherichia coli 733 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 lazuvapagonum lazuvapagon (4S)-N-[(2S)-1-hydroxypropan-2-yl]-methyl-1-[2-methyl-4-(3-methyl- 1H-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-4- carboxamide lazuvapagon (4S)-N-[(2S)-1-hydroxypropan-2-yl]-méthyl-1-[2-méthyl-4-(3-méthyl- 1H-pyrazol-1-yl)benzoyl]-2,3,4,5-tétrahydro-1H-1-benzazépine-4- carboxamide lazuvapagón (4S)-N-[(2S)-1-hidroxipropan-2-il]-metil-1-[2-metil-4-(3-metil-1H- pirazol-1-il)benzoil]-2,3,4,5-tetrahidro-1H-1-benzazepina-4- carboxamida C27H32N4O3 O CH3 H3C OH H3C N N H N N CH3 O lecanemabum # lecanemab immunoglobulin G1-kappa, anti-[Homo sapiens APP (amyloid beta A4 precursor protein) soluble beta-amyloid protofibril], monoclonal antibody; gamma1 heavy chain (1-454) [VH (Homo sapiens IGHV3-48*01 (89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26- 33.51-58.97-113) (1-124) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-219')-disulfide with kappa light chain (1'-219') [V- KAPPA (Mus musculus IGKV1-117*01 (91%) -IGKJ1*02 (90.9%)/Homo sapiens IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')]; dimer (233-233'':236-236'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa lécanémab immunoglobuline G1-kappa, anti-[Homo sapiens APP (protéine précurseur amyloïde bêta A4) protofibrille bêta amyloïde soluble], anticorps monoclonal; chaîne lourde gamma1 (1-454) [VH (Homo sapiens IGHV3-48*01 (89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26- 33.51-58.97-113) (1-124) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-219')-disulfure avec la chaîne légère kappa 734 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (91%) - IGKJ1*02 (90.9%)/Homo sapiens IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'- 219')]; dimère (233-233'':236-236'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa lecanemab inmunoglobulina G1-kappa, anti-[Homo sapiens APP (proteína precusor amiloide beta A4) protofibrilla beta amiloide soluble], anticuerpo monoclonal; cadena pesada gamma1 (1-454) [VH (Homo sapiens IGHV3-48*01 (89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26- 33.51-58.97-113) (1-124) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (91%) -IGKJ1*02 (90.9%)/Homo sapiens IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')]; dímero (233-233'':236-236'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa lorpucitinibum lorpucitinib 2-{1-[trans-4-(cyanomethyl)cyclohexyl]-1,6-dihydroimidazo[4,5- d]pyrrolo[2,3-b]pyridin-2-yl}-N-(2-hydroxy-2-methylpropyl)acetamide lorpucitinib 2-{1-[trans-4-(cyanométhyl)cyclohexyl]-1,6-dihydroimidazo[4,5- d]pyrrolo[2,3-b]pyridin-2-yl}-N-(2-hydroxy-2-méthylpropyl)acetamide lorpucitinib 2-{1-[trans-4-(cianometil)ciclohexil]-1,6-dihidroimidazo[4,5- d]pirrolo[2,3-b]piridin-2-il}-N-(2-hidroxi-2-metilpropil)acetamida 735 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 C22H28N6O2 luvadaxistatum luvadaxistat 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin- 3(2H)-one luvadaxistat 4-hydroxy-6-{2-[4-(trifluorométhyl)phényl]éthyl}pyridazin- 3(2H)-one luvadaxistat 4-hidroxi-6-{2-[4-(trifluorometil)fenil]etil}piridazin-3(2H)-ona C13H11F3N2O2 miptenalimabum # miptenalimab immunoglobulin G4-kappa, anti-[Homo sapiens LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], monoclonal antibody; gamma4 heavy chain (1-448) [VH (Homo sapiens IGHV3- 33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122)- Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), hinge 1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Mus musculus IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/Homo sapiens IGKV1-39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa mipténalimab immunoglobuline G4-kappa, anti-[Homo sapiens LAG3 (activateur 3 des lymhocytes, lymphocyte-activation 3, CD223)], anticorps monoclonal; chaîne lourde gamma4 (1-448) [VH (Homo sapiens IGHV3- 33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122) - Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), charnière 1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (Mus musculus IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/Homo sapiens IGKV1-39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'- 107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228":231-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa 736 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 miptenalimab inmunoglobulina G4-kappa, anti-[Homo sapiens LAG3 (activador 3 de los linfocitos, linfocito-activación 3, CD223)], anticuerpo monoclonal; cadena pesada gamma4 (1-448) [VH (Homo sapiens IGHV3- 33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122) - Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), bisagra 1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (Mus musculus IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/Homo sapiens IGKV1- 39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'- 214')]; dímero (228-228":231-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa mirdametinibum mirdametinib N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4- iodoanilino)benzamide mirdamétinib N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4- iodoanilino)benzamide mirdametinib N-[(2R)-2,3-dihidroxipropoxi]-3,4-difluoro-2-(2-fluoro-4- iodoanilino)benzamide C16H14F3IN2O4 737 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 miromavimabum # miromavimab immunoglobulin G1-kappa, anti-[rabies virus strain ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-II], Mus musculus monoclonal antibody; gamma1 heavy chain Mus musculus (1-445) [VH (Mus musculus IGHV1S130*01 (93.9%) -(IGHD) -IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1- 121) -Mus musculus IGHG1*02 (CH1 Q100>E (199) (122-218), hinge 1-13 (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-214')-disulfide with kappa light chain Mus musculus (1'-214') [V-KAPPA (Mus musculus IGKV6-17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'- 107') -Mus musculus IGKC*01 (100%) (108'-214')]; dimer (225-225":228-228":230-230")-trisdisulfide, produced in mouse myeloma cell line SP2/0-Ag14, glycoform alfa miromavimab immunoglobuline G1-kappa, anti-[épitope G-II de l'ectodomaine de la glycoprotéine de la souche ERA (Evelyn-Rockitniki-Abelseth) du virus de la rage], anticorps monoclonal Mus musculus; chaîne lourde gamma1 Mus musculus (1-445) [VH (Mus musculus IGHV1S130*01 (93.9%) -(IGHD) - IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51- 58.97-110) (1-121) -Mus musculus IGHG1*02 (CH1 Q100>E (199) (122-218), charnière 1-13 (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-214')-disulfure avec la chaîne légère kappa Mus musculus (1'-214') [V-KAPPA (Mus musculus IGKV6- 17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Mus musculus IGKC*01 (100%) (108'-214')]; dimère (225-225":228-228":230-230")-trisdisulfure, produite dans la lignée cellulaire de myélome murin SP2/0-Ag14, glycoforme alfa miromavimab inmunoglobulina G1-kappa, anti-[epítopo G-II del ectodominio de la glicoproteína de la cepa ERA (Evelyn-Rockitniki-Abelseth) del virus de la rabia], anticuerpo monoclonal Mus musculus; cadena pesada gamma1 Mus musculus (1-445) [VH (Mus musculus IGHV1S130*01 (93.9%) -(IGHD) - IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51- 58.97-110) (1-121) -Mus musculus IGHG1*02 (CH1 Q100>E (199) (122-218), bisagra 1-13 (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223- 214')-disulfuro con la cadena ligera kappa Mus musculus (1'-214') [V-KAPPA (Mus musculus IGKV6- 17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Mus musculus IGKC*01 (100%) (108'-214')]; dímero (225-225":228-228":230-230")-trisdisulfuro, producida en la línea celular de mieloma murino SP2/0-Ag14, glicoforma alfa 738 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 modakafuspum alfa # modakafusp alfa immunoglobulin G4-kappa, anti-[human ADP-ribosyl cyclase/cyclic ADP- ribose hydrolase 1 (EC:3.2.2.6) (ADPRC 1/cADRp hydrolase 1, cell surface antigen CD38)], humanized monoclonal antibody, fused at each C-terminus of the heavy chains (1-447, 1''-447'') to attenuated human interferon α-2b (IFNα2b) variant (K23>R470, T106>A553, A145>D592) (448-612, 448''-612''); gamma4 heavy chain humanized fused to IFNα2b (1-612) [VH (Homo sapiens IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120)-Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (121-218), hinge 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), fused to IFNα2b K23>R (470), T106>A (553), A145>D (592) (448-612)],(134-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226":229-229")-bisdisulfide; produced in Chinese hamster ovary (CHO) K1SV cells, glycoform alfa modakafusp alfa immunoglobuline G4-kappa, anti-[ADP-ribosyl cyclase/ ADP cyclique - ribose hydrolase 1 humaine (EC:3.2.2.6) (ADPRC 1/cADRp hydrolase 1, antigène de surface cellulaire CD38)], anticorps monoclonal humain fusionné à chaque partie C-terminale des chaînes lourdes (1-447, 1''-447'') à un variant (K23>R470, T106>A553, A145>D592) de l'interféron α-2b humain (IFNα2b) atténué, (448-612, 448''-612''); chaîne lourde gamma4 humanisée fusionnée à IFNα2b (1-612) [VH (Homo sapiens IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120)-Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (121-218), charnière 1-12 S10>P (228) (219-230), CH2 (231- 340), CH3 (341-445), CHS (446-447))(121-447), fusionné à IFNα2b K23>R (470), T106>A (553), A145>D (592) (448-612)],(134-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50- 52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (226-226":229-229")-bisdisulfure ; produit dans des cellules ovariennes de hamster chinois (CHO) K1SV, glycoforme alfa 739 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 modakafusp alfa inmunoglobulina G4-kappa, anti-[ADP-ribosil ciclasa/ ADP cíclica -ribosa hidrolasa 1 humana (EC:3.2.2.6) (ADPRC 1/cADRp hidrolasa 1, antígeno de superficie celular CD38)], anticuerpo monoclonal humano fusionado a cada parte C-terminal de las cadenas pesadas (1-447, 1''-447'') a una variante (K23>R470, T106>A553, A145>D592) del interferón α-2b humano (IFNα2b) atenuado, (448-612, 448''-612''); cadena pesada gamma4 humanizada fusionada al IFNα2b (1-612) [VH (Homo sapiens IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120)-Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (121-218), bisagra 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341- 445), CHS (446-447))(121-447), fusionado con IFNα2b K23>R (470), T106>A (553), A145>D (592) (448- 612)],(134-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'- 214')]; dímero (226-226":229-229")-bisdisulfuro ; producido en las células ováricas de hamster chino (CHO) K1SV, glicoforma alfa Sequence / Séquence / Secuencia Heavy chain / Chaîne lourde / Cadena pesada (anti-CD38 4-IFN 2b) EVQLVQSGAE VKKPGATVKI SCKVSGYTFT DSVMNWVQQA PGKGLEWMGW 50 IDPEYGRTDV AEKFQGRVTI TADTSTDTAY MELSSLRSED TAVYYCARTK 100 YNSGYGFPYW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200 YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250 LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350 LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGKCDL 450 PQTHSLGSRR TLMLLAQMRR ISLFSCLKDR HDFGFPQEEF GNQFQKAETI 500 PVLHEMIQQI FNLFSTKDSS AAWDETLLDK FYTELYQQLN DLEACVIQGV 550 GVAETPLMKE DSILAVRKYF QRITLYLKEK KYSPCAWEVV RDEIMRSFSL 600 STNLQESLRS KE 612 Light chain / chaîne légère / cadena ligera DIQMTQSPSS LSASVGDRVT ITCKASQNVD SDVDWYQQKP GKAPKLLIYK 50 ASNDYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCMQ SNTHPRTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 147-203 261-321 367-425 22''-96'' 147''-203'' 261''-321'' 367''-425'' Intra-IFN 448-545 476-585 448''-545'' 476''-585'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 134-214' 134''-214''' Inter-H-H 226-226'' 229-229'' Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación H CH2 N84.4: N297, N297'' Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados murizatoclaxum murizatoclax (13S,31R,32R,4R,5E,8S,9R)-6'-chloro-4-methoxy-8,9- dimethyl-4-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin- 2-yl]methyl}-3',4'-dihydro-12H,14H,2'H-spiro[10λ6-thia- 11-aza-1(5,7)-[1,5]benzoxazepina-3(1,2)- cyclobutanacyclododecaphan-5-ene-13,1'- naphthalene]-10,10,12-trione 740 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 murizatoclax (13S,31R,32R,4R,5E,8S,9R)-6'-chloro-4-méthoxy-8,9- diméthyl-4-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin- 2-yl]méthyl}-3',4'-dihydro-12H,14H,2'H-spiro[10λ6-thia- 11-aza-1(5,7)-[1,5]benzoxazépina-3(1,2)- cyclobutanacyclododécaphan-5-ène-13,1'-naphtalène]- 10,10,12-trione murizatoclax (13S,31R,32R,4R,5E,8S,9R)-6'-cloro-4-metoxi-8,9- dimetil-4-{[(9aR)-octahidro-2H-pirido[1,2-a]pirazin-2- il]metil}-3',4'-dihidro-12H,14H,2'H-spiro[10λ6-thia-11- aza-1(5,7)-[1,5]benzoxazepina-3(1,2)- ciclobutanaciclododecafan-5-eno-13,1'-naftaleno]- 10,10,12-triona C42H57ClN4O5S nadunolimabum # nadunolimab immunoglobulin G1-kappa, anti-[Homo sapiens IL1RAP (interleukin-1 receptor accessory protein)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-446) [VH (Homo sapiens IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118- 215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226'':229-229'')- bisdisulfide nadunolimab immunoglobulin G1-kappa, anti-[Homo sapiens IL1RAP (interleukin-1 receptor accessory protein)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-446) [VH (Homo sapiens IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118- 215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226'':229-229'')- bisdisulfide 741 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 nadunolimab immunoglobulin G1-kappa, anti-[Homo sapiens IL1RAP (interleukin-1 receptor accessory protein)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-446) [VH (Homo sapiens IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118- 215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226'':229-229'')- bisdisulfide Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGSSVKV SCKASGYAFT SSWMNWVRQA PGQGLEWMGR 50 IYPGDGNTHY AQKFQGRVTL TADKSTSTAY MELSSLRSED TAVYYCGEGY 100 LDPMDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350 LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG 446 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCQASQGIN NYLNWYQQKP GKAPKLLIHY 50 TSGLHAGVPS RFSGSGSGTD YTLTISSLEP EDVATYYCQQ YSILPWTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfur Intra-H (C23-C104) 22-96 144-200 261-321 367-425 22''-96'' 144''-200'' 261''-321'' 367''-425'' Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) 220-214' 220''-214''' Inter-H-H (h 11, h 14) 226-226" 229-229" N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 297, 297' Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennai complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados. nesolicaftorum nesolicaftor N-(trans-3-{5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2- yl}cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide nésolicaftor N-(trans-3-{5-[(1R)-1-hydroxyéthyl]-1,3,4-oxadiazol-2- yl}cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide nesolicaftor 3-fenil-N-(trans-3-{5-[(1R)-1-hidroxietil]-1,3,4- oxadiazol-2-il}ciclobutil)-1,2-oxazolo-5-carboxamida C18H18N4O4 742 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 nipocalimabum # nipocalimab immunoglobulin G1-lambda, anti-[Homo sapiens FCGRT (Fc fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-445) [VH (Homo sapiens IGHV3-23*01 (90.8%) -(IGHD) - IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97- 105) (1-116) -Homo sapiens IGHG1*03 G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1 R120>K (213) (117-214), hinge 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-215')- disulfide with lambda light chain Homo sapiens (1'- 216') [V-LAMBDA (Homo sapiens IGLV2-23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26- 34.52-54.91-100) (1'-110') -Homo sapiens IGLC3*03 (100%) (111'-216')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa nipocalimab immunoglobuline G1-lambda, anti-[Homo sapiens FCGRT (transporteur et récepteur du fragment Fc des IgG, récepteur Fc néonatal, FcRn, chaîne alpha transmembranaire du récepteur néonatal)], anticorps monoclonal Homo sapiens; chaîne lourde gamma1 Homo sapiens (1-445) [VH (Homo sapiens IGHV3-23*01 (90.8%) -(IGHD) - IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97- 105) (1-116) -Homo sapiens IGHG1*03 G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1 R120>K (213) (117-214), charnière 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219- 215')-disulfure avec la chaîne légère lambda Homo sapiens (1'-216') [V-LAMBDA (Homo sapiens IGLV2- 23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26-34.52-54.91-100) (1'-110') -Homo sapiens IGLC3*03 (100%) (111'-216')]; dimère (225-225'':228-228'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa nipocalimab inmunoglobulina G1-lambda, anti-[Homo sapiens FCGRT (transportador y receptor del fragmento Fc de las IgG, receptor Fc neonatal, FcRn, cadena alfa transmembranaria del receptor neonatal)], anticuerpo monoclonal Homo sapiens; cadena pesada gamma1 Homo sapiens (1-445) [VH (Homo sapiens IGHV3-23*01 (90.8%) -(IGHD) - IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97- 105) (1-116) -Homo sapiens IGHG1*03 G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1 R120>K (213) (117-214), bisagra 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-215')- disulfuro con la cadena ligera lambda Homo sapiens (1'-216') [V-LAMBDA (Homo sapiens IGLV2-23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26- 34.52-54.91-100) (1'-110') -Homo sapiens IGLC3*03 (100%) (111'-216')]; dímero (225-225'':228-228'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa 743 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 Heavy chain / Chaîne lourde / Cadena pesada EVQLLESGGG LVQPGGSLRL SCAASGFTFS TYAMGWVRQA PGKGLEWVSS 50 IGASGSQTRY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARLA 100 IGDSYWGQGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150 EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200 VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250 MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYASTYR 300 VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG 445 Light chain / Chaîne légère / Cadena ligera QSALTQPASV SGSPGQSITI SCTGTGSDVG SYNLVSWYQQ HPGKAPKLMI 50 YGDSERPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYAGSGIYV 100 FGTGTKVTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150 AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHKSYSCQVT 200 HEGSTVEKTV APTECS 216 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 143-199 260-320 366-424 22''-96'' 143''-199'' 260''-320'' 366''-424'' Intra-L (C23-C104) 22'-90' 138'-197' 22'''-90''' 138'''-197''' Inter-H-L (h 5-CL 126) 219-215' 219''-215''' Inter-H-H (h 11, h 14) 225-225'' 228-228'' No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación H CH2 N84.4>A: 296, 296'' olverembatinibum olverembatinib 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3- (trifluoromethyl)phenyl}-3-[(1H-pyrazolo[3,4-b]pyridin- 5-yl)ethynyl]benzamide olvérembatinib 4-méthyl-N-{4-[(4-méthylpipérazin-1-yl)méthyl]-3- (trifluorométhyl)phényl}-3-[(1H-pyrazolo[3,4-b]pyridin- 5-yl)éthynyl]benzamide olverembatinib 4-metil-N-{4-[(4-metilpiperazin-1-il)metil]-3- (trifluorometil)fenil}-3-[(1H-pirazolo[3,4-b]piridin-5- il)etinil]benzamide C29H27F3N6O olvimulogenum nanivacirepvecum # olvimulogene nanivacirepvec A recombinant replication-competent oncolytic vaccinia virus (strain LIVP) comprising the genes encoding a Renilla luciferase - green fluorescent protein fusion protein (ruc-gfp) and enzymes beta-galactosidase (lacZ) and beta-glucuronidase (gusA), inserted into the F14.5L, J2R (thymidine kinase) and A56R (hemagglutinin) loci, respectively. Expression of the three proteins is driven by a synthetic early/late promoter (pSEL), a vaccinia virus strain Western Reserve early/late p7.5 promoter and a vaccinia virus strain Western Reserve late p11 promoter, respectively. A human transferrin receptor gene has also been inserted in the J2R locus but is not expressed. 744 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 olvimulogène nanivacirépvec virus de la vaccine recombinant répliquant oncolytique (souche LIVP) contenant les gènes codant pour une protéine de fusion luciférase de Renilla - protéine fluorescente verte (ruc-gfp) et des enzymes galactosidase bêta (lacZ) et glucuronidase bêta (gusA), insérés dans les loci F14.5L, J2R (thymidine kinase) and A56R (hémagglutinine), respectivement. L'expression des trois protéines est sous le contrôle d'un promoteur synthétique précoce/tardif (pSEL), d'un promoteur p7.5 précoce/tardif du virus de la vaccine souche Western Reserve et d'un promoteur p11 tardif du virus de la vaccine souche Western Reserve, respectivement. Un gène du récepteur de transférine humain a aussi été inséré dans le locus J2R mais n'est pas exprimé. olvimulogén nanivacirepvec Un virus vaccinia recombinante (cepa LIVP) competente para replicación, oncolítico, que contiene los genes que codifican para una proteína de fusión de la luciferasa de Renilla y la proteína fluorescente verde (ruc-gfp) y para las enzimas beta-galactosidasa (LacZ) y beta-glucuronidasa (gusA), insertados en los loci F14.5L, J2R (timidina quinasea) y A56R (hemaglutinina), respectivamente. La expresión de las tres proteínas está dirigida por un promotor temprano/tardío sintético (pSEL), un promotor p7.5 precoz/tardío de la cepa Western Reserve del virus vaccinia y un promotor p11 tardío de la cepa Western Reserve del virus vaccinia, respectivamente. Se ha insertado también un gen del receptor de transferrina humano en el locus J2R pero éste no se expresa. omfiloctocogum alfa # omfiloctocog alfa human coagulation factor VIII (FVIII, antihemophilic factor, AHF, procoagulant component) with deleted B- domain (746-1639)-sequence: single-chain recombinant FVIII composed of domains A1-a1-A2-a2 (1-740), the B-domain N- and C-terminal fragments (741-745) and 1640-1648 (746-754) and domains a3-A3-C1-C2 1649-2332 (755-1438), produced in Chinese hamster ovary (CHO) cells, glycoform alfa omfiloctocog alfa facteur de coagulation VIII humain (FVIII, facteur antihémophilique, AHF, composant procoagulant) dont le domaine B a été supprimé (746-1639): chaîne unique du FVIII humain recombinant composé des domaines A1-a1-A2-a2 (1-740), des fragments N- and C-terminaux du domaine B (741-745) et 1640- 1648 (746-754) et des domaines a3-A3-C1-C2 1649- 2332 (755-1438), produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa omfiloctocog alfa factor de coagulación VIII humano (FVIII, factor antihemofílico, AHF, componente procoagulante) con el dominio B que ha sido suprimido (746-1639): 745 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 cadena única del FVIII humano recombinante compuesto de los dominios A1-a1-A2-a2 (1-740), de los fragmentos N- y C-terminal del dominio B (741- 745) y 1640-1648 (746-754) y de los dominios a3-A3- C1-C2 1649-2332 (755-1438), producido por las células ováricas de hamster chino (CHO), glicoforma alfa Sequence / Séquence / Secuencia ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50 FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100 VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150 PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200 VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250 KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300 MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350 TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400 APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450 PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500 FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550 LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600 VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650 VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700 GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNPPVLK 750 RHQREITRTT LQSDQEEIDY DDTISVEMKK EDFDIYDEDE NQSPRSFQKK 800 TRHYFIAAVE RLWDYGMSSS PHVLRNRAQS GSVPQFKKVV FQEFTDGSFT 850 QPLYRGELNE HLGLLGPYIR AEVEDNIMVT FRNQASRPYS FYSSLISYEE 900 DQRQGAEPRK NFVKPNETKT YFWKVQHHMA PTKDEFDCKA WAYFSDVDLE 950 KDVHSGLIGP LLVCHTNTLN PAHGRQVTVQ EFALFFTIFD ETKSWYFTEN 1000 MERNCRAPCN IQMEDPTFKE NYRFHAINGY IMDTLPGLVM AQDQRIRWYL 1050 LSMGSNENIH SIHFSGHVFT VRKKEEYKMA LYNLYPGVFE TVEMLPSKAG 1100 IWRVECLIGE HLHAGMSTLF LVYSNKCQTP LGMASGHIRD FQITASGQYG 1150 QWAPKLARLH YSGSINAWST KEPFSWIKVD LLAPMIIHGI KTQGARQKFS 1200 SLYISQFIIM YSLDGKKWQT YRGNSTGTLM VFFGNVDSSG IKHNIFNPPI 1250 IARYIRLHPT HYSIRSTLRM ELMGCDLNSC SMPLGMESKA ISDAQITASS 1300 YFTNMFATWS PSKARLHLQG RSNAWRPQVN NPKEWLQVDF QKTMKVTGVT 1350 TQGVKSLLTS MYVKEFLISS SQDGHQWTLF FQNGKVKVFQ GNQDSFTPVV 1400 NSLDPPLLTR YLRIHPQSWV HQIALRMEVL GCEAQDLY 1438 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 153-179, 248-329, 528-554, 630-711, 938-964, 1005-1009, 1127-1275, 1280-1432 (Cys-SH: 310, 692, 1106) Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación N41, N239, N916, N1224 Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados Tyr-sulfation sites / Sites de Tyr-sulfation / Posiciones de Tyr-sulfación 346, 718, 719, 723, 770, 786 onatasertibum onatasertib 7-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-(trans-4- methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin- 2(1H)-one onatasertib 7-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-(trans-4- méthoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin- 2(1H)-one onatasertib 7-[6-(2-hidroxipropan-2-il)piridin-3-il]-1-(trans-4- metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pirazin- 2(1H)-ona C21H27N5O3 746 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 ongericimabum # ongericimab immunoglobulin G4-kappa, anti-[Homo sapiens PCSK9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)], humanized monoclonal antibody; gamma4 heavy chain (1-438) [VH (Homo sapiens IGHV4-59*01 (79.2%) -(IGHD) -IGHJ1*01 (100%)) CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) - Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (112- 209), hinge 1-12 S10>P (219) (210-221), CH2 (222- 331), CH3 (332-436), CHS (437-438)) (112-438)], (125-213')-disulfide with kappa light chain (1'-213') [V- KAPPA (Homo sapiens IGKV1-33*01 (85.1%) - IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89- 96) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (217-217'':220-220'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa ongéricimab immunoglobuline G4-kappa, anti-[Homo sapiens PCSK9 (proprotéine convertase subtilisine/kexine type 9, convertase 1 régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine convertase 9, PC9)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-438) [VH (Homo sapiens IGHV4-59*01 (79.2%) -(IGHD) - IGHJ1*01 (100%)) CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) - Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (112- 209), charnière 1-12 S10>P (219) (210-221), CH2 (222-331), CH3 (332-436), CHS (437-438)) (112-438)], (125-213')-disulfure avec la chaîne légère kappa (1'- 213') [V-KAPPA (Homo sapiens IGKV1-33*01 (85.1%) -IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50- 52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (217-217'':220-220'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa ongericimab inmunoglobulina G4-kappa, anti-[Homo sapiens PCSK9 (proproteína convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la apoptosa neuronal, NARC1, NARC-1, proproteína convertasa 9, PC9)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-438) [VH (Homo sapiens IGHV4-59*01 (79.2%) -(IGHD) - IGHJ1*01 (100%)) CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) - Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (112- 209), bisagra 1-12 S10>P (219) (210-221), CH2 (222- 331), CH3 (332-436), CHS (437-438)) (112-438)], (125-213')-disulfuro con la cadena ligera kappa (1'- 213') [V-KAPPA (Homo sapiens IGKV1-33*01 (85.1%) -IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50- 52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (217-217'':220-220'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa 747 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 ontorpaceptum # ontorpacept human signal-regulatory protein alpha (SIRPα, tyrosine-protein phosphatase non-receptor type substrate 1, inhibitory receptor SHPS-1), (L14>S, T20>S, T22>I, R24>H, A27>V, G45>A, D65>E, L66>S, N70>E, R77>S, G79>S, D101>del, V102>T101)-variant, N- terminal (1-118)-fragment [binding domain for CD47 (inhibitor of phagocytosis by macrophages)], fused to a human immunoglobulin G1 C-terminal Fc fragment (119-345), dimer (124-124':127-127')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa ontorpacept protéine régulatoire de signal alpha, humaine (SIRPα, substrat 1 de type non-récepteur de la tyrosine- protéine phosphatase, récepteur inhibitoire SHPS-1), (L14>S, T20>S, T22>I, R24>H, A27>V, G45>A, D65>E, L66>S, N70>E, R77>S, G79>S, D101>del, V102>T101)- variant, fragment N-terminal (1-118) [domaine se liant au CD47 (inhibiteur de la phagocytose par les macrophages)], fusionnée au fragment Fc C-terminal de l'immunoglobuline G1 (119-345), dimère (124- 124':127-127')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa ontorpacept proteína reguladora de señal alfa, humana (SIRPα, sustrato 1 de tipo no-receptor de la tirosina-proteína fosfatasa, receptor inhibidor SHPS-1), (L14>S, T20>S, T22>I, R24>H, A27>V, G45>A, D65>E, L66>S, N70>E, R77>S, G79>S, D101>del, V102>T101)-variante, fragmento N-terminal (1-118) [dominio unido al CD47 (inhibidor de la fagocitosis por los macrófagos)], fusionado con el fragmento Fc C-terminal de la inmunoglobulina G1 (119-345), dímero (124-124':127-127')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa 748 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 Sequence / Séquence / Secuencia EEELQVIQPD KSVSVAAGES AILHCTVTSL IPVGPIQWFR GAGPARELIY 50 NQKEGHFPRV TTVSESTKRE NMDFSISISN ITPADAGTYY CVKFRKGSPD 100 TEFKSGAGTE LSVRAKPSDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 150 ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 200 VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 250 PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 300 SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 345 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro intra-chain 25-91 159-219 265-323 25'-91' 159'-219' 265'-323' inter-chain: 124-124' 127-127' Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación N80, N195, N80', N195' Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal H CHS K2: 345, 345' opucolimabum # opucolimab immunoglobulin G1-lambda, anti-[Homo sapiens CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], monoclonal antibody; gamma1 heavy chain (1-453) [VH (Homo sapiens IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%)) [8.8.16] (1-123) -Homo sapiens IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124- 221), hinge 1-15 (222-236), CH2 N84.4>A (303) (237- 346), CH3 E12 (362), M14 (364) (347-451), CHS (452- 453)) (124-453)], (226-214')-disulfide with lambda light chain humanized (1'-214') [V-LAMBDA (Homo sapiens IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'- 109') -Homo sapiens IGLC3*03 (98.1%) K119>R (207), P123>L (211) (110'-214')]; dimer (232-232":235-235")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells opucolimab immunoglobuline G1-lambda, anti-[Homo sapiens CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], anticorps monoclonal; chaîne lourde gamma1 (1-453) [VH (Homo sapiens IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%)) [8.8.16] (1-123) -Homo sapiens IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124- 221), charnière 1-15 (222-236), CH2 N84.4>A (303) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère (1'-214') [V-LAMBDA (Homo sapiens IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'- 109') -Homo sapiens IGLC3*03 (98.1%) K119>R (207), P123>L (211) (110'-214')]; dimère (232-232":235-235")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) opucolimab inmunoglobulina G1-lambda, anti-[Homo sapiens CD274 (ligando 1 de muerte programada, PDL1, PD- L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal; 749 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 cadena pesada gamma1 (1-453) [VH (Homo sapiens IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%)) [8.8.16] (1-123) -Homo sapiens IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124- 221), bisagra 1-15 (222-236), CH2 N84.4>A (303) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera lambda (1'-214') [V-LAMBDA (Homo sapiens IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'-109') -Homo sapiens IGLC3*03 (98.1%) K119>R (207), P123>L (211) (110'-214')]; dímero (232-232":235-235")-bisdisulfuro, producido por células ováricas de hamster chino (CHO) Heavy chain / Chaîne lourde / Cadena pesada EVQLVQSGGG LVKPGGSLRL SCAASGFTFS SYTMNWVRQA PGKGLEWVSS 50 ISSGSDYLYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARNE 100 LRWYPQAGAF DRWGQGTMVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150 LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200 TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250 PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300 QYASTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350 EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400 PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450 PGK 453 Light chain / Chaîne légère / Cadena ligera QSVVTQPPSM SAAPGQRVTI SCSGSSSYIE SSYVGWYQQL PGTAPRLLIY 50 DDDMRPSGIP DRFSGSKSGT SATLAITGLQ TGDEADYYCE IWRSGLGGVF 100 GGGTKLTVLS QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150 WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HKSYSCQVTH 200 EGSTVERTVA LTEC 214 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 150-206 267-327 373-431 22''-96'' 150''-206'' 267''-327'' 373''-431'' Intra-L (C23-C104) 22'-89' 137'-196' 22'''-89''' 137'''-196''' Inter-H-L (h 5-CL 126) 226-214' 226''-214''' Inter-H-H (h 11, h 14) 232-232'' 235-235'' No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación: H CH2 N84.4>A: 303, 303'' C-terminal lysine clipping: H CHS K2: 453, 453'' orelabrutinibum orelabrutinib 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-4- yl]pyridine-3-carboxamide orélabrutinib 2-(4-phénoxyphényl)-6-[1-(prop-2-énoyl)pipéridin-4- yl]pyridine-3-carboxamide orelabrutinib 2-(4-fenoxifenil)-6-[1-(prop-2-enoil)piperidin-4- il]piridina-3-carboxamida C26H25N3O3 750 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 orvacabtagenum autoleucelum # orvacabtagene autoleucel autologous CD4+ and CD8+ T lymphocytes obtained from peripheral blood mononuclear cells (PBMC), transduced ex vivo with a replication-incompetent, self- inactivating (SIN) lentiviral vector, encoding a chimeric antigen receptor (CAR) consisting of the human B cell maturation antigen (BCMA)-specific scFv, an lgG4- CH2-CH3 hinge region, CD28 transmembrane domain, CD137 (4-1BB) co-stimulatory domain and CD3 zeta signalling domain, under the control of a hybrid Elongation Factor 1 alpha (EF1α) / Human T cell Leukemia Virus (HTLV) R element promoter. The vector also encodes a truncated human epidermal growth factor receptor (EGFRt) that is expressed separately from the CAR on the cell surface. orvacabtagène autoleucel lymphocytes T autologues CD4+ and CD8+ obtenus de cellules mononuclées du sang périphérique (PBMC), transduits ex vivo avec un vecteur lentiviral non-répliquant, auto-inactivant (SIN) codant pour un récepteur d'antigène chimérique (CAR) ciblant l'antigène spécifique du scFv de maturation des lymphocytes B (BCMA) humain, une région charnière lgG4-CH2-CH3, un domaine transmembranaire du CD28, un domaine co-stimulateur du CD137 (4-1BB), et un domaine de signalisation CD3 zêta, sous le contrôle d'un promoteur hybride du facteur d'élongation 1-alpha humain (EF1α) / élément R du virus du lymphome humain à cellules T (HTLV). Le vecteur exprime un récepteur du facteur de croissance des cellules épidermiques humain tronqué (EGFRt) qui est exprimé séparément du CAR à la surface de la cellule. orvacabtagén autoleucel linfocitos T CD4+ y CD8+ autólogos obtenidos de células mononucleares de sangre periférica, transducidos con un vector lentiviral auto inactivante e incompetente para replicación, que codifica un receptor para antígenos quimérico (CAR) consistente en un ssFv específico del antígeno de maduración de linfocitos B humano (BCMA), una región bisagra IgG4- CH2-CH3, un dominio transmembrana de CD28, un domino coestimulador de CD137 (4-1BB) y un dominio de señalización de CD3 zeta, bajo el control de un promotor híbrido del Factor de Elongación 1 alfa (EF1a) / elemento R del virus de la leucemia de células T (HTLV) humana. El vector también codifica para una forma truncada del receptor del factor de crecimiento epidérmico (EGFRt) humano que se expresa separado del CAR en la superficie celular. osoresnontrinum osoresnontrine 1-(oxan-4-yl)-6-[(pyridin-2-yl)methyl]-1,5-dihydro-4H- pyrazolo[3,4-d]pyrimidin-4-one osoresnontrine 1-(oxan-4-yl)-6-[(pyridin-2-yl)méthyl]-1,5-dihydro-4H- pyrazolo[3,4-d]pyrimidin-4-one osoresnontrina 1-(oxan-4-il)-6-[(piridin-2-il)metil]-1,5-dihidro-4H- pirazolo[3,4-d]pirimidin-4-ona 751 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 C16H17N5O2 O N N N N N H O pelacarsenum pelacarsen all-P-ambo-5'-O-(28-[(2-acetamido-2-deoxy-β-D- galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acetamido- 2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3- oxopropoxy]methyl}-1-hydroxy-1,10,14,21-tetraoxo- 2,18-dioxa-9,15,22-triaza-1λ5-phosphaoctacosan-1-yl)- 2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')- 2'-O-(2-methoxyethyl)guanylyl-(3'→5')-2'-O-(2- methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2- methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2- methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-deoxy-5- methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl- (3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl- (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P- thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy- P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P- thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-(2- methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2- methoxyethyl)guanylyl-(3'→5')-2'-O-(2-methoxyethyl)- 5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)- 5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)- 5-methylcytidine pélacarsen tout-P-ambo-5'-O-(28-[(2-acétamido-2-désoxy-β-D- galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acétamido- 2-désoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3- oxopropoxy]méthyl}-1-hydroxy-1,10,14,21-tétraoxo- 2,18-dioxa-9,15,22-triaza-1λ5-phosphaoctacosan-1-yl)- 2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')- 2'-O-(2-méthoxyéthyl)guanylyl-(3'→5')-2'-O-(2- méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-O-(2- méthoxyéthyl)-5-méthyluridylyl-(3'→5')-2'-O-(2- méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-désoxy-5- méthyl-P-thiocytidylyl-(3'→5')-2'-désoxy-P- thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P- thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanylyl- (3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-P- thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanylyl- (3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P- thiothymidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5- méthyluridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)guanylyl- (3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl- (3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl- (3'→5')-2'-O-(2-méthoxyéthyl)-5-méthylcytidine 752 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 pelacarsén todo-P-ambo-5'-O-(28-[(2-acetamido-2-desoxi-β-D- galactopiranosil)oxi]-16,16-bis{[3-({6-[(2-acetamido-2- desoxi-β-D-galactopiranosil)oxi]hexil}amino)-3- oxopropoxi]metil}-1-hidroxi-1,10,14,21-tetraoxo-2,18- dioxa-9,15,22-triaza-1λ5-fosfaoctacosan-1-il)-2'-O-(2- metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2- metoxietil)guanilil-(3'→5')-2'-O-(2-metoxietil)-5- metilcitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridilil- (3'→5')-2'-O-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'- desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P- tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil- (3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P- tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P- tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')- P-tiotimidilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridilil- (3'→5')-2'-O-(2-metoxietil)guanilil-(3'→5')-2'-O-(2- metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2- metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2- metoxietil)-5-metilcitidina C296H439N71O163P20S13 pelcitoclaxum pelcitoclax (3-{[(10R)-14-chloro-35-fluoro-24-(methanesulfonyl)-25- methyl-7,7-dioxo-10-[(phenylsulfanyl)methyl]-21- (propan-2-yl)-83-(trifluoromethanesulfonyl)-21H-7λ6- thia-6,9-diaza-4(1,4)-piperazina-13(1)-piperidina- 2(2,3)-pyrrola-1(1),3(1,3),5,8(1,4)- tetrabenzenatridecaphane-134- carbonyl]oxy}propyl)phosphonic acid pelcitoclax acide (3-{[(10R)-14-chloro-35-fluoro-24- (méthanesulfonyl)-25-méthyl-7,7-dioxo-10- [(phénylsulfanyl)méthyl]-21-(propan-2-yl)-83- (trifluorométhanesulfonyl)-21H-7λ6-thia-6,9-diaza- 4(1,4)-pipérazina-13(1)-pipéridina-2(2,3)-pyrrola- 1(1),3(1,3),5,8(1,4)-tétrabenzenatridécaphane-134- carbonyl]oxy}propyl)phosphonique pelcitoclax ácido (3-{[(10R)-14-cloro-10-[(fenilsulfanil)metil]-35- fluoro-24-(metanosulfonil)-25-metil-7,7-dioxo-21- (propan-2-il)-83-(trifluorometanosulfonil)-21H-7λ6-tia- 6,9-diaza-4(1,4)-piperazina-13(1)-piperidina-2(2,3)- pirrola-1(1),3(1,3),5,8(1,4)-tetrabencenatridecafano- 134-carbonil]oxi}propil)fosfónico 753 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 C57H66ClF4N6O11PS4 H O N S O N F N CF3 S NH O O S Cl O O S CH3 OH N N O H3C P OH CH3 CH3 O O pexopiprantum pexopiprant ({8-chloro-3-[(4-chlorophenyl)methyl]-4- (difluoromethoxy)-2-ethylquinolin-5-yl}oxy)acetic acid pexopiprant acide ({8-chloro-3-[(4-chlorophényl)méthyl]-4- (difluorométhoxy)-2-éthylquinolin-5-yl}oxy)acétique pexopiprant ácido ({8-cloro-3-[(4-clorofenil)metil]-4-(difluorometoxi)- 2-etilquinolin-5-il}oxi)acético C21H17Cl2F2NO4 F F O O CO2H Cl N CH3 Cl pimurutamabum # pimurutamab immunoglobulin G1-kappa, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine- protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01 (85.7%)) [8.7.13] (1-119) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa pimurutamab immunoglobuline G1-kappa, anti-[Homo sapiens EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB- 1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé; 754 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 chaîne lourde gamma1 humanisée (1-449) [VH (Homo sapiens IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01 (85.7%)) [8.7.13] (1-119) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), charnière 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120- 449)], (222-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (Homo sapiens IGKV3- 11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') - Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228":231-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa pimurutamab inmunoglobulina G1-kappa, anti-[Homo sapiens EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-449) [VH (Homo sapiens IGHV3-48*03 (78.6%) -(IGHD) - IGHJ3*01 (85.7%)) [8.7.13] (1-119) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), bisagra 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'- 107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228":231-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 755 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 posenacaftorum posenacaftor 8-methyl-2-(3-methyl-1-benzofuran-2-yl)-5-[(1R)-1-(oxan-4- yl)ethoxy]quinoline-4-carboxylic acid posénacaftor acide 8-méthyl-2-(3-méthyl-1-benzofuran-2-yl)-5-[(1R)-1- (oxan-4-yl)éthoxy]quinoléine-4-carboxylique posenacaftor ácido 8-metil-2-(3-metil-1-benzofuran-2-il)-5-[(1R)-1-(oxan-4- il)etoxi]quinolina-4-carboxílico C27H27NO5 pudexacianinii chloridum pudexacianinium chloride 3-(3-{[3-(cyclomaltoheptaos-2I-O-yl)propyl]amino}-3- oxopropyl)-2-{(1E)-2-[(3E)-3-{(2E)-2-[3-(3-{[3- (cyclomaltoheptaos-2I-O-yl)propyl]amino}-3-oxopropyl)-1,1- dimethyl-1,3-dihydro-2H-benzo[e]indol-2-ylidene]ethylidene}- 2-methoxycyclohex-1-en-1-yl]ethen-1-yl}-1,1-dimethyl-1H- benzo[e]indol-3-ium chloride chlorure de pudexacianinium chlorure de 3-(3-{[3-(cyclomaltoheptaos-2I-O- yl)propyl]amino}-3-oxopropyl)-2-{(1E)-2-[(3E)-3-{(2E)-2-[3-(3- {[3-(cyclomaltoheptaos-2I-O-yl)propyl]amino}-3-oxopropyl)- 1,1-diméthyl-1,3-dihydro-2H-benzo[e]indol-2- ylidène]éthylidène}-2-méthoxycyclohex-1-en-1-yl]éthèn-1-yl}- 1,1-diméthyl-1H-benzo[e]indol-3-ium cloruro de pudexacianinio cloruro de 3-(3-{[3-(ciclomaltoheptaos-2I-O-il)propil]amino}-3- oxopropil)-2-{(1E)-2-[(3E)-3-{(2E)-2-[3-(3-{[3- (ciclomaltoheptaos-2I-O-il)propil]amino}-3-oxopropil)-1,1- dimetil-1,3-dihidro-2H-benzo[e]indol-2-ilideno]etilideno}-2- metoxiciclohex-1-en-1-il]eten-1-il}-1,1-dimetil-1H- benzo[e]indol-3-ium C135H197ClN4O73 CH3 H3C CH3 OCH3 H3C N N R R HO HO . Cl O O O O HO OH 6 HO O R = CH2 HN O 756 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 quavonlimabum # quavonlimab immunoglobulin G1-kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-445) [VH (Homo sapiens IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1- 115) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-6*01 (81.6%) -IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'- 107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa quavonlimab immunoglobuline G1-kappa, anti-[Homo sapiens CTLA4 (protéine 4 associée aux lymphocytes T cytotoxiques, CD152)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-445) [VH (Homo sapiens IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1- 115) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), charnière 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (Homo sapiens IGKV1-6*01 (81.6%) -IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'- 107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224":227-227")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa quavonlimab inmunoglobulina G1-kappa, anti-[Homo sapiens CTLA4 (proteína 4 asociada a los linfocitos T citotóxicos, CD152)], anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-445) [VH (Homo sapiens IGHV3-72*01 (84.7%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51- 60.99-104) (1-115) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), bisagra 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')- disulfuro con la cadena ligera kappa humanizada (1'- 214') [V-KAPPA (Homo sapiens IGKV1-6*01 (81.6%) - IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50- 52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224":227-227")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 757 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 ragifilimabum # ragifilimab immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF18 (tumor necrosis factor receptor (TNFR) superfamily member 18, activation-inducible TNFR family receptor, AITR, glucocorticoid- induced TNFR-related, GITR, CD375)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-447) [VH (Homo sapiens IGHV1-2*02 (80.6%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS K>del (447)) (119-447)], (221-220')-disulfide with kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27-38.56-58.95- 103) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa ragifilimab immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF18 (membre 18 de la superfamille des récepteurs du TNF, récepteur de la famille TNFR induit par activation, AITR, récepteur apparenté au TNFR et induit par les glucocorticoïdes, GITR, CD375), anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-447) [VH (Homo sapiens IGHV1-2*02 (80.6%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), charnière 1- 15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342- 446), CHS K>del (447)) (119-447)], (221-220')-disulfure avec la chaîne légère kappa humanisée (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27-38.56-58.95-103) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (227-227":230-230")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa 758 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 ragifilimab inmunoglobulina G1-kappa, anti-[Homo sapiens TNFRSF18 (miembro 18 de la superfamilia de los receptores del TNF, receptor de la familia TNFR inducido por activación, AITR, receptor relacionado con el TNFR e inducido por los glucocorticoides, GITR, CD375), anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-447) [VH (Homo sapiens IGHV1-2*02 (80.6%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51- 58.97-107) (1-118) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), bisagra 1- 15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS K>del (447)) (119-447)], (221- 220')-disulfuro con la cadena ligera kappa humanizada (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27- 38.56-58.95-103) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (227-227":230-230")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGASVKV SCKGSGYTFT DYAMYWVRQA PGQGLEWIGV 50 IRTYSGDVTY NQKFKDRATM TVDKSISTAY MELSRLRSDD TAVYYCAKSG 100 TVRGFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200 CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350 TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG 447 Light chain / Chaîne légère / Cadena ligera DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSGNQKNYLT WYQQKPGQPP 50 KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYHCQNDYSY 100 PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150 KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200 EVTHQGLSSP VTKSFNRGEC 220 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 145-201 262-322 368-426 22''-96'' 145''-201'' 262''-322'' 368''-426'' Intra-L (C23-C104) 23'-94' 140'-200' 23'''-94''' 140'''-200''' Inter-H-L (h 5-CL 126) 221-220' 221''-220''' Inter-H-H (h 11, h 14) 227-227'' 230-230'' N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl) H VH Q1: 1, 1'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 298, 298'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados reciferceptum # recifercept human fibroblast growth factor receptor 3 (FGFR-3, CD333) (1-336)-(401-413) fragment (1-349) [soluble isoform (337-400>del, 414-784>del)-sFGFR3], produced in Chinese hamster ovary (CHO) cells, glycoform alfa récifercept fragment (1-336)-(401-413) du récepteur 3 du facteur de croissance des fibroblastes humain (FGFR-3, CD333) (1-349) [isoforme soluble (337-400>del, 414- 784>del)-sFGFR3], produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa 759 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 recifercept fragmento (1-336)-(401-413) del receptor 3 del factor de crecimiento de los fibroblastos humanos (FGFR-3, CD333) (1-349) [isoforma soluble (337-400>del, 414- 784>del)-sFGFR3], producido en las células ováricas de hamster chino (CHO), glicoforma alfa Sequence / Séquence / Secuencia ESLGTEQRVV GRAAEVPGPE PGQQEQLVFG SGDAVELSCP PPGGGPMGPT 50 VWVKDGTGLV PSERVLVGPQ RLQVLNASHE DSGAYSCRQR LTQRVLCHFS 100 VRVTDAPSSG DDEDGEDEAE DTGVDTGAPY WTRPERMDKK LLAVPAANTV 150 RFRCPAAGNP TPSISWLKNG REFRGEHRIG GIKLRHQQWS LVMESVVPSD 200 RGNYTCVVEN KFGSIRQTYT LDVLERSPHR PILQAGLPAN QTAVLGSDVE 250 FHCKVYSDAQ PHIQWLKHVE VNGSKVGPDG TPYVTVLKTA GANTTDKELE 300 VLSLHNVTFE DAGEYTCLAG NSIGFSHHSA WLVVLPVSLE SNASMSSNT 349 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro intra-chain 39-97 154-206 253-317 (Cys-SH: 87) Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación N76, N203, N240, N272, N293, N306, N342 Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados relzomostatum relzomostat (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3- methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan- 6-yl 6-(2,2-difluoroethyl)-2,6-diazaspiro[3.3]heptane-2- carboxylate relzomostat 6-(2,2-difluoroéthyl)-2,6-diazaspiro[3.3]heptane-2- carboxylate de (3R,4S,5S,6R)-5-méthoxy-4-[(2R,3R)- 2-méthyl-3-(3-méthylbut-2-én-1-yl)oxiran-2-yl]-1- oxaspiro[2.5]octan-6-yle relzomostat 6-(2,2-difluoroetil)-2,6-diazaspiro[3.3]heptano-2- carboxilato de (3R,4S,5S,6R)-5-metoxi-4-[(2R,3R)-2- metil-3-(3-metilbut-2-en-1-il)oxiran-2-il]-1- oxaspiro[2.5]octan-6-ilo C24H36F2N2O5 resiquimodum pegolum resiquimod pegol 2,2',2'',2'''-{methanetetrayltetrakis[methylenepoly (oxyethylene)oxy]}tetrakis[N-(2-{[2-(ethoxymethyl)-1- (2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin- 4-yl]amino}-2-oxoethyl)acetamide] résiquimod pégol 2,2',2'',2'''-{méthanetétrayltétrakis[méthylènepoly (oxyéthylène)oxy]}tétrakis[N-(2-{[2-(éthoxyméthyl)-1- (2-hydroxy-2-méthylpropyl)-1H-imidazo[4,5- c]quinoléin-4-yl]amino}-2-oxoéthyl)acétamide] resiquimod pegol 2,2',2'',2'''-{metanotetrailtetrakis[metilenepoli (oxietileno)oxi]}tetrakis[N-(2-{[2-(etoximetil)-1-(2- hidroxi-2-metilpropil)-1H-imidazo[4,5-c]quinolin-4- il]amino}-2-oxoetil)acetamida] 760 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 C89H112N20O20 . (C2H4O)4n H3C O R O O R n n H3C CH3 OH N N R O n O n R O H N N N O = R H O revdofilimabum # revdofilimab immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, ACT35, OX40, CD134)], monoclonal antibody; gamma1 heavy chain (1-450) [VH (Mus musculus IGHV5-6-3*01 (88.8%) -IGHJ4*01 (93.8%)/Homo sapiens IGHV3-7*01 (88.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1- 120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-218')- disulfide with kappa light chain (1'-218') [V-KAPPA (Mus musculus IGKV3-4*01 (83.8%) -IGKJ1*01 (90.9%)/Homo sapiens IGKV4-1*01 (83.2%) - IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54- 56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (229-229":232-232")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa revdofilimab immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF4 (membre 4 de la superfamille des récepteurs du facteur de nécrose tumorale, ACT35, OX40, CD134)], anticorps monoclonal; chaîne lourde gamma1 (1-450) [VH (Mus musculus IGHV5-6-3*01 (88.8%) -IGHJ4*01 (93.8%)/Homo sapiens IGHV3-7*01 (88.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1- 120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-218')- disulfure avec la chaîne légère kappa (1'-218') [V- KAPPA (Mus musculus IGKV3-4*01 (83.8%) - IGKJ1*01 (90.9%)/Homo sapiens IGKV4-1*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54- 56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (229-229":232-232")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa revdofilimab inmunoglobulina G1-kappa, anti-[Homo sapiens TNFRSF4 (miembro 4 de la superfamilia de los receptores del factor de necrosis tumoral, ACT35, OX40, CD134)], anticuerpo monoclonal; 761 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 cadena pesada gamma1 (1-450) [VH (Mus musculus IGHV5-6-3*01 (88.8%) -IGHJ4*01 (93.8%)/Homo sapiens IGHV3-7*01 (88.8%) - (IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.13] (26-33.51-58.97- 109) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), bisagra 1-15 (219-233), CH2 (234- 343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121- 450)], (223-218')-disulfuro con la cadena ligera kappa (1'-218') [V- KAPPA (Mus musculus IGKV3-4*01 (83.8%) -IGKJ1*01 (90.9%)/Homo sapiens IGKV4-1*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (229-229":232-232")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa rezivertinibum rezivertinib N-(2-[2-(dimethylamino)ethoxy]-4-methoxy-5-{[4-(1-methyl-1H- indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide rézivertinib N-(2-[2-(diméthylamino)éthoxy]-4-méthoxy-5-{[4-(1-méthyl-1H- indol-3-yl)pyrimidin-2-yl]amino}phényl)prop-2-énamide rezivertinib N-(2-[2-(dimetilamino)etoxi]-5-{[4-(1-metil-1H-indol-3-il)pirimidin-2- il]amino}fenil)-4-metoxiprop-2-enamida C27H30N6O3 762 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 rilematovirum rilematovir 3-({5-chloro-1-[3-(methanesulfonyl)propyl]-1H-indol-2- yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H- imidazo[4,5-c]pyridin-2-one rilématovir 3-({5-chloro-1-[3-(méthanesulfonyl)propyl]-1H-indol-2- yl}méthyl)-1-(2,2,2-trifluoroéthyl)-1,3-dihydro-2H- imidazo[4,5-c]pyridin-2-one rilematovir 3-({5-cloro-1-[3-(metanosulfonil)propil]-1H-indol-2- il}metil)-1-(2,2,2-trifluoroetil)-1,3-dihidro-2H- imidazo[4,5-c]piridin-2-ona C21H20ClF3N4O3S ripafollitropinum alfa (bovinum) # ripafollitropin alfa (bovine) bovine follicle-stimulating hormone (synthetic analog): [follitropin (Bos taurus) subunit β (1-109)]-[human chorionic gonadotropin (hCG) C-terminal 28-peptide linker (110-137)]-[glycoprotein hormones α chain (follitropin subunit α) (Bos taurus) (138-233)] fusion protein, produced in Chinese hamster ovary (CHO) cells, glycoform alfa ripafollitropine alfa (bovine) hormone folliculostimulante bovine (analogue synthétique): protéine de fusion [follitropine (Bos taurus) sous-unité β (1-109)]-[peptide liant: 28-peptide C-terminal de la gonadotrophine chorionique humaine (hCG) (110- 137)]-[chaîne α des hormones glycoprotéiques (follitropine sous-unité α) (Bos taurus) (138-233)], produit par des cellules ovariennes de hamster chinois (CHO), forme glycosylée alfa ripafolitropina alfa (bovina) hormona estimulante del folículo bovina (análogo sintético): proteína de fusión [folitropina (Bos taurus) subunidad β (1-109)]-[conector: 28-péptido C-terminal de la gonadotropina coriónica humana (hCG) (110-137)]- [cadena α de las hormonas glicoproteicas (folitropina subunidad α) (Bos taurus) (138-233)], producida por células ováricas de hamster chino (CHO), forma glicosilada alfa 763 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 ripertamabum # ripertamab immunoglobulin G1-kappa, anti-[Homo sapiens MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], chimeric monoclonal antibody; gamma1 heavy chain chimeric (1-451) [VH (Mus musculus IGHV1-12*01 (91.8%) -(IGHD) -IGHJ1*01 (87.5%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1- 121) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122-451)], (224-213')-disulfide with kappa light chain chimeric (1'-213') [V-KAPPA (Mus musculus IGKV4-72*01 (95.8%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-106') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa ripertamab immunoglobuline G1-kappa, anti-[Homo sapiens MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal chimérique; chaîne lourde gamma1 chimérique (1-451) [VH (Mus musculus IGHV1-12*01 (91.8%) -(IGHD) -IGHJ1*01 (87.5%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1- 121) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (218) (122-219), charnière 1-15 (220-234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122-451)], (224-213')-disulfure avec la chaîne légère kappa chimérique (1'-213') [V-KAPPA (Mus musculus IGKV4-72*01 (95.8%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'- 106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (230-230'':233-233'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa ripertamab inmunoglobulina G1-kappa, anti-[Homo sapiens MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal quimérico; 764 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 cadena pesada gamma1 quimérica (1-451) [VH (Mus musculus IGHV1-12*01 (91.8%) -(IGHD) -IGHJ1*01 (87.5%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (218) (122-219), bisagra 1-15 (220- 234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122-451)], (224-213')-disulfuro con la cadena ligera kappa quimérica (1'-213') [V-KAPPA (Mus musculus IGKV4- 72*01 (95.8%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49- 51.88-96) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (230-230'':233-233'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa Heavy chain / Chaîne lourde / Cadena pesada QVQLQQPGAE LVKPGASVKM SCKASGYTFT SYNMHWVKQT PGRGLEWIGA 50 IYPGNGDTSY NQKFKGKATL TADKSSSTAY MQLSSLTSED SAVYYCARST 100 YYGGDWYFNV WGAGTTVTVS AASTKGPSVF PLAPSSKSTS GGTAALGCLV 150 KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200 TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350 QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400 VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450 K 451 Light chain / Chaîne légère / Cadena ligera QIVLSQSPAI LSASPGEKVT MTCRASSSVS YIHWFQQKPG SSPKPWIYAT 50 SNLASGVPVR FSGSGSGTSY SLTISRVEAE DAATYYCQQW TSNPPTFGGG 100 TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150 NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200 SSPVTKSFNR GEC 213 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 148-204 265-325 371-429 22''-96'' 148''-204'' 265''-325'' 371''-429'' Intra-L (C23-C104) 23'-87' 133'-193' 23'''-87''' 133'''-193''' Inter-H-L (h 5-CL 126) 224-213' 224''-213''' Inter-H-H (h 11, h14) 230-230'' 233-233'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 301, 301'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados rocakinogenum sifuplasmidum # rocakinogene sifuplasmid A DNA plasmid encoding both subunits of human interleukin-12 (IL12), subunit alpha (IL12A, IL-12 subunit p35) and subunit beta (IL12B; IL-12 subunit p40), under the control of a human cytomegalovirus (CMV) immediate-early 1 (IE1) promoter and a simian cytomegalovirus (sCMV) promoter, respectively. rocakinogène sifuplasmide plasmide dont l'ADN code pour les deux sous-unités de l'interleukine 12 humaine (IL-12), sous-unité alpha (IL12A, sous-unité p35 de l'IL-12) et sous-unité bêta (IL12B; sous-unité p40 de l'IL-12), sous le contrôle d'un activateur/promoteur immédiat-précoce 1 (IE1) du cytomégalovirus (CMV) et d'un promoteur du cytomégalovirus simiesque (sCMV), respectivement rocakinogén sifuplasmida Un plásmido de DNA que codifica para ambas subunidades de la interleucina 12 (IL12) humana, la subunidad alfa (IL12A, IL- 12 subunidad p35) y la subunidad beta (IL12B; IL-12 subunidad p40), bajo el control de un promotor inmediato-temprano 1 (IE1) del citomegalovirus (CMV) humano y un promotor del citomegalovirus de simio (sCMV), respectivamente. 765 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 rosopatamabum # rosopatamab immunoglobulin G1-kappa, anti-[Homo sapiens FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)], monoclonal antibody; gamma1 heavy chain (1-445) [VH (Mus musculus IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116- 213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with kappa light chain (1'-214') [V- KAPPA (Mus musculus IGKV6-23*01 (80.9%) - IGKJ2*03 (72.7%)Homo sapiens IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'- 214')]; dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa rosopatamab immunoglobuline G1-kappa, anti-[Homo sapiens FOLH1 (folate hydrolase, antigène membranaire spécifique de la prostate, PSMA)], anticorps monoclonal; chaîne lourde gamma1 (1-445) [VH (Mus musculus IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116- 213), charnière 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116- 445)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA Mus musculus IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)/(Homo sapiens IGKV1- 13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') - Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224":227-227")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa rosopatamab inmunoglobulina G1-kappa, anti-[Homo sapiens FOLH1 (folato hidrolasa, antígeno membranario específico de la próstata, PSMA)], anticuerpo monoclonal; cadena pesada gamma1 (1-445) [VH (Mus musculus IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116- 213), bisagra 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA Mus musculus IGKV6-23*01 (80.9%) - IGKJ2*03 (72.7%)/(Homo sapiens IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224":227-227")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 766 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 rosopatamabum tetraxetanum # rosopatamab tetraxetan immunoglobulin G1-kappa, anti-[Homo sapiens FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)], monoclonal antibody, tetraxetan conjugate; gamma1 heavy chain (1-445) [VH (Mus musculus IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')- disulfide with kappa light chain (1'-214') [V-KAPPA (Mus musculus IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)Homo sapiens IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":227-227")-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa, tetraxetan (DOTA) conjugate (on an average of 3 to 5 lysyl, linked to the chelator by their N6) rosopatamab tétraxétan immunoglobuline G1-kappa, anti-[Homo sapiens FOLH1 (folate hydrolase, antigène membranaire spécifique de la prostate, PSMA)], anticorps monoclonal, conjugué au tétraxétan; chaîne lourde gamma1 (1-445) [VH (Mus musculus IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), charnière 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')- disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA Mus musculus IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)/(Homo sapiens IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; 767 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 dimère (224-224":227-227")-bisdisulfure; produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa, conjugué au tétraxétan (DOTA) (avec une moyenne de 3 à 5 lysyl liés au chélateur par leur N6) rosopatamab tetraxetán inmunoglobulina G1-kappa, anti-[Homo sapiens FOLH1 (folato hidrolasa, antígeno membranario específico de la próstata, PSMA)], anticuerpo monoclonal, conjugado con tetraxetán ; cadena pesada gamma1 (1-445) [VH (Mus musculus IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) - (IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), bisagra 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA Mus musculus IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)/(Homo sapiens IGKV1- 13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') - Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224":227-227")-bisdisulfuro; producido por células ováricas de hamster chino (CHO), forma glicosilada alfa, conjugado con tetraxetán (DOTA) (con una media de 3 a 5 restos lisil unidos al quelante por sus respectivos N6) Heavy chain / Chaîne lourde / Cadena pesada EVQLVQSGPE VKKPGATVKI SCKTSGYTFT EYTIHWVKQA PGKGLEWIGN 50 INPNNGGTTY NQKFEDKATL TVDKSTDTAY MELSSLRSED TAVYYCAAGW 100 NFDYWGQGTL LTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150 PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200 NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250 ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300 VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350 PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400 SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 445 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSTSVGDRVT LTCKASQDVG TAVDWYQQKP GPSPKLLIYW 50 ASTRHTGIPS RFSGSGSGTD FTLTISSLQP EDFADYYCQQ YNSYPLTFGP 100 GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 142-198 259-319 365-423 22''-96'' 142''-198'' 259''-319'' 365''-423'' Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) 218-214' 218''-214''' Inter-H-H (h 11, h 14) 224-224'' 227-227'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 295, 295'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados Potential modified residues / résidus modifiés potentiels / restos modificados potenciales 3 to 5 lysyl (K) NH 3 à 5 lysyl (K) CO2H 3 a 5 lisil (K) O N N H N6-(tetraxetan)-L-lysyl N C H N N O HO2C CO2H 768 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 sabatolimabum # sabatolimab immunoglobulin G4-kappa, anti-[Homo sapiens HAVCR2 (hepatitis A virus cellular receptor 2, T-cell immunoglobulin mucin family member 3, Tim-3, TIM3, TIMD3, CD366)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-444) [VH (Homo sapiens IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1- 118)-Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (119-216), hinge 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS K>del (444)) (119- 444)], (132-218')-disulfide with kappa light chain humanized (1'-218') [V-KAPPA (Homo sapiens IGKV1- 39*01 (81.6%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'- 218')]; dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa sabatolimab immunoglobuline G4-kappa, anti-[Homo sapiens HAVCR2 (récepteur cellulaire 2 du virus de l'hépatite A, CD366, membre 3 de la famille mucine immunoglobuline des cellules T, Tim-3, TIM3, TIMD3, CD366)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-444) [VH (Homo sapiens IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1- 118) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (119-216), charnière 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS K>del (444)) (119-444)], (132-218')-disulfure avec la chaîne légère kappa humanisée (1'-218') [V-KAPPA (Homo sapiens IGKV1-39*01 (81.6%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'- 218')]; dimère (224-224":227-227")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa sabatolimab inmunoglobulina G4-kappa, anti-[Homo sapiens HAVCR2 (receptor celular 2 del virus de la hepatitis A, CD366, miembro 3 de la familia mucina inmunoglobulina de las células T, Tim-3, TIM3, TIMD3, CD366)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-444) [VH (Homo sapiens IGHV1-46*01 (87.8%) -(IGHD) - IGHJ4*01 (92.3%)) CDR-IMGT [8.8.11] (26-33.51- 58.97-107) (1-118) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (119-216), bisagra 1-12 S10>P (226) (217- 228), CH2 (229-338), CH3 (339-443), CHS K>del (444)) (119-444)], (132-218')-disulfuro con la cadena ligera kappa humanizada (1'-218') [V-KAPPA (Homo sapiens IGKV1-39*01 (81.6%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (224-224":227-227")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 769 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 samelisantum samelisant N-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-2- (morpholin-4-yl)acetamide samélisant N-{4-[(1-cyclobutylpipéridin-4-yl)oxy]phényl}-2- (morpholin-4-yl)acetamide samelisant N-{4-[(1-ciclobutilpiperidin-4-il)oxi]fenil}-2-(morfolin-4- il)acetamida C21H31N3O3 samuraciclibum samuraciclib (3R,4R)-4-({[7-(benzylamino)-3-(propan-2- yl)pyrazolo[1,5-a]pyrimidin-5-yl]amino}methyl)piperidin- 3-ol samuraciclib (3R,4R)-4-({[7-(benzylamino)-3-(propan-2- yl)pyrazolo[1,5-a]pyrimidin-5-yl]amino}méthyl)pipéridin- 3-ol samuraciclib (3R,4R)-4-({[7-(benzilamino)-3-(propan-2- il)pirazolo[1,5-a]pirimidin-5-il]amino}metil)piperidin-3-ol 770 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 C22H30N6O OH HN H H N N N N N H3C CH3 seralutinibum seralutinib N-{3-[(1S)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2- yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide séralutinib N-{3-[(1S)-1-{[6-(3,4-diméthoxyphényl)pyrazin-2- yl]amino}éthyl]phényl}-5-méthylpyridine-3-carboxamide seralutinib N-{3-[(1S)-1-{[6-(3,4-dimetoxifenil)pirazin-2- il]amino}etil]fenil}-5-metilpiridina-3-carboxamida C27H27N5O3 simoladagenum autotemcelum # simoladagene autotemcel autologous CD34+ hematopoietic stem cells (HSC), obtained by leukapheresis or from bone marrow, transduced ex vivo with a non-replicating, self- inactivating (SIN) lentiviral vector encoding codon optimised human adenosine deaminase (ADA) under the internal control of elongation factor 1α short promoter (EFS) simoladagène autotemcel cellules souches hématopoïétiques CD34+ autologues obtenues par leucophérèse ou de la moëlle osseuse, transduites ex vivo avec un vecteur lentiviral non- répliquant, auto-inactivant (SIN) codant pour l'adénosine déaminase (ADA) humaine codon optimisé sous le contrôle interne d'un promoteur court du facteur d'élongation 1α (EFS) simoladagén autotemcel células madre hematopoyéticas CD34+ autólogas obtenidas por leucoaféresis o de médula ósea, transducidas ex vivo con un vector lentiviral no replicativo y auto inactivante (SIN), que codifica para la adenosina deaminasa (ADA) humana con codones optimizados bajo el control interno del promotor corto del factor de elongación 1α (EFS) sisunatovirum sisunatovir 1'-{[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H- benzimidazol-2-yl]methyl}-6'-fluorospiro[cyclopropane- 1,3'-indol]-2'(1'H)-one 771 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 sisunatovir 1'-{[5-(aminométhyl)-1-(4,4,4-trifluorobutyl)-1H- benzimidazol-2-yl]méthyl}-6'-fluoro-spiro[cyclopropane- 1,3'-[3H]indol]-2'(1'H)-one sisunatovir 1'-{[5-(aminometil)-1-(4,4,4-trifluorobutil)-1H- benzimidazol-2-il]metil}-6'-fluoro-spiro[ciclopropano- 1,3'-[3H]indol]-2'(1'H)-ona C23H22F4N4O sovesudilum sovesudil propyl 2'-(aminomethyl)-5'-[(3-fluoropyridin-4- yl)carbamoyl][1,1'-biphenyl]-3-carboxylate sovésudil 2'-(aminométhyl)-5'-[(3-fluoropyridin-4- yl)carbamoyl][1,1'-biphényl]-3-carboxylate de propyle sovesudil 2'-(aminometil)-5'-[(3-fluoropiridin-4-il)carbamoil][1,1'- bifenil]-3-carboxilato de propilo C23H22FN3O3 O O CH3 F N O N H NH2 sugemalimabum # sugemalimab immunoglobulin G4-lambda, anti-[Homo sapiens CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], Homo sapiens monoclonal antibody; gamma4 heavy chain Homo sapiens (1-448) [VH (Homo sapiens IGHV3-23*01 (98.0%) -(IGHD) - IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 (232-341), CH3 (342- 446), CHS (447-448)) (122-448)], (135-213')-disulfide with lambda light chain Homo sapiens (1'-214') [V- LAMBDA (Homo sapiens IGLV3-21*02 (100%) - IGLJ2*01 (100%)) [6.3.11] (1'-108') -Homo sapiens IGLC2*01 (100%) (109'-214')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa sugémalimab immunoglobuline G4-lambda, anti-[Homo sapiens CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], anticorps monoclonal Homo sapiens; 772 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 chaîne lourde gamma4 Homo sapiens (1-448) [VH (Homo sapiens IGHV3-23*01 (98.0%) -(IGHD) - IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (122-219), charnière 1- 12 S10>P (229) (220-231), CH2 (232-341), CH3 (342- 446), CHS (447-448)) (122-448)], (135-213')-disulfure avec la chaîne légère lambda Homo sapiens (1'-214') [V-LAMBDA (Homo sapiens IGLV3-21*02 (100%) - IGLJ2*01 (100%)) [6.3.11] (1'-108') -Homo sapiens IGLC2*01 (100%) (109'-214')]; dimère (227-227'':230-230'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa sugemalimab inmunoglobulina G4-lambda, anti-[Homo sapiens CD274 (ligando 1 de muerte programada, PDL1, PD- L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal Homo sapiens; cadena pesada gamma4 Homo sapiens (1-448) [VH (Homo sapiens IGHV3-23*01 (98.0%) -(IGHD) - IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (122-219), bisagra 1-12 S10>P (229) (220-231), CH2 (232-341), CH3 (342- 446), CHS (447-448)) (122-448)], (135-213')-disulfuro con la cadena ligera lambda Homo sapiens (1'-214') [V-LAMBDA (Homo sapiens IGLV3-21*02 (100%) - IGLJ2*01 (100%)) [6.3.11] (1'-108') -Homo sapiens IGLC2*01 (100%) (109'-214')]; dímero (227-227'':230-230'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa Heavy chain / Chaîne lourde / Cadena pesada EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSG 50 ISGSGGFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPP 100 RGYNYGPFDY WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150 KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200 TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD 250 TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300 YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350 TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400 SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK 448 Light chain / Chaîne légère / Cadena ligera SYVLTQPPSV SVAPGQTARI TCGGNNIGSK SVHWYQQKPG QAPVLVVYDD 50 SDRPSGIPER FSGSNSGNTA TLTISRVEAG DEADYYCQVW DSSSDHVVFG 100 GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150 KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200 GSTVEKTVAP TECS 214 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 148-204 262-322 368-426 22''-96'' 148''-204'' 262''-322'' 368''-426'' Intra-L (C23-C104) 22'-87' 136'-195' 22'''-87''' 136'''-195''' Inter-H-L (CH1 10-CL 126) 135-213' 135''-213''' Inter-H-H (h 8, h 11) 227-227'' 230-230'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 298, 298'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados Deamidation sites / Sites de déamidation / Posiciones de desamidación H CH3 N44: 385, 385'' H CH3 N114: 435, 435'' Oxidation sites / Sites de oxydation / Posiciones de oxidación H CH2 M15.1: 253, 253'' H CH3 M107: 429, 429'' 773 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 suvecaltamidum suvecaltamide 2-[4-(propan-2-yl)phenyl]-N-{(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2- yl]ethyl}acetamide suvécaltamide 2-[4-(propan-2-yl)phényl]-N-{(1R)-1-[5-(2,2,2-trifluoroéthoxy)pyridin-2- yl]éthyl}acetamide suvecaltamida 2-[4-(propan-2-il)fenil]-N-{(1R)-1-[5-(2,2,2-trifluoroetoxi)piridin-2- il]etil}acetamida C20H23F3N2O2 tebotelimabum # tebotelimab immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD-1, PD1, CD279)] and anti-[Homo sapiens LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], humanized monoclonal antibody, bispecific tetravalent; gamma4 heavy chain scFv-h-CH2-CH3 humanized (1-496) [V-KAPPA anti- LAG3 (Homo sapiens IGKV1-39*01 (88.4%) -IGKJ4*01 (90.9%)) [6.3.9] (1- 107) -8-mer linker (108-115)-VH anti-PDCD1 (Homo sapiens IGHV1- 46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (116-234) -6-mer diglycyl-cysteinyl-triglycyl linker (235-240)-E-coil motif (241-268) -Homo sapiens IGHG4*01, G4v5 h P10, G4v21 CH2 Y15.1, T16, E18 (hinge 1-12 S10>P (278) (269-280), CH2 M15.1>Y (302), S16>T (304), T18>E (306) (281-390), CH3 (391-495), CHS K>del (496) (269-496))], (237-240':245- 248')-bisdisulfide with kappa light chain humanized (1'-271')[V-KAPPA anti- PDCD1 (Homo sapiens IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -8-mer linker (112'-119')-VH anti LAG3 (Homo sapiens IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (82.7%)) [8.8.11] (120'-237') -6- mer diglycyl-cysteinyl-triglycyl linker (238'-243') -K-coil motif (244'-271')]; dimer (276-276":279-279")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa tébotélimab immunoglobuline G4-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)] et anti-[Homo sapiens LAG3 (activateur 3 des lymphocytes, lymphocyte-activation 3, CD223)], anticorps monoclonal humanisé, bispécifique tétravalent; chaîne lourde gamma4 scFv-h-CH2-CH3 humanisée (1-496) [V-KAPPA anti-LAG3 (Homo sapiens IGKV1-39*01 (88.4%) -IGKJ4*01 (90.9%)) [6.3.9] (1-107) -8-mer linker (108-115) -VH anti-PDCD1 (Homo sapiens IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (116-234) -6- mer diglycyl-cystéinyl-triglycyl linker (235-240)-E-coil motif (241-268) - Homo sapiens IGHG4*01, G4v5 h P10, G4v21 CH2 Y15.1, T16, E18 (charnière 1-12 S10>P (278) (269-280), CH2 M15.1>Y (302), S16>T (304), T18>E (306) (281-390), CH3 (391-495), CHS K>del (496) (269-496))],(237- 240':245-248')-bisdisulfure avec la chaîne légère kappa humanisée (1'- 271') [V-KAPPA anti-PDCD1 (Homo sapiens IGKV3D-11*02 (77.7%) - IGKJ4*01 (100%)) [10.3.9] (1'-111') -8-mer linker (112'-119')-VH anti- LAG3(Homo sapiens IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (82.7%)) [8.8.11] (120'-237') -6-mer diglycyl-cystéinyl-triglycyl linker (238'-243') -K- coil motif (244'-271')]; dimère (276-276":279-279")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa 774 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 tebotelimab inmunoglobulina G4-kappa, anti-[Homo sapiens PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)] y anti-[Homo sapiens LAG3 (activador 3 de los linfocitos, linfocito-activación 3, CD223)], anticuerpo monoclonal humanizado, biespecífico tetravalente; cadena pesada gamma4 scFv-h-CH2-CH3 humanizada (1-496) [V- KAPPA anti-LAG3 (Homo sapiens IGKV1-39*01 (88.4%) -IGKJ4*01 (90.9%)) [6.3.9] (1-107) -conector octámero (108-115) -VH anti-PDCD1 (Homo sapiens IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (116-234) -conector sexámero diglicil-cisteinil-triglicil (235-240) - E-coil motif (241-268) -Homo sapiens IGHG4*01, G4v5 h P10, G4v21 CH2 Y15.1, T16, E18 (bisagra 1-12 S10>P (278) (269-280), CH2 M15.1>Y (302), S16>T (304), T18>E (306) (281-390), CH3 (391-495), CHS K>del (496) (269-496))],(237-240':245-248')-bisdisulfuro con la cadena ligera kappa humanizada (1'-271') [V-KAPPA anti-PDCD1 (Homo sapiens IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') - conector octámero (112'-119')-VH anti-LAG3(Homo sapiens IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (82.7%)) [8.8.11] (120'-237') -conector sexámero diglicil-cisteinil-triglicil (238'-243') -K-coil motif (244'-271')]; dímero (276-276":279-279")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa Heavy chain / Chaîne lourde / Cadena pesada DIQMTQSPSS LSASVGDRVT ITCRASQDVS SVVAWYQQKP GKAPKLLIYS 50 ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSTPWTFGG 100 GTKLEIKGGG SGGGGQVQLV QSGAEVKKPG ASVKVSCKAS GYSFTSYWMN 150 WVRQAPGQGL EWIGVIHPSD SETWLDQKFK DRVTITVDKS TSTAYMELSS 200 LRSEDTAVYY CAREHYGTSP FAYWGQGTLV TVSSGGCGGG EVAACEKEVA 250 ALEKEVAALE KEVAALEKES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 300 LYITREPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 350 RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 400 LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 450 DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLG 496 Light chain / Chaîne légère / Cadena ligera EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL 50 LIHAASNQGS GVPSRFSGSG SGTDFTLTIS SLEPEDFAVY FCQQSKEVPY 100 TFGGGTKVEI KGGGSGGGGQ VQLVQSGAEV KKPGASVKVS CKASGYTFTD 150 YNMDWVRQAP GQGLEWMGDI NPDNGVTIYN QKFEGRVTMT TDTSTSTAYM 200 ELRSLRSDDT AVYYCAREAD YFYFDYWGQG TTLTVSSGGC GGGKVAACKE 250 KVAALKEKVA ALKEKVAALK E 271 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 23-88 137-211 311-371 417-475 23''-88'' 137''-211'' 311''-371'' 417''-475'' Intra-L (C23-C104) 23'-92' 141'-215' 23'''-92''' 141'''-215''' Inter-H-L 237-240' 245-248' 237''-240''' 245''-248''' Inter-H-H (h 8, h 11) 276-276'' 279-279'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 347, 347'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados telazorlimabum # telazorlimab immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, ACT35, OX40, CD134)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV2- 70*10 (93.0%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [10.7.10] (26- 35.53-59.98-107) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-213')- disulfide with kappa light chain humanized (1'-213') [V-KAPPA (Homo sapiens IGKV3-11*01 (87.4%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.38-46) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa 775 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 télazorlimab immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF4 (membre 4 de la superfamille des récepteurs du facteur de nécrose tumorale, ACT35, OX40, CD134)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-448) [VH (Homo sapiens IGHV2-70*10 (93.0%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [10.7.10] (26-35.53-59.98-107) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-213')-disulfure avec la chaîne légère kappa humanisée (1'-213') [V-KAPPA (Homo sapiens IGKV3-11*01 (87.4%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27- 31.49-51.38-46) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (227-227":230-230")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa telazorlimab inmunoglobulina G1-kappa, anti-[Homo sapiens TNFRSF4 (miembro 4 de la superfamilia de los receptores del factor de necrosis tumoral, ACT35, OX40, CD134)], anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-448) [VH (Homo sapiens IGHV2-70*10 (93.0%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [10.7.10] (26-35.53-59.98-107) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), bisagra 1-15 (217- 231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-213')-disulfuro con la cadena ligera kappa humanizada (1'-213') [V-KAPPA (Homo sapiens IGKV3- 11*01 (87.4%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49- 51.38-46) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (227-227":230-230")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa Heavy chain / Chaîne lourde / Cadena pesada QVTLKESGPA LVKPTQTLTL TCSFSGFSLS TSGMGVGWIR QPPGKALEWI 50 AHIWWDDDKY YNTALKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI 100 DWDGFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200 CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350 TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448 Light chain / Chaîne légère / Cadena ligera EIVLTQSPAT LSLSPGERAT LSCRASSSVS YMHWYQQKPG QAPRPWIYAT 50 SNRATGIPAR FSGSGSGTDY TLTISSLEPE DFAVYYCQQW SSNPWTFGQG 100 TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150 NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200 SSPVTKSFNR GEC 213 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-97 145-201 262-322 368-426 22''-97'' 145''-201'' 262''-322'' 368''-426'' Intra-L (C23-C104) 23'-87' 133'-193' 23'''-87''' 133'''-193''' Inter-H-L (h 5-CL 126) 221-213' 221''-213''' Inter-H-H (h 11, h 14) 227-227'' 230-230'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 298, 298'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados C-terminal lysine clipping: H CHS K2: 448, 448'' 776 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 tesnatilimabum tesnatilimab immunoglobulin G4-kappa, anti-[Homo sapiens KLRK1 (killer cell lectin like receptor K1, NKG2D, KLR, NKG2- D, CD314)], Homo sapiens monoclonal antibody; gamma4 heavy chain Homo sapiens (1-442) [VH (Homo sapiens IGHV4-59*01 (93.8%) -(IGHD) - IGHJ3*02 (93.8%)) CDR-IMGT [8.7.9] (26-33.51- 57.96-104) (1-115) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (116-213), hinge S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116- 442)], (129-215')-disulfide with kappa light chain Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV3- 20*01 (100%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.9] (27-33.51-53.90-98) (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (221-221'':224-224'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa tesnatilimab immunoglobuline G4-kappa, anti-[Homo sapiens KLRK1 (récepteur lectine like K1 de cellule tueuse, NKG2D, KLR, NKG2-D, CD314)], anticorps monoclonal Homo sapiens; chaîne lourde gamma1 Homo sapiens (1-442) [VH (Homo sapiens IGHV4-59*01 (93.8%) -(IGHD) - IGHJ3*02 (93.8%)) CDR-IMGT [8.7.9] (26-33.51- 57.96-104) (1-115) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (116-213), charnière S10>P (223) (214- 225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-215')-disulfure avec la chaîne légère kappa Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (100%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.9] (21-33.51-53.90-98) (1'-108') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (221-221'':224-224'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa tesnatilimab inmunoglobulina G4-kappa, anti-[Homo sapiens KLRK1 (receptor lectina like K1 de célula asesina, NKG2D, KLR, NKG2-D, CD314)], anticuerpo monoclonal Homo sapiens; cadena pesada gamma1 Homo sapiens (1-442) [VH (Homo sapiens IGHV4-59*01 (93.8%) -(IGHD) - IGHJ3*02 (93.8%)) CDR-IMGT [8.7.9] (26-33.51- 57.96-104) (1-115) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (116-213), bisagra S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116- 442)], (129-215')-disulfuro con la cadena ligera kappa Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (100%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.9] (21-33.51-53.90-98) (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'- 215')]; dímero (221-221'':224-224'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 777 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 tezatabepum matraxetanum # tezatabep matraxetan three-alpha-helix binding protein, derived from an immunoglobulin G (IgG)-binding domain of a staphylococcal protein A (SpA), designed to bind receptor tyrosine-protein kinase erbB-2 (ERBB2, Neu, HER2), produced by peptide synthesis, conjugated at the C-terminal Cys61 to one (3RS)-2,5-dioxo-1-(2-{2- [4,7,10-tris(carboxymethyl)-1,4,7,10- tetraazacyclododecan-1-yl]acetamido}ethyl)pyrrolidin- 3-yl (matraxetan) group tézatabep matraxétan protéine à trois hélices alpha, dérivée du domaine de l'immunoglobuline G (IgG) se liant à la protéine staphylococcique A (SpA), mise au point pour se lier au récepteur tyrosine-protéine kinase erbB-2 (ERBB2, Neu, HER2), produite par synthèse peptidique, conjuguée sur la Cys61 en sa partie C-terminale à un groupe (3RS)-2,5-dioxo-1-(2-{2-[4,7,10- tris(carboxyméthyl)-1,4,7,10-tétraazacyclododécan-1- yl]acétamido}éthyl)pyrrolidin-3-yle (matraxétan) tezatabep matraxetán proteína de tres hélices alfa, derivada del dominio de la inmunoglobulina G (IgG) que se une a la proteína estafilocócica A (SpA), diseñada para unirse al receptor tirosina-proteína kinasa erbB-2 (ERBB2, Neu, HER2), producida por síntesis peptídica, conjugada con la Cys61 en su parte C-terminal a un grupo (3RS)- 2,5-dioxo-1-(2-{2-[4,7,10-tris(carboximetil)-1,4,7,10- tetraazaciclododecan-1-il]acetamido}etil)pirrolidin-3-ilo (matraxetán) 778 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 tifalibepum # tifalibep fusion protein composed of 3 binding domains, each consisting of a three-alpha-helix motif derived from the immunoglobulin (Ig)-binding Z-domain of staphylococcal protein A (SpA), engineered for binding to the human neonatal Fc receptor (FcRn) with the two identical N- and C-terminal domains (1-58, 116-173), and for binding to the domain II of human serum albumin (HSA) with the central domain (59-110), connected via a G4S peptide linker (111-115); [FcRn-binding engineered SpA peptide (1-58)]-[HSA- binding engineered SpA peptide (59-110)]-[G4S linker (111-115)]-[FcRn-binding engineered SpA peptide (116-173] fusion protein; produced in Escherichia coli tifalibep protéine de fusion composée de 3 domaines liants, chacun consistant en un motif à 3 hélices alfa dérivé du domaine Z de la protéine staphylococcique A (SpA) se liant à l'immunoglobuline (Ig), mis au point pour se lier au récepteur Fc néonatal humain (FcRn) avec les deux domaines N- et C-terminaux identiques (1-58, 116-173), et au domaine II de l'albumine sérique humaine (ASH, HSA) avec le domaine central (59- 110), connecté via un peptide liant G4S (111-115) ; protéine de fusion [peptide SpA mis au point pour se lier au FcRn (1-58)]-[peptide SpA mis au point pour se lier au HSA (59-110)]-[peptide liant G4S (111-115)]- [peptide SpA mis au point pour se lier au FcRn (116- 173)]; produite par Escherichia coli tifalibep proteína de fusión compuesta de 3 dominios de unión, cada uno consistente en un motivo con 3 hélices alfa derivado del dominio Z de la proteína estafilocócica A (SpA) que se une a la inmunoglobulina (Ig), diseñada para unirse al receptor Fc neonatal humano (FcRn) con los dos dominios N- y C-terminal idénticos (1-58, 116-173), y con el dominio II de la albúmina sérica humana (ASH, HSA) con el dominio central (59-110), conectado a través de un péptido linker G4S (111- 115) ; proteína de fusión [péptido SpA diseñado para unirse al FcRn (1-58)]-[péptido SpA diseñado para unirse al HSA (59-110)]-[G4S linker (111-115)]-[péptido SpA diseñado para unirse al FcRn (116-173)]; producida por Escherichia coli 779 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 tilogotamabum # tilogotamab immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF- related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-447) [VH (Homo sapiens IGHV1-3*01 (84.7%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1- 118) -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v34 CH3 G109 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), E109>G (431) (342-446), CHS K>del (447)) (119-447)], (221-213')-disulfide with kappa light chain humanized (1'-213') [V-KAPPA (Homo sapiens IGKV1- 16*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa tilogotamab immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF10B (membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale (TNFR), récepteur de mort 5, DR5, TRAILR2, TRAIL-R2, TR-2, CD262)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-447) [VH (Homo sapiens IGHV1-3*01 (84.7%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1- 118) -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v34 CH3 G109 (CH1 R120 (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), E109>G (431) (342-446), CHS K>del (447)) (119-447)], (221-213')-disulfure avec la chaîne légère kappa humanisée (1'-213') [V-KAPPA (Homo sapiens IGKV1-16*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'- 106') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (227-227":230-230")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa tilogotamab inmunoglobulina G1-kappa, anti-[Homo sapiens TNFRSF10B (miembro 10B de la superfamilia de los receptores del factor de necrosis tumoral (TNFR), receptor de muerte 5, DR5, TRAILR2, TRAIL-R2, TR- 2, CD262)], anticuerpo monoclonal humanizado; 780 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 cadena pesada gamma1 humanizada (1-447) [VH (Homo sapiens IGHV1-3*01 (84.7%) -(IGHD) - IGHJ4*01 (93.3%)) CDR-IMGT [8.8.11] (26-33.51- 58.97-107) (1-118) -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v34 CH3 G109 (CH1 R120 (215) (119- 216), bisagra 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), E109>G (431) (342-446), CHS K>del (447)) (119-447)], (221-213')-disulfuro con la cadena ligera kappa humanizada (1'-213') [V-KAPPA (Homo sapiens IGKV1-16*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'- 106') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (227-227":230-230")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa tolebrutinibum tolebrutinib 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-(prop-2- enoyl)piperidin-3-yl]-1,3-dihydro-2H-imidazo[4,5- c]pyridin-2-one tolébrutinib 4-amino-3-(4-phénoxyphényl)-1-[(3R)-1-(prop-2- énoyl)pipéridin-3-yl]-1,3-dihydro-2H-imidazo[4,5- c]pyridin-2-one tolebrutinib 4-amino-3-(4-fenoxifenil)-1-[(3R)-1-(prop-2- enoil)piperidin-3-il]-1,3-dihidro-2H-imidazo[4,5- c]piridin-2-ona C26H25N5O3 781 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 tovinontrinum tovinontrine 6-{(3S,4S)-4-methyl-1-[(pyrimidin-2-yl)methyl]pyrrolidin-3- yl}-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one tovinontrine 6-{(3S,4S)-4-méthyl-1-[(pyrimidin-2-yl)méthyl]pyrrolidin-3- yl}-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one tovinontrina 6-{(3S,4S)-4-metil-1-[(pirimidin-2-il)metil]pirrolidin-3-il}-3- (oxan-4-il)imidazo[1,5-a]pirazin-8(7H)-ona C21H26N6O2 O HN N N N N CH3 N O udonitrectagum udonitrectag (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3- azabicyclo[3.2.1]octane-7-carboxylic acid udonitrectag acide (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3- azabicyclo[3.2.1]octane-7-carboxylique udonitrectag ácido (1S,4R,5R,7S)-3,4-dibencil-2-oxo-6,8-dioxa-3- azabiciclo[3.2.1]octano-7-carboxílico C20H19NO5 H CO2H H O O O N H H upifitamabum # upifitamab immunoglobulin G1-kappa, anti-[Homo sapiens SLC34A2 (solute carrier family 34 (sodium phosphate) member 2, sodium/phosphate cotransporter 2B, NaPi2b, NaPi3b)], monoclonal antibody; gamma1 heavy chain (1-449) [VH (Homo sapiens IGHV1- 46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1- 119) -glycyl (120) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K>del (449)) (121-449)], (223-215')-disulfide with kappa light chain (1'-215') [V-KAPPA (Mus musculus IGKV10-94*01 (84.2%) -IGKJ5*01 (91.7%)/Homo sapiens IGKV1-16*01 (83.2%) -IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -arginyl (108') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (229-229":232-232")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa 782 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 upifitamab immunoglobuline G1-kappa, anti-[Homo sapiens SLC34A2 (membre 2 de la famille 34 (phosphate de sodium) de transporteurs de solutés, cotransporteur 2B de sodium/phosphate, NaPi2b, NaPi3b)], anticorps monoclonal; chaîne lourde gamma1 (1-449) [VH (Homo sapiens IGHV1- 46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) - glycyl (120) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (217) (121-218), charnière 1-15 (219-233), CH2 (234- 343), CH3 E12 (359), M14 (361) (344-448), CHS K>del (449)) (121-449)], (223-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA (Mus musculus IGKV10-94*01 (84.2%) - IGKJ5*01 (91.7%)/Homo sapiens IGKV1-16*01 (83.2%) - IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -arginyl (108') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'- 215')]; dimère (229-229":232-232")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa upifitamab inmunoglobulina G1-kappa, anti-[Homo sapiens SLC34A2 (miembro 2 de la familia 34 (fosfato de sodio) de transportadores de solutos, cotransportador 2B de sodio/fosfato, NaPi2b, NaPi3b)], anticuerpo monoclonal; cadena pesada gamma1 (1-449) [VH (Homo sapiens IGHV1- 46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) - glicil (120) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234- 343), CH3 E12 (359), M14 (361) (344-448), CHS K>del (449)) (121-449)], (223-215')-disulfuro con la cadena ligera kappa (1'- 215') [V-KAPPA (Mus musculus IGKV10-94*01 (84.2%) - IGKJ5*01 (91.7%)/Homo sapiens IGKV1-16*01 (83.2%) - IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -arginil (108') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'- 215')]; dímero (229-229":232-232")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 783 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 urabrelimabum # urabrelimab immunoglobulin G4-kappa, anti-[Homo sapiens CD47 (integrin associated protein, IAP, MER6, OA3)], Homo sapiens monoclonal antibody; gamma4 heavy chain Homo sapiens (1-452) [VH (Homo sapiens IGHV4-4*02 (94.9%) -(IGHD) - IGHJ6*01 (94.7%)) CDR-IMGT [9.7.18] (26-34.52- 58.97-114) (1-125)-Homo sapiens IGHG4*01 (CH1 (126-223), hinge 1-12 (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-212')- disulfide with kappa light chain Homo sapiens (1'-212') [V-KAPPA (Homo sapiens IGKV3-11*01 (94.7%) - IGKJ4*01 (91.7%)) CDR-IMGT [6.3.8] (27-32.50- 52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (151), V101 (189) (107'-212')]; dimer (231-231":234-234")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa urabrélimab immunoglobuline G4-kappa, anti-[Homo sapiens CD47 (protéine associée à l'intégrine, IAP, MER6, OA3)], anticorps monoclonal Homo sapiens; chaîne lourde gamma4 Homo sapiens (1-452) [VH (Homo sapiens IGHV4-4*02 (94.9%) -(IGHD) - IGHJ6*01 (94.7%)) CDR-IMGT [9.7.18] (26-34.52- 58.97-114) (1-125)-Homo sapiens IGHG4*01 (CH1 (126-223), charnière 1-12 (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139- 212')-disulfure avec la chaîne légère kappa Homo sapiens (1'-212') [V-KAPPA (Homo sapiens IGKV3- 11*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (151), V101 (189) (107'-212')]; dimère (231-231":234-234")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa urabrelimab inmunoglobulina G4-kappa, anti-[Homo sapiens CD47 (proteína asociada a la integrina, IAP, MER6, OA3)], anticuerpo monoclonal Homo sapiens; cadena pesada gamma4 Homo sapiens (1-452) [VH (Homo sapiens IGHV4-4*02 (94.9%) -(IGHD) - IGHJ6*01 (94.7%)) CDR-IMGT [9.7.18] (26-34.52- 58.97-114) (1-125)-Homo sapiens IGHG4*01 (CH1 (126-223), bisagra 1-12 (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139- 212')-disulfuro con la cadena ligera kappa Homo sapiens (1'-212') [V-KAPPA (Homo sapiens IGKV3- 11*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (151), V101 (189) (107'-212')]; dímero (231-231":234-234")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 784 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 uzansertibum uzansertib N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5- methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5- fluoropyridine-2-carboxamide uzansertib N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5- méthylpipéridin-1-yl]-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophényl)-5- fluoropyridine-2-carboxamide uzansertib N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hidroxi-5- metilpiperidin-1-il]-7-hidroxi-6,7-dihidro-5H- ciclopenta[b]piridin-3-il}-6-(2,6-difluorofenil)-5- fluoropiridina-2-carboxamida C26H26F3N5O3 F O NH2 N OH NH F N F CH3 N HO vebicorvirum vebicorvir 5,5,11-trioxo-N-{[2-(trifluoromethyl)-1,3-thiazol-5- yl]methyl}-10,11-dihydro-5H-5λ6- dibenzo[b,f][1,4]thiazepine-8-carboxamide vébicorvir 5,5,11-trioxo-N-{[2-(trifluorométhyl)-1,3-thiazol-5- yl]méthyl}-10,11-dihydro-5H-5λ6- dibenzo[b,f][1,4]thiazépine-8-carboxamide 785 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 vebicorvir 5,5,11-trioxo-N-{[2-(trifluorometil)-1,3-tiazol-5-il]metil}- 10,11-dihidro-5H-5λ6-dibenzo[b,f][1,4]tiazepina-8- carboxamida C19H12F3N3O4S2 velmupressinum velmupressin 1,5-anhydro{4-chloro-L-phenylalanyl-3-(thiophen-2-yl)- L-alanyl-L-valyl-L-asparaginyl-S-(3-carboxypropyl)-L- cysteinyl-N-[4-(carbamimidoylamino)butyl]-L- prolinamide} velmupressine 1,5-anhydro{4-chloro-L-phénylalanyl-3-(thiophén-2-yl)- L-alanyl-L-valyl-L-asparaginyl-S-(3-carboxypropyl)-L- cystéinyl-N-[4-(carbamimidoylamino)butyl]-L- prolinamide} velmupresina 1,5-anhidro{4-cloro-L-fenilalanil-3-(tiofen-2-il)-L-alanil-L- valil-L-asparaginil-S-(3-carboxipropil)-L-cisteinil-N-[4- (carbamimidoilamino)butil]-L-prolinamida} C42H60ClN11O8S2 velufenacinum velufenacin [(3R)-1-methylpyrrolidin-3-yl]methyl (3'-chloro-4'- fluoro[1,1'-biphenyl]-2-yl)carbamate vélufénacine (3'-chloro-4'-fluoro[1,1'-biphényl]-2-yl)carbamate de [(3R)-1-méthylpyrrolidin-3-yl]méthyle velufenacina (3'-cloro-4'-fluoro[1,1'-bifenil]-2-il)carbamato de [(3R)- 1-metilpirrolidin-3-il]metilo C19H20ClFN2O2 786 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 verbrinacogenum setparvovecum # verbrinacogene setparvovec A recombinant non-replicating adeno-associated virus of a modified liver-tropic serotype (S3) (rAAVS3) vector, encoding a gain-of-function variant (R338L; Padua) of codon-optimised human coagulation factor IX (hFIX) under the control of a liver-specific promoter (FRE1) comprising a truncated version of the human apolipoprotein E locus control region (i.e. enhancer) with a truncated version of the human alpha-1- antitrypsin promoter. verbrinacogène setparvovec vecteur viral adéno-associé recombinant, non- répliquant, d'un sérotype hépatotropique modifié (S3) (rAAVS3), codant pour le variant Padua (R338L) du facteur de coagulation IX humain (F9, Facteur IX, FIX) dont les codons sont optimisés, sous le contrôle du promoteur spécifique du foie (FRE1) comprenant une version tronquée de la région de contrôle du locus de l'apoprotéine E humaine (c.-à-d. amplificateur) avec une version tronquée du promoteur de l'antitrypsine alpha-1 humaine. verbrinacogén setparvovec Un vector de virus adeno-asociado recombinante, no replicativo, de un serotipo hepatotrópico modificado (S3) (rAAVS3), que codifica una variante de ganancia de función (R338L; Padua) del factor de coagulación IX humano (hFIX) con codones optimizados, bajo el control de un promotor específico de hígado (FRE1) que consta de una versión truncada de la región de control del locus de la apolipoproteína E humana (es decir, potenciador) con una versión truncada del promotor de la alfa-1-antitripsina humana. vilobelimabum # vilobelimab immunoglobulin G4-kappa, anti-[Homo sapiens C5 (complement 5) anaphylatoxin (C5a, C5 Pr678-751)], chimeric monoclonal antibody; gamma4 heavy chain chimeric (1-446) [VH (Mus musculus IGHV1-61*01 (81.6%) -(IGHD) -IGHJ3*01 (92.9%)/Homo sapiens IGHV1-46*01 (62.2%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.13] (1-119) -Homo sapiens IGHG4*01 (CH1 (120-217), hinge 1-12 (218-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-disulfide with kappa light chain chimeric (1'- 218') [V-KAPPA (Mus musculus IGKV3-4*01 (98.0%) - IGKJ2*01 (100%)/Homo sapiensIGKV3D-11*02 (69.1%) -IGKJ2*01 (91.7%)) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (225-225":228-228")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa vilobélimab immunoglobuline G4-kappa, anti-[Homo sapiens C5 (complément 5) anaphylatoxine (C5a, C5 Pr678-751)], anticorps monoclonal chimérique; 787 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 chaîne lourde gamma4 chimérique (1-446) [VH (Mus musculus IGHV1-61*01 (81.6%) -(IGHD) -IGHJ3*01 (92.9%)/Homo sapiens IGHV1-46*01 (62.2%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.13] (1-119) -Homo sapiens IGHG4*01 (CH1 (120-217), charnière 1-12 (218-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (120- 446)], (133-218')-disulfure avec la chaîne légère kappa chimérique (1'-218') [V-KAPPA (Mus musculus IGKV3- 4*01 (98.0%) -IGKJ2*01 (100%)/Homo sapiensIGKV3D-11*02 (69.1%) -IGKJ2*01 (91.7%)) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (225-225":228-228")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa vilobelimab inmunoglobulina G4-kappa, anti-[Homo sapiens C5 (complemento 5) anafilatoxina (C5a, C5 Pr678-751)], anticuerpo monoclonal quimérico; cadena pesada gamma4 quimérica (1-446) [VH (Mus musculus IGHV1-61*01 (81.6%) -(IGHD) -IGHJ3*01 (92.9%)/Homo sapiens IGHV1-46*01 (62.2%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.13] (1-119) -Homo sapiens IGHG4*01 (CH1 (120-217), bisagra 1-12 (218-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (120- 446)], (133-218')-disulfuro con la cadena ligera kappa quimérica (1'-218') [V-KAPPA (Mus musculus IGKV3- 4*01 (98.0%) -IGKJ2*01 (100%)/Homo sapiensIGKV3D-11*02 (69.1%) -IGKJ2*01 (91.7%)) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (225-225":228-228")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 788 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 vonafexorum vonafexor 4-chloro-5-[4-(2,6-dichlorobenzene-1- sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid vonafexor acide 4-chloro-5-[4-(2,6-dichlorobenzène-1- sulfonyl)pipérazin-1-yl]-1-benzofuran-2-carboxylique vonafexor ácido 4-cloro-5-[4-(2,6-diclorobenceno-1- sulfonil)piperazin-1-il]-1-benzofuran-2-carboxílico C19H15Cl3N2O5S vosilasarmum vosilasarm 2-chloro-4-({(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4- oxadiazol-2-yl]-2-hydroxypropyl}amino)-3- methylbenzonitrile vosilasarm 2-chloro-4-({(1R,2S)-1-[5-(4-cyanophényl)-1,3,4- oxadiazol-2-yl]-2-hydroxypropyl}amino)-3- méthylbenzonitrile vosilasarm 4-({(1R,2S)-1-[5-(4-cianofenil)-1,3,4-oxadiazol-2-il]-2- hidroxipropil}amino)-2-cloro-3-metilbenzonitrilo C20H16ClN5O2 vulinacimabum # vulinacimab immunoglobulin G1-kappa, anti-[Homo sapiens VEGFR2 (vascular endothelial growth factor receptor 2, KDR, kinase insert domain receptor, FLK1, CD309)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV3-23*04 (90.8%) -(IGHD) - IGHJ1*01 (100%)) [8.8.10] (1-117) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), hinge 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-457)) (118-447)], (220-219')-disulfide with kappa light chain Homo sapiens (1'-219') [V-KAPPA (Homo sapiens IGKV2-30*01 (83.0%) -IGKJ2*01 (100%)) [11.3.9] (1'- 112') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (226-226":229-229")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa 789 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 vulinacimab immunoglobuline G1-kappa, anti-[Homo sapiens VEGFR2 (récepteur 2 du facteur de croissance endothélial vasculaire, KDR, récepteur à domaine insert kinase, FLK1, CD309)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 Homo sapiens (1-447) [VH (Homo sapiens IGHV3-23*04 (90.8%) -(IGHD) -IGHJ1*01 (100%)) [8.8.10] (1-117) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), charnière 1-15 (216- 230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-457)) (118-447)], (220-219')-disulfure avec la chaîne légère kappa Homo sapiens (1'-219') [V-KAPPA (Homo sapiens IGKV2-30*01 (83.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112') - Homo sapiens IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (226-226":229-229")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa vulinacimab inmunoglobulina G1-kappa, anti-[Homo sapiens VEGFR2 (receptor 2 del factor de crecimiento endotelial vascular, KDR, receptor con dominio inserto kinasa, FLK1, CD309)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 Homo sapiens (1-447) [VH (Homo sapiens IGHV3-23*04 (90.8%) -(IGHD) -IGHJ1*01 (100%)) [8.8.10] (1-117) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), bisagra 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-457)) (118-447)], (220-219')-disulfuro con la cadena ligera kappa Homo sapiens (1'-219') [V-KAPPA (Homo sapiens IGKV2-30*01 (83.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112') - Homo sapiens IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (226-226":229-229")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGGG LVQPGGSLRL SCAASGFSFS TYAMSWVRQA PGKGLEWVSG 50 ISGSGGTTHY ADSVKGRFTI SRDNSKNTVN LQMNSLRAED TAVYYCAKGL 100 WFGEGLWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350 LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447 Light chain / Chaîne légère / Cadena ligera DVVMTQSPLS LPVTLGQPAS ISCRSSQSLY YRSGYTFLDW YVQKPGQSPQ 50 LLIYQSSKRD SGVPDRISGS GSGTDFTLRI SRVEAEDVGV YYCFQGTHWP 100 YTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150 VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200 VTHQGLSSPV TKSFNRGEC 219 Post-translational modifications Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 144-200 261-321 367-425 22''-96'' 144''-200'' 261''-321'' 367''-425'' Intra-L (C23-C104) 23'-93' 139'-199' 23'''-93''' 139'''-199''' Inter-H-L (h 5-CL 126) 220-219' 220''-219''' Inter-H-H (h 11, h 14) 226-226'' 229-229'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 297, 297'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados C-terminal lysine clipping: H CHS K2: 447, 447'' 790 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 xevinapantum xevinapant (5S,8S,10aR)-N-(diphenylmethyl)-5-[(2S)-2- (methylamino)propanamido]-3-(3-methylbutanoyl)-6- oxodecahydropyrrolo[1,2-a][1,5]diazocine-8- carboxamide xévinapant (5S,8S,10aR)-N-(diphénylméthyl)-5-[(2S)-2- (méthylamino)propanamido]-3-(3-méthylbutanoyl)-6- oxodécahydropyrrolo[1,2-a][1,5]diazocine-8- carboxamide xevinapant (5S,8S,10aR)-N-(difenilmetil)-5-[(2S)-2- (metilamino)propanamido]-3-(3-metilbutanoil)-6- oxodecahidropirrolo[1,2-a][1,5]diazocina-8- carboxamida C32H43N5O4 H3C NH H H O O N H H3C N N H O H3C N H CH3 O zandelisibum zandelisib 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-N-{2- methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2- yl}-6-(morpholin-4-yl)-1,3,5-triazin-2-amine zandélisib 4-[2-(difluorométhyl)-1H-benzimidazol-1-yl]-N-{2- méthyl-1-[2-(1-méthylpipéridin-4-yl)phényl]propan-2- yl}-6-(morpholin-4-yl)-1,3,5-triazin-2-amine zandelisib 4-[2-(difluorometil)-1H-benzimidazol-1-il]-N-{2-metil-1- [2-(1-metilpiperidin-4-il)fenil]propan-2-il}-6-(morfolin-4- il)-1,3,5-triazin-2-amina C31H38F2N8O CH3 N O H N N N N N H3C CH3 F N F N zoligratinibum zoligratinib [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H- pyrazol-4-yl](1H-indol-2-yl)methanone zoligratinib [5-amino-1-(2-méthyl-1H-benzimidazol-5-yl)-1H- pyrazol-4-yl](1H-indol-2-yl)méthanone 791 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 zoligratinib [5-amino-1-(2-metil-1H-benzimidazol-5-il)-1H-pirazol-4- il](1H-indol-2-il)metanona C20H16N6O zotiraciclibum zotiraciclib (8E)-6-methyl-12-oxa-3,6-diaza-2(4,2)-pyrimidina- 1,4(1,3)-dibenzenacyclododecaphan-8-ene zotiraciclib (8E)-6-méthyl-12-oxa-3,6-diaza-2(4,2)-pyrimidina- 1,4(1,3)-dibenzénacyclododécaphan-8-ène zotiraciclib (8E)-6-metil-12-oxa-3,6-diaza-2(4,2)-pirimidina- 1,4(1,3)-dibencenaciclododecafan-8-eno C23H24N4O zuberitamabum # zuberitamab immunoglobulin G1-kappa, anti-[Homo sapiens MS4A1 (membrane spanning 4-domains subfamily A member 1, CD20)], chimeric monoclonal antibody; gamma1 heavy chain chimeric (1-452) [VH (Mus musculus IGHV1-12*01 (96.9%) -(IGHD) -IGHJ1*03 (100%)/Homo sapiens IGHV1-46*01 (70.4%) -(IGHD) - IGHJ1*03 (85.7%)) [8.8.15] (1-122) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (219) (123- 220), hinge 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123- 452)], (225-213')-disulfide with kappa light chain chimeric (1'-213') [V-KAPPA (Mus musculus IGKV4- 72*01 (96.8%) -IGKJ1*01 (90.9 %)/Homo sapiens IGKV3-11*01 (64.9%) -IGKJ2*01 (90.9%)) [5.3.9] (1'- 106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (231-231'':234-234'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa zubéritamab immunoglobuline G1-kappa, anti-[Homo sapiens MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal chimérique; 792 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 chaîne lourde gamma1 chimérique (1-452) [VH (Mus musculus IGHV1-12*01 (96.9%) -(IGHD) -IGHJ1*03 (100%)/Homo sapiens IGHV1-46*01 (70.4%) -(IGHD) - IGHJ1*03 (85.7%)) [8.8.15] (1-122) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (219) (123-220), charnière 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-213')- disulfure avec la chaîne légère kappa chimérique (1'-213') [V- KAPPA (Mus musculus IGKV4-72*01 (96.8%) -IGKJ1*01 (90.9 %)/Homo sapiens IGKV3-11*01 (64.9%) -IGKJ2*01 (90.9%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (231-231'':234-234'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa zuberitamab inmunoglobulina G1-kappa, anti-[Homo sapiens MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal quimérico; cadena pesada gamma1 quimérica (1-452) [VH (Mus musculus IGHV1-12*01 (96.9%) -(IGHD) -IGHJ1*03 (100%)/Homo sapiens IGHV1-46*01 (70.4%) -(IGHD) - IGHJ1*03 (85.7%)) [8.8.15] (1-122) -Homo sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (219) (123-220), bisagra 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-213')- disulfuro con la cadena ligera kappa quimérica (1'-213') [V- KAPPA (Mus musculus IGKV4-72*01 (96.8%) -IGKJ1*01 (90.9 %)/Homo sapiens IGKV3-11*01 (64.9%) -IGKJ2*01 (90.9%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (231-231'':234-234'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa 793 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES Recommended International Nonproprietary Names (Rec. INN): List 63 Dénominations communes internationales recommandées (DCI Rec.): Liste 63 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63 (WHO Drug Information, Vol. 24, No. 1, 2010) p.45 bardoxolonum bardoxolone replace the molecular formula by the following one bardoxolone remplacer la formule moléculaire brute par la suivante bardoxolona sustitúyase la fórmula molecular por la siguiente C31H41NO4 Recommended International Nonproprietary Names (Rec. INN): List 79 Dénominations communes internationales recommandées (DCI Rec.): Liste 79 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 79 (WHO Drug Information, Vol. 32, No. 1, 2018) p.112 davamotecanum pegadexamerum davamotecan pegadexamer replace the structure by the following one davamotécan pégadexamère remplacer la structure par la suivante davamotecán pegadexámero sustitúyase la estructura por la siguiente p.123 ianalumabum # -124 ianalumab replace the description and the structure by the following ones ianalumab remplacer la description et la structure par les suivantes ianalumab sustitúyase la descripción y la estructura por las siguientes immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BAFF-R, BR3, B cell activating factor receptor, CD268)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-454) [Homo sapiens VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223- 237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453- 454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -Homo sapiens IGKC*01, Km3 A45.1 (154), V101 (192) (109'- 215')]; dimer (233-233'':236-236'')-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa 794 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF13C (membre 13C de la super famille du récepteur du facteur de nécrose tumorale (TNFR), BAFFR, BAFF-R, BR3, récepteur du facteur d'activation des lymphocytes B, CD268], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-454) [Homo sapiens VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfure avec la chaîne légère (1'- 215') [Homo sapiens V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -Homo sapiens IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (233-233'':236-236'')-bisdisulfure, produit dans des cellules de hamster chinois (CHO), glycoforme alfa inmunoglobulina G1-kappa, anti-[Homo sapiens TNFRSF13C (miembro 13C de la super familia del receptor del factor de necrosis tumoral (TNFR), BAFFR, BAFF-R, BR3, receptor del factor de activación de los linfocitos B, CD268], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-454) [Homo sapiens VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223- 237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453- 454)) (125-454)], (227-215')-disulfuro con la cadena ligera (1'-215') [Homo sapiens V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -Homo sapiens IGKC*01, Km3 A45.1 (154), V101 (192) (109'- 215')]; dímero (233-233'':236-236'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa 795 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended International Nonproprietary Names (Rec. INN): List 81 Dénominations communes internationales recommandées (DCI Rec.): Liste 81 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 81 (WHO Drug Information, Vol. 33, No. 1, 2019) p.128 vutrisiranum vutrisiran replace the structure by the following one vutrisiran remplacer la structure par la suivante vutrisirán sustitúyase la estructura por la siguiente Recommended International Nonproprietary Names (Rec. INN): List 82 Dénominations communes internationales recommandées (DCI Rec.): Liste 82 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 82 (WHO Drug Information, Vol. 33, No. 3, 2019) p.606 adlinacogenum civaparvovecum # -607 adlinacogene civaparvovec replace the description by the following one adlinacogène civaparvovec remplacer la description par la suivante adlinacogén civaparvovec sustitúyase la descripción por la siguiente a recombinant non-replicating adeno-associated virus type 2/6 (rAAV6) vector, which contains a promoter-less human coagulation factor IX (hF9, Factor IX or FIX) transgene cassette, encoding exons 2-8 and splice acceptor site sequence (SA) from hF9 exon 2, flanked by a sequence homologous to the zinc-finger nuclease (ZFN) cleavage site of the human albumin (hALB) intron 1 vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non- répliquant, contenant la cassette avec le transgène du facteur de coagulation IX humain (hF9, Facteur IX, FIX) sans promoteur, codant pour les exons 2-8 et la séquence du site accepteur (SA) d'épissage de l'exon 2 de hF9, flanqué par une séquence homologue au site de clivage de la nucléase à doigts de zinc (ZFN) de l'intron 1 l'albumine humaine (hALB). un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6), no replicativo, que contiene un casete con el transgen del factor de coagulación IX (hF9, Factor IX o FIX) humano sin promotor, que codifica para los exones 2-8 y la secuencia del sitio aceptor (SA) del splicing del exon 2 de hf9, flanqueado por una secuencia homóloga al sitio de rotura por la nuclease con dedos de zinc (ZFN) del intron 1 de la albúmina humana (hALB) 796 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 p.625 devafidugenum civaparvovecum # -626 devafidugene civaparvovec replace the description by the following one devafidugène civaparvovec remplacer la description par la suivante devafidugén civaparvovec sustitúyase la descripción por la siguiente a recombinant non-replicating adeno-associated virus type 2/6 (rAAV6) vector, which contains a promoter-less human alpha-L-iduronidase (hIDUA) transgene cassette, encoding partial exon 1 and full exons 2-14 with the first 28 amino acids removed, and splice acceptor site sequence (SA) from hIDUA exon 2, flanked by a sequence homologous to the zinc- finger nuclease (ZFN) cleavage site of the human albumin (hALB) intron 1 vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non- répliquant, contenant la cassette du transgène de l'alpha-L-iduronidase humaine (hIDUA) sans promoteur, codant partiellement l'exon 1 et entièrement les exons 2-14 dont la partie correspondant aux 28 premiers acides aminés a été retirée, et la séquence du site accepteur (SA) d'épissage de l'exon 2 de l'hIDUA, flanqué d'une séquence homologue au site de clivage de la nucléase à doigts de zinc (ZFN) de l'intron 1 de l'albumine humaine (hALB) un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6), no replicativo, que contiene un casete con el transgen de la alfa-L- iduronidasa humana (hIDUA) sin promotor, que codifica para el exón 1 parcial y los exones 2-14 completos con los primeros 28 amino ácidos eliminados, y la secuencia del sitio aceptor (SA) del splicing del exón 2 de hIDUA, flanqueado por una secuencia homóloga al sitio de rotura por la nuclease con dedos de zinc (ZFN) del intron 1 de la albúmina humana (hALB) p.645 inlezifigenum civaparvovecum # inlezifigene civaparvovec replace the description by the following one inlezifigène civaparvovec remplacer la description par la suivante inlezifigén civaparvovec sustitúyase la descripción por la siguiente a recombinant non-replicating adeno-associated virus type 2/6 (rAAV6) vector, expressing a cDNA that targets 447-461 bp of the albumin locus (relative to the transcription initiation site), fused to the obligate heterodimeric FokI nuclease domain ELD, under the control of an apolipoprotein E hepatic control region and human alpha-1-antitrypsin promoter (ApoE/hAAT) vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non- répliquant, exprimant un ADNc ciblant les paires de bases 447-461 du locus de l'albumine (en relation avec le site initial de transcription), fusionné au domaine hétérodimérique ELD de la nucléase Fokl, sous le contrôle d'une région de contrôle de l'apolipoprotéine E (ApoE) spécifique du foie et du promoteur de l'alpha1-antitrypsine humaine (ApoE/hAAT) un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6), no replicativo, que expresa un cDNA dirigido a unirse a los pares de bases 447-461 (en relación al sitio de iniciación de la transcripción) del locus de la albúmina, fusionado al dominio heterodimérico ELD de la nuclease FokI, bajo el control de una región de control hepático de la apolipoproteína E y el promotor de la alfa 1 antitripsina humana (ApoE/hAAT) 797 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 p.669 ranuzifigenum civaparvovecum # -670 ranuzifigene civaparvovec replace the description by the following one ranuzifigène civaparvovec remplacer la description par la suivante ranuzifigén civaparvovec sustitúyase la descripción por la siguiente a recombinant non-replicating adeno-associated virus type 2/6 (rAAV6) vector, expressing a cDNA that targets 468-485 bp of the albumin locus (relative to the transcription initiation site), fused to the obligate heterodimeric FokI nuclease domain ELD, under the control of an apolipoprotein E hepatic control region and human alpha-1-antitrypsin promoter (ApoE/hAAT) vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non- répliquant, exprimant un ADNc ciblant les paires de bases 468-485 du locus de l'albumine (en relation avec le site initial de transcription), fusionné au domaine hétérodimérique ELD de la nucléase Fokl, sous le contrôle d'une région de contrôle de l'apolipoprotéine E (ApoE) spécifique du foie et du promoteur de l'alpha1-antitrypsine humaine (ApoE/hAAT) un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6), no replicativo, que expresa un cDNA dirigido a unirse a los pares de bases 468-485 (en relación al sitio de iniciación de la transcripción) del locus de la albúmina, fusionado al dominio heterodimérico ELD de la nuclease FokI, bajo el control de una región de control hepático de la apolipoproteína E y el promotor de la alfa 1 antitripsina humana (ApoE/hAAT) p.676 selitrectinibum selitrectinib replace the chemical name by the following one sélitrectinib remplacer le nom chimique par le suivant selitrectinib sustitúyase el nombre químico por el siguiente (22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina- 3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one (22R,6R)-35-fluoro-6-méthyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina- 3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one (22R,6R)-35-fluoro-6-metil-7-aza-1(5,3)-pirazolo[1,5-a]pirimidina-3(3,2)- piridina-2(1,2)-pirrolidinaciclooctafan-8-ona p.688 tefidsogenum civaparvovecum # -689 tefidsogene civaparvovec replace the description by the following one téfidsogène civaparvovec remplacer la description par la suivante tefidsogén civaparvovec sustitúyase la descripción por la siguiente a recombinant non-replicating adeno-associated virus type 2/6 (rAAV6) vector, which contains a promoter-less human iduronate 2- sulfatase (hIDS) transgene cassette, encoding parts of exon 1 plus exons 2-9 from hIDS and a splice acceptor site (SA) derived from human coagulation factor IX (hF9, factor IX or FIX) exon 2, flanked by a sequence homologous to the zinc-finger nuclease (ZFN) cleavage site of the human albumin (hALB) intron 1 798 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non- répliquant, contenant la cassette du transgène de l’iduronate 2- sulfatase humaine (hIDS) sans promoteur, codant partiellement l’exon 1 et les exons 2-9 de hIDS, et la séquence du site accepteur (SA) d’épissage dérivé de l’exon 2 du facteur de coagulation IX humain (hF9, facteur IX, FIX), flanqué d’une séquence homologue au site de clivage de la nucléase à doigts de zinc (ZFN) de l’intron 1 de l’albumine humaine (hALB) un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6), no replicativo, que contiene un casete con el transgen de la iduronato 2-sulfatasa humana (hIDS) sin promotor, que codifica para partes del exón 1 más los exones 2-9 de hIDS y un sitio aceptor del splicing derivado del exón 2 del factor de coagulación IX humano (hF9, factor IX o FIX), flanqueado por una secuencia homóloga al sitio de rotura por la nuclease con dedos de zinc (ZFN) del intron 1 de la albúmina humana (hALB) Recommended International Nonproprietary Names (Rec. INN): List 83 Dénominations communes internationales recommandées (DCI Rec.): Liste 83 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 83 (WHO Drug Information, Vol. 34, No. 1, 2020) p.25 avalotcagenum ontaparvovecum # -26 avalotcagene ontaparvovec replace the description by the following one avalotcagène ontaparvovec remplacer la description par la suivante avalotcagén ontaparvovec sustitúyase la descripción por la siguiente A recombinant non-replicating adeno-associated virus type 2/8 (rAAV8) vector, encoding codon-optimized, wild-type human ornithine transcarbamylase (OTC) under the control of a hybrid human thyroxine-binding globulin (TBG) / human alpha 1- microglobulin/bikunin precursor (AMBP) promoter/enhancer. The vector genome is a head-to-head dimer, with the vector genome cassette located 5' of the mutated internal inverted terminal repeat (ITR) in a reverse orientation and the vector genome cassette located 3' of the mutated internal ITR in a forward orientation. vecteur viral adéno-associé de type 2/8 recombinant non-répliquant (rAAV8), codant pour l'ornithine transcarbamylase humaine sauvage (OTC) avec des codons optimisés, sous le contrôle de l'activateur/promoteur hybride de la globuline liant la thyroxine (TBP) humaine /précurseur de microglobuline alpha 1 / bikunine (AMBP). Le génome du vecteur est un dimère en tête à tête avec la cassette contenant le génome du vecteur en position 5´ de la séquence inverse terminale répétée (ITR) interne et mutée dont l'orientation est inverse et la cassette contenant le vecteur du génome en position 3´ de l'ITR interne et mutée dont l'orientation est vers l'avant Un vector de virus adenoasociado recombinante no replicativo del serotipo 2/8 (rAAV8), que codifica para la ornitina transcarbamilasa silvestre humana (OTC) con codones optimizados, bajo el control de un promotor/potenciador híbrido de la globulina fijadora de tiroxina humana (TBG) / precursor de microglobulina alfa 1 humana/bicunina (AMBP). El genoma del vector es un dímero de cabeza con cabeza, con el casete del genoma del vector en posición 5' a la repetición terminal invertida (ITR) interna y mutada localizado en orientación inversa. y el casete del genoma del vector en posición 3' a la ITR localizado en orientación hacia adelante. 799 Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020 p.49 epcoritamabum # epcoritamab replace the structure by the following one épcoritamab remplacer la structure par la suivante epcoritamab sustitúyase la estructura por la siguiente p.55 giroctocogenum fitelparvovecum # giroctocogene fitelparvovec replace the description by the following one giroctocogène fitelparvovec remplacer la description par la suivante giroctocogén fitelparvovec sustitúyase la descripción por la siguiente A recombinant non-replicating adeno-associated virus type 2/6 (rAAV6) vector, encoding human B-domain-deleted blood coagulation factor VIII (hF8, FVIII) under the control of a synthetic liver-specific promoter. Vecteur viral adéno-associé de type 2/6 recombinant non-répliquant (rAAV6), codant pour le facteur de coagulation sanguine VIII humain (hF8, FVIII), dont le domaine B a été supprimé, sous le contrôle d'un promoteur synthétique spécifique du foie. 800 WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84 Un vector de virus adenoasociado recombinante no replicativo del tipo 2/6 (rAAV6), que codifica para el factor de coagulación sanguíneo VIII humano (hF8, FVIII) con el dominio B delecionado, bajo el control de un promotor sintético específico del hígado. p.63 supprimer insérer lététresgéne autoleucel lététresgène autoleucel p.132 zildistrogenum varoparvovecum # zildistrogene varoparvovec replace the description by the following one zildistrogène varoparvovec remplacer la description par la suivante zildistrogén varoparvovec sustitúyase la descripción por la siguiente A recombinant non-replicating adeno-associated virus type 2/9 (rAAV9) vector, encoding human microdystrophin 5 (h-μD5) under control of CK8 muscle creatine kinase promoter and enhancer elements vecteur viral adéno-associé de type 2/9 recombinant non-répliquant (rAAV9) codant pour la microdystrophine 5 humaine (h-mD5) sous le contrôle de l'activateur/promoteur de la créatine kinase musculaire CK8 Un vector de virus adenoasociado recombinante no replicativo del tipo 2/9 (rAAV9), que codifica para la microdistrofina 5 humana (h-mD5) bajo el control del promotor y elementos potenciadores (enhancer) de la creatina quinasa CK8 de músculo. # Electronic structure available on Mednet: http://mednet.who.int/ # Structure électronique disponible sur Mednet: http://mednet.who.int/ # Estructura electrónica disponible en Mednet: http://mednet.who.int/ * http://www.who.int/medicines/services/inn/publication/en/ Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in proposed INN lists only. Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées. El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en las listas de DCI propuestas. 801
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel